ビジネスワイヤ(バフェットのBerkshire Hathaway group)

Takeda Announces FDA Accelerated Approval of ALUNBRIGTM (br… 2017年04月29日 07時13分


ALUNBRIG Approved for ALK+ Metastatic Non-Small Cell Lung
Cancer (NSCLC) Patients Who Have Progressed on or are Intolerant to
Crizotinib


CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:
4502
) today announced that ALUNBRIG™ (brigatinib) has received
Accelerated Approval from the U.S. Food and Drug Administration (FDA)
for the treatment of patients with anaplastic lymphoma kinase-positive
(ALK+) metastatic non-small cell lung cancer (NSCLC) who have progressed
on or are intolerant to crizotinib. This indication is approved under
Accelerated Approval based on tumor response rate and duration of
response. Continued approval for this indication may be contingent upon
verification and description of clinical benefit in a confirmatory
trial. ALUNBRIG, which previously received Breakthrough Therapy
Designation from the FDA, is a once-daily oral therapy that may be taken
with or without food.








“In recent years, small molecule ALK inhibitors have revolutionized the
treatment options for those with advanced ALK+ non-small cell lung
cancer. Nevertheless, there is still a need for additional ALK
inhibitors like brigatinib (ALUNBRIG), which have a manageable safety
profile and may address mechanisms of clinical resistance to crizotinib,
including progression in the central nervous system,” said D. Ross
Camidge, M.D., Ph.D., director of thoracic oncology at the University of
Colorado. “The ALTA trial showed that brigatinib (ALUNBRIG) was highly
effective post-crizotinib with the majority of patients who received 180
mg once daily with a seven-day lead in at 90 mg once daily achieving an
overall response and a median duration of response greater than one
year. Importantly, the extent of activity among those with brain
metastases was also notable.”



“For patients with ALK+ metastatic NSCLC who have progressed on or are
intolerant to crizotinib, who are facing the uncertainty of disease
progression and the potentially devastating impact of brain metastases,
the approval of ALUNBRIG offers a new hope,” said Bonnie Addario,
founder and chair of the Addario Lung Cancer Foundation (ALCF).



“The rapid development of ALUNBRIG is a tribute to the dedication of
many research scientists and clinicians who carefully designed and
developed this new medicine to address unmet medical needs in the ALK+
NSCLC patient population. Most importantly, we would like to thank the
patients and families who participated in the clinical trials,” said
Andy Plump, M.D., Ph.D., Takeda Chief Medical and Scientific Officer.



“Today’s FDA approval of ALUNBRIG is an important milestone in the
treatment of patients with ALK+ metastatic NSCLC who have progressed on
or are intolerant to crizotinib,” said Christophe Bianchi, M.D.,
President, Takeda Oncology. “Takeda is committed to the continued
development of ALUNBRIG around the globe and to bringing this important
therapy to more patients in need.”



About the ALTA Trial



The FDA approval of ALUNBRIG was primarily based on results from the
pivotal Phase 2 ALTA (ALK in Lung Cancer Trial of AP26113)
trial of brigatinib in adults. This ongoing, two-arm, open-label,
multicenter trial enrolled 222 patients with locally advanced or
metastatic ALK+ NSCLC who had progressed on crizotinib. Patients
received either 90 mg of ALUNBRIG once daily (n=112) or 180 mg once
daily following a seven-day lead-in of 90 mg once daily (n=110). The
major efficacy outcome measure was confirmed overall response rate (ORR)
according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1)
as evaluated by an Independent Review Committee (IRC). Additional
efficacy outcome measures included Investigator-assessed ORR, duration
of response (DOR), intracranial ORR, and intracranial DOR.



The recommended dosing regimen for ALUNBRIG is 90 mg orally once daily
for the first 7 days. If 90 mg is tolerated during the first 7 days,
increase the dose to 180 mg orally once daily.



With a median follow-up of 8 months (range 0.1 - 20.2), results
demonstrated that of the patients who received the recommended dosing
regimen (90→180 mg), 53 percent achieved a confirmed overall response
(OR) as assessed by IRC and 54 percent as assessed by Investigator. At
the recommended dosing regimen, the median duration of response was 13.8
months as assessed by IRC and 11.1 months by Investigator assessment.
Additionally, at the recommended dosing regimen, 67 percent of patients
with measurable brain metastases (n=18) achieved a confirmed
intracranial OR by IRC assessment.



Efficacy data are as follows:






























































ALTA Efficacy Results



 

Efficacy parameter

IRC Assessment

 

 

Investigator Assessment


90 mg once daily




(N=112)



90→180 mg


once daily



(N=110)



 

 


90 mg once
daily




(N=112)



90→180 mg


once daily



(N=110)



Overall Response Rate (95% CI)

48% (39-58)

53% (43-62)

 

 

45% (35-54)

54% (44-63)

Complete Response, n (%)

4 (3.6%)

5 (4.5%)

 

 

1 (0.9%)

4 (3.6%)

Partial Response, n (%)

50 (45%)

53 (48%)

 

 

49 (44%)

55 (50%)

Duration of Response, median in months


(95% CI)



13.8


(7.4-NE)



13.8


(9.3-NE)



 

 

13.8


(5.6-13.8)



11.1


(9.2-13.8)




CI = Confidence Interval; NE = Not Estimable



IRC assessment of intracranial efficacy is shown below:

















































Intracranial Overall Response in Patients with Measurable Brain
Metastases in ALTA



 

Efficacy parameter

IRC Assessment

90 mg once daily


(N=26)



 

 

90→180 mg once daily


(N=18)



Intracranial Overall Response Rate, (95 % CI)

42% (23-63)

 

 

67% (41-87)

Complete Response, n (%)

2 (7.7%)

 

 

0

Partial Response, n (%)

9 (35%)

 

 

12 (67%)

Duration of Intracranial Response, median (months)


(range)



NE


(1.9+ - 9.2+)



 

 

5.6


(1.9+ - 9.2+)




CI = Confidence Interval; NE = Not Estimable



Among the 23 patients who exhibited an intracranial response, 78% of
patients in the 90 mg arm and 68% of patients in the 90→180 mg group
maintained a response for at least four months.



The warnings and precautions for ALUNBRIG are: interstitial lung disease
(ILD)/pneumonitis, hypertension, bradycardia, visual disturbance,
creatine phosphokinase (CPK) elevation, pancreatic enzyme elevation,
hyperglycemia and embryo-fetal toxicity.



Serious adverse reactions occurred in 38% of patients in the 90 mg group
and 40% of patients in the 90→180 mg group. The most common serious
adverse reactions were pneumonia (5.5% overall, 3.7% in the 90 mg group,
and 7.3% in the 90→180 mg group) and ILD/pneumonitis (4.6% overall, 1.8%
in the 90 mg group and 7.3% in the 90→180 mg group). Fatal adverse
reactions occurred in 3.7% of patients and consisted of pneumonia (2
patients), sudden death, dyspnea, respiratory failure, pulmonary
embolism, bacterial meningitis and urosepsis (1 patient each).



At the recommended dosing regimen, the most common adverse reactions
(≥25%) with ALUNBRIG were nausea, diarrhea, fatigue, cough, and headache.



About ALK+ NSCLC



Non-small cell lung cancer (NSCLC) is the most common form of lung
cancer, accounting for approximately 85 percent of the estimated 222,500
new cases of lung cancer diagnosed each year in the United States,
according to the American Cancer Society. Genetic studies indicate that
chromosomal rearrangements in anaplastic lymphoma kinase (ALK) are key
drivers in a subset of NSCLC patients as well. Approximately two to
eight percent of patients with NSCLC have a rearrangement in the ALK
gene.



The central nervous system (CNS) is a frequent site for ALK+ NSCLC
progression, with up to 70 percent of patients with ALK+ NSCLC who have
been treated with a first-line ALK inhibitor facing brain metastases.



About ALUNBRIG™ (brigatinib)



ALUNBRIG is a targeted cancer medicine discovered by ARIAD
Pharmaceuticals, Inc., which was acquired by Takeda in February 2017.
ALUNBRIG received Breakthrough Therapy Designation from the FDA for the
treatment of patients with ALK+ NSCLC whose tumors are resistant to
crizotinib, and was granted Orphan Drug Designation by the FDA for the
treatment of ALK+ NSCLC, ROS1+ and EGFR+ NSCLC. A Marketing
Authorization Application (MAA) for ALUNBRIG was submitted to the
European Medicines Agency (EMA) in February 2017.



The ALTA clinical development program further reinforces Takeda’s
ongoing commitment to developing innovative therapies for people living
with ALK+ NSCLC worldwide and the healthcare professionals who treat
them. In addition to the ongoing Phase 1/2 and Phase 2 ALTA trial,
brigatinib is also being studied in the Phase 3 ALTA 1L trial to assess
its efficacy and safety in comparison to crizotinib in patients with
locally advanced or metastatic ALK+ NSCLC who have not received prior
treatment with an ALK inhibitor.



To learn more about ALUNBRIG, please visit www.ALUNBRIG.com or
call A1Point: 1-844-A1POINT (1-844-217-6468).



For additional information on the brigatinib clinical trials, please
visit www.clinicaltrials.gov.



IMPORTANT SAFETY INFORMATION



WARNINGS AND PRECAUTIONS
Interstitial Lung Disease
(ILD)/Pneumonitis:
Severe, life-threatening, and fatal pulmonary
adverse reactions consistent with interstitial lung disease
(ILD)/pneumonitis have occurred with ALUNBRIG. In Trial ALTA (ALTA),
ILD/pneumonitis occurred in 3.7% of patients in the 90 mg group (90 mg
once daily) and 9.1% of patients in the 90→180 mg group (180 mg once
daily with 7-day lead-in at 90 mg once daily). Adverse reactions
consistent with possible ILD/pneumonitis occurred early (within 9 days
of initiation of ALUNBRIG; median onset was 2 days) in 6.4% of patients,
with Grade 3 to 4 reactions occurring in 2.7%. Monitor for new or
worsening respiratory symptoms (e.g., dyspnea, cough, etc.),
particularly during the first week of initiating ALUNBRIG. Withhold
ALUNBRIG in any patient with new or worsening respiratory symptoms, and
promptly evaluate for ILD/pneumonitis or other causes of respiratory
symptoms (e.g., pulmonary embolism, tumor progression, and infectious
pneumonia). For Grade 1 or 2 ILD/pneumonitis, either resume ALUNBRIG
with dose reduction after recovery to baseline or permanently
discontinue ALUNBRIG. Permanently discontinue ALUNBRIG for Grade 3 or 4
ILD/pneumonitis or recurrence of Grade 1 or 2 ILD/pneumonitis.



Hypertension: In ALTA, hypertension was reported in 11% of
patients in the 90 mg group who received ALUNBRIG and 21% of patients in
the 90→180 mg group. Grade 3 hypertension occurred in 5.9% of patients
overall. Control blood pressure prior to treatment with ALUNBRIG.
Monitor blood pressure after 2 weeks and at least monthly thereafter
during treatment with ALUNBRIG. Withhold ALUNBRIG for Grade 3
hypertension despite optimal antihypertensive therapy. Upon resolution
or improvement to Grade 1 severity, resume ALUNBRIG at a reduced dose.
Consider permanent discontinuation of treatment with ALUNBRIG for Grade
4 hypertension or recurrence of Grade 3 hypertension. Use caution when
administering ALUNBRIG in combination with antihypertensive agents that
cause bradycardia.



Bradycardia: Bradycardia can occur with ALUNBRIG. In ALTA, heart
rates less than 50 beats per minute (bpm) occurred in 5.7% of patients
in the 90 mg group and 7.6% of patients in the 90→180 mg group. Grade 2
bradycardia occurred in 1 (0.9%) patient in the 90 mg group. Monitor
heart rate and blood pressure during treatment with ALUNBRIG. Monitor
patients more frequently if concomitant use of drug known to cause
bradycardia cannot be avoided. For symptomatic bradycardia, withhold
ALUNBRIG and review concomitant medications for those known to cause
bradycardia. If a concomitant medication known to cause bradycardia is
identified and discontinued or dose adjusted, resume ALUNBRIG at the
same dose following resolution of symptomatic bradycardia; otherwise,
reduce the dose of ALUNBRIG following resolution of symptomatic
bradycardia. Discontinue ALUNBRIG for life-threatening bradycardia if no
contributing concomitant medication is identified.



Visual Disturbance: In ALTA, adverse reactions leading to visual
disturbance including blurred vision, diplopia, and reduced visual
acuity, were reported in 7.3% of patients treated with ALUNBRIG in the
90 mg group and 10% of patients in the 90→180 mg group. Grade 3 macular
edema and cataract occurred in one patient each in the 90→180 mg group.
Advise patients to report any visual symptoms. Withhold ALUNBRIG and
obtain an ophthalmologic evaluation in patients with new or worsening
visual symptoms of Grade 2 or greater severity. Upon recovery of Grade 2
or Grade 3 visual disturbances to Grade 1 severity or baseline, resume
ALUNBRIG at a reduced dose. Permanently discontinue treatment with
ALUNBRIG for Grade 4 visual disturbances.



Creatine Phosphokinase (CPK) Elevation: In ALTA, creatine
phosphokinase (CPK) elevation occurred in 27% of patients receiving
ALUNBRIG in the 90 mg group and 48% of patients in the 90 mg→180 mg
group. The incidence of Grade 3-4 CPK elevation was 2.8% in the 90 mg
group and 12% in the 90→180 mg group. Dose reduction for CPK elevation
occurred in 1.8% of patients in the 90 mg group and 4.5% in the 90→180
mg group. Advise patients to report any unexplained muscle pain,
tenderness, or weakness. Monitor CPK levels during ALUNBRIG treatment.
Withhold ALUNBRIG for Grade 3 or 4 CPK elevation. Upon resolution or
recovery to Grade 1 or baseline, resume ALUNBRIG at the same dose or at
a reduced dose.



Pancreatic Enzyme Elevation: In ALTA, amylase elevation occurred
in 27% of patients in the 90 mg group and 39% of patients in the 90→180
mg group. Lipase elevations occurred in 21% of patients in the 90 mg
group and 45% of patients in the 90→180 mg group. Grade 3 or 4 amylase
elevation occurred in 3.7% of patients in the 90 mg group and 2.7% of
patients in the 90→180 mg group. Grade 3 or 4 lipase elevation occurred
in 4.6% of patients in the 90 mg group and 5.5% of patients in the
90→180 mg group. Monitor lipase and amylase during treatment with
ALUNBRIG. Withhold ALUNBRIG for Grade 3 or 4 pancreatic enzyme
elevation. Upon resolution or recovery to Grade 1 or baseline, resume
ALUNBRIG at the same dose or at a reduced dose.



Hyperglycemia: In ALTA, 43% of patients who received ALUNBRIG
experienced new or worsening hyperglycemia. Grade 3 hyperglycemia, based
on laboratory assessment of serum fasting glucose levels, occurred in
3.7% of patients. Two of 20 (10%) patients with diabetes or glucose
intolerance at baseline required initiation of insulin while receiving
ALUNBRIG. Assess fasting serum glucose prior to initiation of ALUNBRIG
and monitor periodically thereafter. Initiate or optimize
anti-hyperglycemic medications as needed. If adequate hyperglycemic
control cannot be achieved with optimal medical management, withhold
ALUNBRIG until adequate hyperglycemic control is achieved and consider
reducing the dose of ALUNBRIG or permanently discontinuing ALUNBRIG.



Embryo-Fetal Toxicity: Based on its mechanism of action and
findings in animals, ALUNBRIG can cause fetal harm when administered to
pregnant women. There are no clinical data on the use of ALUNBRIG in
pregnant women. Advise pregnant women of the potential risk to a fetus.
Advise females of reproductive potential to use effective non-hormonal
contraception during treatment with ALUNBRIG and for at least 4 months
following the final dose. Advise males with female partners of
reproductive potential to use effective contraception during treatment
and for at least 3 months after the last dose of ALUNBRIG.



ADVERSE REACTIONS
Serious adverse reactions occurred in 38%
of patients in the 90 mg group and 40% of patients in the 90→180 mg
group. The most common serious adverse reactions were pneumonia (5.5%
overall, 3.7% in the 90 mg group, and 7.3% in the 90→180 mg group) and
ILD/pneumonitis (4.6% overall, 1.8% in the 90 mg group and 7.3% in the
90→180 mg group). Fatal adverse reactions occurred in 3.7% of patients
and consisted of pneumonia (2 patients), sudden death, dyspnea,
respiratory failure, pulmonary embolism, bacterial meningitis and
urosepsis (1 patient each).



The most common adverse reactions (≥25%) in the 90 mg group were nausea
(33%), fatigue (29%), headache (28%), and dyspnea (27%) and in the
90→180 mg group were nausea (40%), diarrhea (38%), fatigue (36%), cough
(34%), and headache (27%).



DRUG INTERACTIONS
CYP3A Inhibitors:
Avoid concomitant use of ALUNBRIG with strong CYP3A inhibitors. Avoid
grapefruit or grapefruit juice as it may also increase plasma
concentrations of brigatinib. If concomitant use of a strong CYP3A
inhibitor is unavoidable, reduce the dose of ALUNBRIG.
CYP3A
Inducers
: Avoid concomitant use of ALUNBRIG with strong CYP3A
inducers.
CYP3A Substrates: Coadministration
of ALUNBRIG with CYP3A substrates, including hormonal contraceptives,
can result in decreased concentrations and loss of efficacy of CYP3A
substrates.



USE IN SPECIFIC POPULATIONS
Pregnancy: ALUNBRIG can
cause fetal harm. Advise females of reproductive potential of the
potential risk to a fetus.
Lactation: Advise lactating women
not to breastfeed during treatment with ALUNBRIG and for 1 week
following the final dose.
Females and Males of Reproductive
Potential:

Contraception: Advise
females of reproductive potential to use effective non-hormonal
contraception during treatment with ALUNBRIG and for at least 4 months
after the final dose. Advise males with female partners of reproductive
potential to use effective contraception during treatment with ALUNBRIG
and for at least 3 months after the final dose.
Infertility:
ALUNBRIG may cause reduced fertility in males.
Pediatric Use:
The safety and efficacy of ALUNBRIG in pediatric patients have not been
established.
Geriatric Use: Clinical studies of ALUNBRIG did
not include sufficient numbers of patients aged 65 years and older to
determine whether they respond differently from younger patients. Of the
222 patients in ALTA, 19.4% were 65-74 years and 4.1% were 75 years or
older. No clinically relevant differences in safety or efficacy were
observed between patients ≥65 and younger patients.
Hepatic or
Renal Impairment:
No dose adjustment is recommended for patients
with mild hepatic impairment or mild or moderate renal impairment. The
safety of ALUNBRIG in patients with moderate or severe hepatic
impairment or severe renal impairment has not been studied.



Please see the full Prescribing Information for ALUNBRIG at www.ALUNBRIG.com



About Takeda



Takeda Pharmaceutical Company Limited is a global, research and
development-driven pharmaceutical company committed to bringing better
health and a brighter future to patients by translating science into
life-changing medicines. Takeda focuses its R&D efforts on oncology,
gastroenterology and central nervous system therapeutic areas plus
vaccines. Takeda conducts R&D both internally and with partners to stay
at the leading edge of innovation. New innovative products, especially
in oncology and gastroenterology, as well as our presence in Emerging
Markets, fuel the growth of Takeda. More than 30,000 Takeda employees
are committed to improving quality of life for patients, working with
our partners in health care in more than 70 countries. For more
information, visit http://www.takeda.com/news.



Additional information about Takeda is available through its corporate
website, www.takeda.com,
and additional information about Takeda Oncology, the brand for the
global oncology business unit of Takeda Pharmaceutical Company Limited,
is available through its website, www.takedaoncology.com.






Contacts


Takeda Pharmaceutical Company Limited
Japanese Media
Tsuyoshi
Tada, +81 (0) 3-3278-2417
tsuyoshi.tada@takeda.com
or
Media
outside Japan
Amy Atwood, +1-617-444-2147
amy.atwood@takeda.com
or
Liza
Heapes, +1-617-621-2315
Liza.heapes@ariad.com

Tofacitinib Sales, Price Analysis, & Sales Forecast - 2017 … 2017年04月29日 03時29分

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Tofacitinib
Sales, Price Analysis, & Sales Forecast - 2017"
report to
their offering.




Introducing the new research, Tofacitinib Sales, Price Analysis, & Sales
Forecast - 2017. Find out the sales of Tofacitinib worldwide and by
countries in North America, Europe, Japan, BRIC, and Australia. Discover
the growth trends of Tofacitinib by countries, and also find out the
sales forecast until 2021. The research also provides Tofacitinib unit
price by countries. The sales and price data from this report is useful
for analyzing Tofacitinib sales trends, sales forecast for Tofacitinib,
brand planning, Tofacitinib generics trends, product positioning,
strategic forecasts, BD&L, competitive intelligence, pricing analysis,
and price benchmarks.



Research Scope:




  • Product: Tofacitinib


  • Country Scope: US, Germany, France, Italy, Spain, UK, Japan, Brazil,
    Russia, India, China, Canada, and Australia


  • Companies marketing Tofacitinib and by brand name in major countries


  • Historic Tofacitinib sales revenues ($mn) worldwide and by countries,
    sales trends


  • Tofacitinib unit price by countries, trends, and benchmarks


  • Tofacitinib sales forecast ($mn) worldwide and by countries



Benefits to the User




  • Identify companies marketing Tofacitinib by major countries


  • Find out Tofacitinib sales, growth, and sales forecast by major
    countries; use it for your market planning - market assessments,
    market sizing, market shares, BD&L, product strategy, positioning, and
    competitive intelligence


  • Determine the price of Tofacitinib in major markets; use it to devise
    pricing strategies, estimate patient shares, develop patient forecast
    models, and estimate annual therapy costs


  • Derive unit sales of Tofacitinib by countries using pricing and sales
    data; use it for your market planning - market assessments, market
    sizing, market shares, BD&L, product strategy, positioning, and
    competitive intelligence



Key Topics Covered:



1. Tofacitinib - Introduction



2. Tofacitinib Sales Analysis



3. Tofacitinib Sales by Countries



4. Tofacitinib Price Analysis by Countries



5. Tofacitinib Sales Forecast



6. Tofacitinib Sales Forecast by Countries



7. Methodology



For more information about this report visit http://www.researchandmarkets.com/research/vnllgm/tofacitinib.


Contacts


Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For
EST Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related
Topics: Immune
Disorders Drugs
, Musculoskeletal
Disorders Drugs

Environmentalists Call Japan’s Plan to Increase Ivory Trade… 2017年04月28日 22時51分

WASHINGTON--(BUSINESS WIRE)--#china--The Environmental Investigation Agency (EIA) today accused the
Government of Japan of planning to increase its ivory trade by launching
a campaign to register ivory tusks that will directly threaten the
success of China’s ban on domestic ivory trade. The government claims
the new campaign is intended to “control” ivory trade.




“Japan’s tusk registration scheme is effectively a major laundering
operation that enables poached ivory to be legalized and sold on the
domestic market, without requiring any proof of legality of origin,”
said EIA president Allan Thornton. “Over 8,000 tusks were registered
between 2010 and 2015. Increasing registration just means that even more
illegal tusks will be legalized for sale and the increased supply of
illegal ivory in the Japanese market will be available for illegal
export to China and Hong Kong.”



Japan is the world’s second largest consumer of ivory after China and
has over 8,000 ivory retailers and 300 ivory manufacturers.



Last year EIA released undercover
video
of Japanese ivory traders boasting of selling large amounts of
ivory to Chinese buyers for illegal export to China and Hong Kong. “You
should have come two years ago,” said one trader, “all of the ivory has
been sent from Japan to China.”



In October 2016, 180 nations including Japan, that are party to the
Convention on International Trade in Endangered Species (CITES)
unanimously agreed to a resolution calling for the closure of domestic
ivory markets in countries linked to poaching or illegal ivory trade.
Japan claimed it is not obliged to abide by the resolution despite
extensive evidence of illegal ivory trade.



China, the biggest consumer of illegal ivory, announced on December 30,,
2016 that it would enact a domestic ban on ivory trade that would
be completed by the end of 2017. On March 31, China began this process
by announcing the closure of 67 ivory facilities which included 12 of
its 35 ivory carving factories and dozens of ivory retail stores.



Danielle Grabiel, EIA Senior Wildlife Campaigner, stated, “The
registration of illegal tusks fuels Japan’s illegal ivory tusk and hanko
trade and drives illegal exports of tusks to China, Hong Kong, and
Thailand.”



“We are extremely concerned that Japan’s expansion of its ivory
registration and trade will undercut China’s efforts to successfully
close its ivory market,” Grabiel added.




Contacts


Environmental Investigation Agency
Danielle Grabiel
dgrabiel@eia-global.org
or
Allan
Thornton
allanthornton@eia-global.org

Jaguar Signs Distribution Agreement for Japan for Neonorm F… 2017年04月28日 22時00分


Jaguar Receives Extension of Nasdaq Listing


SAN FRANCISCO--(BUSINESS WIRE)--Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar”), an animal health
company focused on developing and commercializing first-in-class
gastrointestinal products for companion and production animals, foals,
and high value horses, today announced that it has signed an exclusive
distribution agreement with JP Equine Services for distribution of
Jaguar’s lead non-prescription products, Neonorm Foal and
Neonorm Calf, in Japan.



Neonorm Foal is a natural, clinically-tested, non-drug
product designed for use as an anti-diarrheal in newborn horses.
Diarrhea is one of the most common clinical complaints in foals,
especially within the first 30 days of life. The crippling effects of
dehydration that often result from secretory diarrhea in foals can
manifest quickly, precipitate adverse health effects and lead to death.
Neonorm Calf has been formulated and clinically tested to
help proactively retain fluid in dairy calves and reduce the severity of
diarrhea—aiding calves in avoiding debilitating, dangerous levels of
dehydration associated with scours.



In the year 2000, there were an estimated 115,000 horses in Japan1—a
country where more than 21,000 horse races are held annually. According
to the Japan Dairy Council, there were an estimated 1,450,000 dairy
cattle in Japan in 2012, spread across 20,100 dairy farms. Although
dairy products have traditionally not represented a large portion of the
Japanese diet, increases in disposable income in recent years have led
to an increased interest in foreign products and growth in the intake of
dairy.2



Headquartered in Jamaica, NY and established in 2001, JP Equine Services
began as a shipping company handling transport of thoroughbred
racehorses to Japan, Korea, Saudi Arabia and Italy. The company later
expanded into distribution of equine products to breeding farms and
veterinary practices throughout the world.



“We’re very excited to represent Neonorm Foal and Neonorm
Calf in Japan and look forward to a successful relationship with Jaguar
Animal Health,” commented Jimmy Preziosi, founder of JP Equine Services.



Henry Schein, Inc., the world’s largest provider of health care products
and services to office-based dental, animal health and medical
practitioners, continues to serve as Jaguar’s exclusive distributor of
Neonorm Foal in the U.S. equine market.



Extension of Nasdaq Listing



Jaguar also announced today that, on April 27, 2017, the Company was
notified that the Nasdaq Hearings Panel (the “Panel”) determined to
grant the Company’s request for continued listing on Nasdaq. The
Company’s continued listing is subject to the completion of Jaguar’s
proposed merger with Napo Pharmaceuticals, Inc. on or before July 31,
2017, and the Company’s compliance with Nasdaq’s $2.5 million
stockholders’ equity requirement as a result of the merger. The Company
is diligently working to timely evidence compliance with the terms of
the Panel’s decision. The decision follows the Company’s recent hearing
before the Panel, at which it presented its plan to evidence compliance
with the stockholders’ equity requirement concurrent with the merger.



About Jaguar Animal Health, Inc.



Jaguar Animal Health, Inc. is an animal health company focused on
developing and commercializing first-in-class gastrointestinal products
for companion and production animals, foals, and high value horses.
Canalevia is Jaguar’s lead prescription drug product
candidate, intended for the treatment of various forms of diarrhea in
dogs. Equilevia (formerly referred to as SB-300) is Jaguar’s
prescription drug product candidate for the treatment of
gastrointestinal ulcers in horses. Canalevia and Equilevia
contain ingredients isolated and purified from the Croton lechleri
tree, which is sustainably harvested. Neonorm Calf and
Neonorm Foal are the Company’s lead non-prescription
products. Neonorm is a standardized botanical extract
derived from the Croton lechleri tree. Canalevia and
Neonorm are distinct products that act at the same last step
in a physiological pathway generally present in mammals. Jaguar has nine
active investigational new animal drug applications, or INADs, filed
with the FDA and intends to develop species-specific formulations of
Neonorm in six additional target species, formulations of
Equilevia in horses, and Canalevia for cats and
dogs.



For more information about Jaguar, please visit www.jaguaranimalhealth.com.



Forward-Looking Statements



Certain statements in this press release constitute “forward-looking
statements.” These include statements regarding the completion of
Jaguar’s proposed merger with Napo Pharmaceuticals, Inc. on or before
July 31, 2017, the Company’s ability to timely evidence compliance with
the terms of the Panel’s decision, Jaguar’s intention to develop
species-specific formulations of Neonorm in additional
target species, and the Company’s plan to develop formulations of
Canalevia for cats, horses and dogs. In some cases, you can
identify forward-looking statements by terms such as “may,” “will,”
“should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,”
“target,” “project,” “contemplate,” “believe,” “estimate,” “predict,”
“potential” or “continue” or the negative of these terms or other
similar expressions. The forward-looking statements in this release are
only predictions. Jaguar has based these forward-looking statements
largely on its current expectations and projections about future events.
These forward-looking statements speak only as of the date of this
release and are subject to a number of risks, uncertainties and
assumptions, some of which cannot be predicted or quantified and some of
which are beyond Jaguar’s control. Except as required by applicable law,
Jaguar does not plan to publicly update or revise any forward-looking
statements contained herein, whether as a result of any new information,
future events, changed circumstances or otherwise.



1A. Fotovati1, Y. Mizuno, T. Ito and H. Moriyama, A
Statistical Study of the Horse Industry in Japan, Asian-Aus. J. Anim.
Sci. 13 Supplement July 2000 C: 403



2The Food and Beverage Market Entry Handbook: Japan: A
Practical Guide to the Market in Japan for European Agri-food Products



Jaguar-JAGX




Contacts


KCSA Strategic Communications
Garth Russell, 212-896-1250
grussell@kcsa.com

Pacifico Energy Commences Construction of Japan's Largest S… 2017年04月28日 20時00分


Sakuto Mega Solar Power Plant 257.7 MW (DC)


TOKYO--(BUSINESS WIRE)--Pacifico Energy K.K. (Head Office: Minato, Tokyo) is pleased to announce
the commencement of construction on Japan's largest solar power
generation plant, the 257.7 MW (DC) Sakuto Mega Solar Power Plant in
Mimasaka, Okayama.




The plant will be constructed on land in Mimasaka City, Okayama
Prefecture that was previously the proposed site of the Sakuto
St.Valentine Resort and the former site of the Peninsula Golf Club's
Yunogo Course (approx. 400ha). Operations are expected to start in
September 2019, representing a 30 month construction period. Once
commissioned, the plant will generate approximately 290 million kilowatt
hours of electricity annually, representing an annual reduction of
approximately 200,000 tonnes of CO2 emissions. Chugoku Electric Power
Company (CEPCO) will purchase all electricity generated by the plant.



Pacifico Energy has already completed construction of two other solar
power plants in Okayama (in Kumenan and Mimasaka), which are both now in
commercial operation, so the Sakuto Mega Solar Power Plant will be the
third project for Pacifico Energy in Okayama. Leveraging know-how and
experience gained through developing, constructing, and operating
utility scale solar power plants all over the world, we shall continue
constructing power plants that contribute to the development of regional
communities in an environmentally friendly way.



About Pacifico Energy K.K. : Founded in 2012 to help meet Japan’s
domestic energy needs, Pacifico Energy currently has 3 commissioned
solar plants in Japan (total capacity: 131 MW (DC)) and is developing
more projects, including another 96 MW (DC) currently under construction
in Miyazaki.



For more information, please see: http://www.pacificoenergy.jp/en/




Contacts


Inquiries in Japan
Pacifico Energy K.K.
Mia Ihara, +81 3 4540
7830
Public Relations
info@pacificoenergy.jp
http://www.pacificoenergy.jp/en/info/



デンソーと東芝、IoTを活用したモノづくり、高度運転支援・自動… 2017年04月28日 16時22分

刈谷 & 東京--(BUSINESS WIRE)--(ビジネスワイヤ) -- 株式会社デンソー(本社:愛知県刈谷市、社長:有馬
浩二、以下デンソー)と株式会社東芝(本社:東京都港区、代表執行役社長:綱川
智、以下東芝)は、IoTを活用したモノづくり、高度運転支援・自動運転などの分野における協業関係の強化に向けた協議を開始したことを発表します。




本協業は、デンソーが自動車市場で培った“高度な技術力とモノづくり力”と、東芝が持つ画像認識技術、IoT・AI技術、ソフトウェア開発技術を融合させることにより、自動車業界を取り巻くパラダイムシフトを勝ち抜くための競争力を強化するためのものです。



これまでも両社は、高度運転支援・自動運転の分野において、画像認識システム向けの人工知能技術を共同で開発してきました。また自動車用リチウムイオン電池パックや、自動車部品に使用されるECUのソフトウェア開発など、様々な分野で連携してきました。



両社は今後もビジョンを共有する分野における協業関係を強化し、技術開発を加速します。




Contacts


◇本件に関するお問い合わせ先
株式会社デンソー
広報部 上原・松田・吉田
TEL 0566-25-5593、5594
または
株式会社東芝
広報・IR部
平木・内田
TEL 03-3457-2100



DENSO and Toshiba to Collaborate on IoT-based Manufacturing… 2017年04月28日 16時22分

KARIYA, Japan & TOKYO--(BUSINESS WIRE)--DENSO
Corporation
and Toshiba
Corporation
today announced that the two companies have begun talks
to enhance collaborations in the fields of Internet of Things
(IoT)-based manufacturing, advanced driver assistance, automated
driving, and others.




The collaborations aim to combine DENSO’s high level of technology and
manufacturing capability accumulated through its experience in the
automotive market and Toshiba’s image recognition, IoT, artificial
intelligence (AI), and software development technologies, in order to
increase the competitiveness to make it through the paradigm shift that
is taking place in the automotive industry.



In the fields of advanced driver assistance and automated driving, DENSO
and Toshiba have jointly developed AI technologies used in image
recognition systems. Moreover, the two companies have worked together in
a wide range of areas including the development of automotive
lithium-ion battery packs and software for ECUs used in automotive
components.



DENSO and Toshiba will collaborate more closely in fields where they can
share their visions and speed up the development of technology.




Contacts


Press Contact:
DENSO Corporation
Junko
Uehara
junko_uehara@denso.co.jp
Yu
Matsuda
yuu_matsuda@denso.co.jp
or
Toshiba
Corporation
Public Relations & Investor Relations Div.
1-1-1
Shibaura, Minato-ku, Tokyo 105-8001, Japan
Kaori Hiraki / Yukihito
Uchida
media.relations@toshiba.co.jp



Mitsubishi Electric Announces Consolidated Financial Result… 2017年04月28日 13時25分

TOKYO--(BUSINESS WIRE)--Mitsubishi
Electric Corporation
(TOKYO:6503) announced today its consolidated
financial results for fiscal 2017 (April 1, 2016- March 31, 2017).




The full document on Mitsubishi Electric’s financial results can be
viewed at the following link:
www.MitsubishiElectric.com/news















































Consolidated Financial Results



Net sales:

 

4,238.6

 

billion yen

 

(4% decrease from the previous fiscal year)

Operating income:


270.1


billion yen


(10% decrease from the previous fiscal year)

Income before income taxes:


296.2


billion yen


(7% decrease from the previous fiscal year)


Net income attributable to
Mitsubishi Electric Corp.:




210.4


billion yen


(8% decrease from the previous fiscal year)

 


During the fiscal year ended March 31, 2017, the business environment
was buoyed by the expanding U.S. economy and gradual recoveries in Japan
and Europe, as well as modest improvement in China’s economic slowdown.
In addition, the yen became stronger against foreign currencies compared
to the previous year, but weakened after the U.S. presidential election
in November.



Under these circumstances, the Mitsubishi Electric Group has been
working even harder than before to promote growth strategies rooted in
its advantages, while continuously implementing initiatives to
strengthen its competitiveness and business structure.



As a result, the Mitsubishi Electric Group has recorded a net sales of
4,238.6 billion yen for fiscal 2017, a decrease of 4% compared to the
previous fiscal year, with decreased sales in the Energy and Electric
Systems, Industrial Automation Systems, Information and Communication
Systems, and Electronic Devices segments.



Consolidated operating income decreased by 10% compared to the previous
fiscal year to 270.1 billion yen, due to decreased profits in the Energy
and Electric Systems, Industrial Automation Systems, Information and
Communication Systems, and Electronic Devices segments.



Current Forecast for Fiscal 2018
Despite
the uncertainty in business performance remaining high due to factors
such as the U.K. government’s policies on Brexit and operations of the
new U.S. administration, the economic slowdown in China is expected to
be mild, and global business conditions are facing gradual growth in the
economy with buoyant expansion in the U.S. and a continued trend of
recovery in Japan and Europe.



Under these circumstances, the Mitsubishi Electric Group aims to achieve
its management targets by uplifting its business performance and
financial standings through initiatives such as promoting more strongly
its global operations centered around its growth-driving businesses,
continuously increasing and strengthening profitability in each business
and continuously implementing various Group-wide business improvement
measures.



The current financial performance forecast for fiscal 2018 follows below.















































Current consolidated forecast for fiscal 2018



Net sales

 

4,300.0

 

billion yen

 

(1% increase from fiscal 2017)

Operating income


280.0


billion yen


(4% increase from fiscal 2017)

Income before income taxes


300.0


billion yen


(1% increase from fiscal 2017)


Net income attributable to
Mitsubishi Electric Corp.




215.0


billion yen


(2% increase from fiscal 2017)

 


Exchange rates for the forecast above is 105 yen to the US dollar and
110 yen to the euro.













 

Note: The results forecast above is based on assumptions
deemed reasonable by the company at the present time, and actual
results may differ significantly from forecasts. Please refer to the
cautionary statement in the full document.


 


About Mitsubishi Electric Corporation
With
over 90 years of experience in providing reliable, high-quality
products, Mitsubishi Electric Corporation (TOKYO: 6503) is a recognized
world leader in the manufacture, marketing and sales of electrical and
electronic equipment used in information processing and communications,
space development and satellite communications, consumer electronics,
industrial technology, energy, transportation and building equipment.
Embracing the spirit of its corporate statement, Changes for the Better,
and its environmental statement, Eco Changes, Mitsubishi Electric
endeavors to be a global, leading green company, enriching society with
technology. The company recorded consolidated group sales of 4,238.6
billion yen (US$ 37.8 billion*) in the fiscal year ended March 31, 2017.
For more information visit:
www.MitsubishiElectric.com
*At
an exchange rate of 112 yen to the US dollar, the rate given by the
Tokyo Foreign Exchange Market on March 31, 2017


Contacts


Mitsubishi Electric Corporation
Investor Relations Inquiries
Investor
Relations Group, Corporate Finance Division
Tel: +81-3-3218-2391
Cad.Irg@rk.MitsubishiElectric.co.jp
or
Media
Inquiries

Yurika Fujimoto, +81-3-3218-3380
Public
Relations Division
prd.gnews@nk.MitsubishiElectric.co.jp
www.MitsubishiElectric.com/news/



KITERETSU Now Launches a New Mobile Game "Dr. SUM" for All … 2017年04月28日 11時00分


Do Fun Maths with "Dr. SUM" KITERETSU's New Release on iOS and Android


TOKYO--(BUSINESS WIRE)--KITERETSU’s newest game app out now on App Store and Google Play. It is
a simple but very fun sum puzzle game everyone can enjoy.








Dr. SUM is a sum puzzle game with very new ideas! You switch the number
panels to make the sums right in both row and column. However, in some
stages, you have to make 6 as 9 and vice versa, reverse plus and minus
and many other tricks are included. As you clear the regular stages, you
can unlock some bonus stages such as Time Attack mode and Endless Level
mode.



If you connect Dr. SUM with your Facebook account, you can post your
high score and you can see how your friends are doing on Friends
Leaderboard.



Download the game now!
App Store: https://itunes.apple.com/jp/app/id1197286886
Google
Play: https://play.google.com/store/apps/details?id=jp.kiteretsu.DrSum



About KITERETSU



KITERETSU is an entertainment company founded in 2007. It creates games
and animation. Its most successful game “Zookeeper” has been played by
over 30 million people in many countries. KITERETSU is now focusing on
HTML5 games and is planning to develop/release over 10 games in the next
6 months. Also, it is developing the brand new Zookeeper game for
iOS/Android.



Title: Dr. SUM
Genre: Sum Puzzle
Official
KITERETSU website: http://kiteretsu.jp/en




Contacts


KITERETSU inc.
Yuko Ando, +81-3-5725-1102
corporate@kiteretsu.jp



Famotidine Sales, Price Analysis, & Sales Forecasts 2017 - … 2017年04月28日 05時05分

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Famotidine
Sales, Price Analysis, & Sales Forecast - 2017"
report to
their offering.




Find out the sales of Famotidine worldwide and by countries in North
America, Europe, Japan, BRIC, and Australia. Discover the growth trends
of Famotidine by countries, and also find out the sales forecast until
2021.



The research also provides Famotidine unit price by countries. The sales
and price data from this report is useful for analyzing Famotidine sales
trends, the sales forecast for Famotidine, brand planning, Famotidine
generics trends, product positioning, strategic forecasts, BD&L,
competitive intelligence, pricing analysis, and price benchmarks.



Benefits to the User



- Identify companies marketing Famotidine by major countries



- Find out Famotidine sales, growth, and sales forecast by major
countries; use it for your market planning - market assessments, market
sizing, market shares, BD&L, product strategy, positioning, and
competitive intelligence



- Determine the price of Famotidine in major markets; use it to devise
pricing strategies, estimate patient shares, develop patient forecast
models, and estimate annual therapy costs



- Derive unit sales of Famotidine by countries using pricing and sales
data; use it for your market planning - market assessments, market
sizing, market shares, BD&L, product strategy, positioning, and
competitive intelligence



Key Topics Covered:



1. Famotidine - Introduction



2. Famotidine Sales Analysis



3. Famotidine Sales by Countries



4. Famotidine Price Analysis by Countries



5. Famotidine Sales Forecast



6. Famotidine Sales Forecast by Countries



For more information about this report visit http://www.researchandmarkets.com/research/gd7q2g/famotidine_sales.




Contacts


Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For
EST Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related
Topics: Gastrointestinal
Drugs

Imperas Software Selects eSOL TRINITY for Distribution Part… 2017年04月28日 01時38分


eSOL TRINITY Partners with Imperas to Deliver Sales and Support for
Imperas Virtual Platforms Accelerating Embedded Systems and Software
Development, Debug and Test





OXFORD, England--(BUSINESS WIRE)--#Imperas--Imperas
Software Ltd.
, the leader in high-performance software simulation
and virtual platforms for embedded systems and software development,
debug and test, today announced an extended sales and technical support
partnership with eSOL TRINITY Co., Ltd. (TRINITY) for Imperas virtual
platform solutions in Japan.



TRINITY, focusing on design and development of embedded software, will
provide pre- and post-sales technical support, consulting, training, and
implementation for the complete portfolio of Imperas virtual prototyping
solutions. With this new relationship, TRINITY will now handle sales of
Imperas products in Japan. TRINITY also leverages the power of their
parent company eSOL
Co., Ltd.
, the leading provider in Japan of RTOS and real-time
embedded software solutions.



TRINITY has proven expertise in embedded software technology in the
Japanese market as well as in supporting customers, and will represent
Imperas solutions in embedded systems markets such as automotive,
industrial, consumer electronics, defense and aerospace.



Many such Japanese manufacturers are already using Imperas solutions,
supported by TRINITY, which especially benefits automotive embedded
software developers.



"Virtual platforms are moving into the mainstream of embedded software
flows. Imperas tools and models lead the market, and adding distribution
to our relationship enables us to provide complete and comprehensive
solutions to our customers," said Shuzo Tanaka, Vice President of eSOL
TRINITY



“We are excited to extend the relationship with TRINITY because of their
demonstrated expertise and leadership in the embedded software
community, including the automotive segment,” said Larry Lapides,
Imperas Vice President of Sales. “With our growing list of users in
Japan, it is important to provide them with the high level of
capabilities that TRINITY brings to our partnership.”



TRINITY will demonstrate Imperas solutions at the Embedded
Systems Expo & Conference
, in May 2017, at Tokyo Big Sight in
Japan.



The Imperas product portfolio represented by TRINITY includes Imperas
virtual platform -based embedded software development, debug, analysis
and verification solutions including the Open
Virtual Platforms™ (OVP™)
models. In addition to the sales and
support provided by TRINITY, the technology partnership between Imperas
and TRINITY includes:




This new partnership builds on the previous
relationship between Imperas and eSOL TRINITY
dating from November
2015.



About eSOL TRINITY



For more information about eSOL TRINITY, please see www.esol-trinity.co.jp.



About Imperas



For more information about Imperas, please see www.imperas.com.
Follow us on Twitter
@ImperasSoftware
and on LinkedIn.



All trademarks or registered trademarks are the property of Imperas
Software Limited or their respective holders.




Contacts


Imperas Software Ltd.
Larry Lapides, 925-519-1234
larryl@imperas.com

Sex Toys Market in Japan - Analysis, Technologies & Forecas… 2017年04月27日 22時09分

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Sex
Toys Market in Japan 2017-2021"
report to their offering.




The sex toys market in Japan to grow at a CAGR of 7.72% during the
period 2017-2021.



The report, Sex Toys Market in Japan 2017-2021, has been prepared based
on an in-depth market analysis with inputs from industry experts. The
report covers the market landscape and its growth prospects over the
coming years. The report also includes a discussion of the key vendors
operating in this market.



One trend in the market is growing use of vibrators for therapeutic
purposes. Vaginal dryness, changes in the firmness and elasticity of
vaginal muscles, and imbalance in hormonal levels that affect vaginal
moisture are some of the key issues affecting aging women.



According to the report, one driver in the market is evolving perception
of sex toys. Sexuality and sexual experimentation have long been subject
to social stigmas and taboos in most societies. However, the perception
of sex has been changing as consumers are becoming more sexually
empowered with increased awareness and a supportive environment. Various
masturbation aids such as vibrators are available through retail and
online channels. Atypical sexual practices such as BDSM and diverse
sexualities such as homosexuality were earlier viewed as a perversion in
most cultures. However, they are gaining acceptance in most cultures.
This, along with increased sexual exploration has strengthened the
demand in the market.



Key vendors




  • California Exotic Novelties


  • TENGA


  • FUN FACTORY




Other prominent vendors




  • Kanojo Toys (e-commerce)


  • Meiki Toys.com


  • NIGHT LOVE STORY (NLS)


  • TOMAX USA




Key Topics Covered:



PART 01: Executive summary



PART 02: Scope of the report



PART 03: Research Methodology



PART 04: Introduction



PART 05: Market landscape



PART 06: Market segmentation by distribution channel



PART 07: Market segmentation by product type



PART 08: Decision framework



PART 09: Drivers and challenges



PART 10: Market trends



PART 11: Vendor landscape



PART 12: Key vendor analysis



PART 13: Appendix



For more information about this report visit http://www.researchandmarkets.com/research/jmrs2q/sex_toys_market


Contacts


Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related
Topics: Personal
Care Products

Kyocera, Gaia Power, Kyudenko and Tokyo Century Announce Gr… 2017年04月27日 21時07分


Spanning across approximately 494 acres, the plant provides
equivalent power for roughly 33,370 households


KYOTO, Japan--(BUSINESS WIRE)--Kyocera Corporation, K.K. GAIA POWER, Kyudenko Corporation and Tokyo
Century Corporation announced today that Kanoya Osaki Solar Hills LLC, a
solar power operating company jointly established by the four companies,
has launched construction of a 92-megawatt (MW) solar power plant.
Located on a site stretching across Kanoya City and Osaki Town in
Kagoshima Prefecture, the project will become one of the largest*1
solar installations in the Kyushu region of Japan spanning across
approximately 494 acres (2,000,000m2), making it almost the
same size as the country Monaco. A ceremony was held on April 27 to
commemorate the plant’s groundbreaking.



















































Project Overview



Project name

 

Kanoya Osaki Solar Hills Solar Power Plant

Location


Kanoya City and Osaki Town in Kagoshima Prefecture, Japan

Output


Approx. 92MW


Expected annual power
generation




Approx. 99,230MWh/year
Electricity generated will provide the
equivalent power for roughly 33,370 average households*2.

Solar modules



340,740 Kyocera modules (planned)



Total investment


Approx. 35 billion yen (approx. USD315 million*3)

Project timeline

 


April 3, 2017: Start of construction
January 2020: Start of
operation (planned)



 


Project planning began in January 2014, as the local community expressed
interest in repurposing land that was designated for a golf course more
than 30 years ago but subsequently abandoned. The site plan will
accommodate 340,740 Kyocera solar modules and is expected to generate
roughly 99,230MWh annually — enough electricity to power approximately
33,370 typical households, offsetting roughly 52,940 tons of CO2
emissions per year*4.



Under the agreement, Kanoya Osaki Solar Hills LLC will operate the
business, and a consortium established by Kyudenko and Gaia Power is
undertaking the design, construction and maintenance of the solar
installation. Kyocera is supplying its high-efficiency solar modules and
Tokyo Century is responsible for the finance arrangement. Approximately
35 billion yen (approx. USD315 million) in investment is planned for the
project, with a goal to begin operations in January 2020.



The massive installation is expected to contribute to the local
community through job creation and increase of tax revenues in Kanoya
City and Osaki Town. In addition to obtaining forestland development
permission, a year-long environmental impact assessment has been
completed for the large-scale project. Furthermore, the plant will
feature an environmentally friendly design by minimizing land
development. The companies will continually work with Kagoshima
Prefecture, Kanoya City, Osaki Town and other members of the community
to complete construction, and they remain committed to promoting
renewable energy as well as contributing to environmental protection and
the creation of a sustainable society.































Company Overview



Company name

 

Kanoya Osaki Solar Hills LLC

Location


Kanoya City, Kagoshima Prefecture, Japan

Established


May 27, 2014

Shareholders

 


K.K. GAIA POWER: 72.7%
Kyocera Corporation: 9.1%
Kyudenko
Corporation: 9.1%
Tokyo Century Corporation: 9.1%



 






























Role of Participating Companies



Business operation

 

Kanoya Osaki Solar Hills LLC


Design, construction and
maintenance




Consortium established by Kyudenko Corporation and K.K. GAIA POWER

Supply of solar modules


Kyocera Corporation

Finance arrangement

 

Tokyo Century Corporation

 


























*1

 

Among operating solar power plants. Based on research by the four
companies (as of April 1, 2017)

*2


Based on average annual use of 2,973.6kWh per household. Source:
Japan Atomic Energy Relations Organization (Graphical Flip-chart of
Nuclear & Energy Related Topics 2016)

*3


For the reader’s convenience; based on an exchange rate of JPY111 =
USD1 (as of April 26, 2017).

*4


Based on calculations derived from standards created by JPEA in 2016

 


About
KYOCERA



Kyocera
Corporation
(NYSE:KYO)(TOKYO:6971), the parent and global
headquarters of the Kyocera Group, was founded in 1959 as a producer of fine
ceramics
(also known as “advanced ceramics”). By combining these
engineered materials with metals and integrating them with other
technologies, Kyocera has become a leading supplier of solar power
generating systems, mobile phones, printers, copiers, electronic
components, semiconductor packages, cutting tools and industrial
ceramics. During the year ended March 31, 2016, the company’s
consolidated net sales totaled 1.48 trillion yen (approx. USD13.1
billion). Kyocera appears on the “Top 100 Global Innovators” list by
Clarivate Analytics and is ranked #531 on Forbes magazine’s 2016 “Global
2000” list of the world’s largest publicly traded companies.


Contacts


KYOCERA Corporation (Japan)
Hina Morioka, +81-(0)75-604-3416
Corporate
Communications
webmaster.pressgl@kyocera.jp
Fax:
+81-(0)75-604-3516

Toshiba Tec's Pioneering Carbon Zero Initiative Receives Un… 2017年04月27日 20時00分

TOKYO--(BUSINESS WIRE)--#Carbonzeroscheme--Toshiba
Tec Corporation
(TOKYO:6588) has announced that its pan-European Carbon
Zero Scheme
is an official partner to the United
Nations’ (UN) Sustainable Development Goals (SDGs)
and is now listed
on its website.
This significant achievement is the latest development in Toshiba Tec’s
longstanding objective of reducing its environmental impact, as well as
helping its customers lower their own carbon footprints.




In September 2015, 193 world leaders agreed to 17 universal goals
consisting of 169 individual targets that frame their agendas and
political policies until 2030 with the aim of ending poverty, protecting
the planet, and ensuring prosperity for all. The Partnerships for SDGs
online platform functions as a tool to inform all stakeholders on
initiatives carried out by multi-stakeholder partnerships in support of
SDGs and links progress of those initiatives to various follow up
mechanisms of the 2030 Agenda.



Responsible business and investment are considered essential to attain
transformational change through the SDGs. For companies, successful
implementation will strengthen the enabling environment for doing
business and building markets around the world. At present more than
2,000 partnership initiatives and commitments are listed on the UN’s
website, including Toshiba’s Carbon Zero Scheme.



Since its launch in 2009, Toshiba Carbon Zero Scheme offsets the carbon
generated from parts procurement and manufacture of devices through to
delivery to the customer, in cooperation with CO2balance,
the leading global carbon management company. Toshiba Tec has reached
the milestone to offset 500,000 tons of CO2e which its amount is
equivalent to the annual emission from almost 110,000 European homes or
keeping 11.5 million energy saving light bulbs switched on for a year.
All carbon emissions have been offset through projects that help benefit
the lives of individuals in developing countries.



Initiatives include an energy efficient stoves project, in which
villagers in Kenya reduce their use of wood for fuel through the
provision of highly efficient stoves. Further projects currently
underway include the creation of boreholes in Uganda that supply clean,
safe water, as well as work on reducing deforestation in the Amazon
rainforest in Brazil. The Carbon Zero Scheme therefore aligns itself
perfectly with the SDGs relating to no poverty, zero hunger and clean
water and sanitation.



In addition to the European Carbon Zero Scheme, Toshiba Tec is actively
involved in similar initiatives across the world. These are one of the
activities to achieve its environmental policy, the “Three Greens”:
Greening of Products, Greening of Process, and Green Management.



About Toshiba Tec



Toshiba Tec Corporation is a Toshiba’s group company, a leading provider
of technology solutions, operating across multiple industries – ranging
from retail, education and business services to hospitality and
manufacturing. With headquarters in Japan and over 80 subsidiaries
worldwide, Toshiba Tec Corporation helps organizations transform the way
they create, record, share, manage and display information.



Please visit http://www.toshibatec.co.jp/en/
For
Europe please visit: https://www.toshibatec.eu/
For
Global site please visit http://www.toshibatec.com/global/



Unless otherwise specified and/or credited all images, artwork, text and
graphics, logos and logotypes are the copyright and/or trademark of the
respective owners. All rights reserved.




Contacts


Media Contact
Toshiba Tec Germany Imaging Systems GmbH
Andreas
Kleinschmidt, +49-2131-1245-252
European Marketing & Business
Development
andreas.kleinschmidt@toshibatec-tgis.com
or
Toshiba
Tec Corporation
Toshihiko “Tommy” Minato, +81-(0)50-3681-5528
Marketing
Department
Products, Marketing & Service Division
Printing
Solutions Business Group
Toshihiko_Minato@toshibatec.co.jp

Announcement of Additional Disclosure with Respect to Panas… 2017年04月27日 19時42分

OSAKA, Japan--(BUSINESS WIRE)--As announced in the press release titled “Announcement of Commencement
of Tender Offer for Share Certificates, Etc. of PanaHome Corporation
(Stock Code: 1924) and Termination of Share Exchange Agreement between
Panasonic Corporation and PanaHome Corporation” dated April 21, 2017
(the “April 21, 2017 Press Release”), Panasonic Corporation (the “Tender
Offeror”) resolved at a meeting of its board of directors held on April
21, 2017 to implement a tender offer (the “Tender Offer”), with the
commencement date of the Tender Offer being April 28, 2017, as a part of
a transaction aiming to acquire all of the shares of common stock (the
“Target Company’s Shares”) of PanaHome Corporation (Stock Code: 1924,
First Section of the Tokyo Stock Exchange, Inc. (the “Tokyo Stock
Exchange”), the “Target Company”) (excluding the Target Company’s Shares
held by the Tender Offeror and the treasury shares held by the Target
Company) and make the Target Company a wholly owned subsidiary of the
Tender Offeror. Pursuant to the “Memorandum of Understanding with
respect to the Termination of the Share Exchange Agreement and
Implementation of the Tender Offer” entered into by and between the
Tender Offeror and the Target Company as of April 21, 2017 (the “MoU”),
the implementation of the Tender Offer is subject to each of the
following conditions being satisfied: (i) from the execution date of the
MoU until the commencement date of the Tender Offer, no event that will
have a material adverse effect on the businesses, assets, debts,
financial position, results of operations, cash flow or profit plans has
occurred or realized in relation to the Target Company itself or the
whole group including the Target Company and its subsidiaries, and no
other event that will be a material interference of the achievement of a
purpose of the Tender Offer has occurred or realized; (ii) the Target
Company’s meetings of its board of directors lawfully and validly
resolve to express an opinion in favor of the Tender Offer, and to
recommend that the shareholders of the Target Company accept the Tender
Offer, and such resolution has not been changed or withdrew; (iii) there
are no judgements, decisions or orders, etc. by a judicial or
administrative body that restrict or prohibit the commencement of the
Tender Offer and there are no procedures pending in a judicial or
administrative body seeking to restrict or prohibit the commencement of
the Tender Offer; and (iv) there are no unpublicized material facts (the
material facts set forth in paragraph 2, Article 166 of the Financial
Instruments and Exchange Act (Act No. 25 of 1948, as amended, the “Act”)
with respect to the Target Company and the Tender Offeror is not aware
of any unpublicized facts concerning a tender offer, etc. (the facts set
forth in paragraph 3, Article 167 of the Act) of the Target Company’s
Shares. At this time, the Tender Offeror has confirmed that such
conditions have been satisfied. Therefore, the Tender Offeror hereby
announces that it will, in accordance with the resolution of its board
of directors mentioned above, implement the Tender Offer with the
commencement date of the Tender Offer being April 28, 2017 as scheduled.
For details of the Tender Offer, please refer to the April 21, 2017
Press Release.




Furthermore, since it has become necessary to make certain additions and
changes with respect to the statements in the April 21, 2017 Press
Release due to developments on and after April 21, 2017, we hereby
announce such additions and changes as set forth below. The added and
changed portions are underlined.



2. Outline of the Tender Offer



(4) Basis of Calculation, etc. of the Tender Offer Price



(i) Basis of Calculation



(Before addition and change)



(Omitted)



The Tender Offer Price, 1,200 yen per share, represents (a) a premium of
40.35% (rounded to second decimal place; the same
applies to the calculation of premium
) on 855 yen, which is the
closing price of the Target Company’s Share quoted on the First Section
of the Tokyo Stock Exchange on December 19, 2016, which is the business
day immediately preceding the announcement date of the Share Exchange
and it is considered that such price is not affected by the Transaction
to Make the Target Company a Wholly Owned Subsidiary, (b) a premium of
47.24% on 815 yen, which is the simple average closing price of the
Target Company’s Share quoted for the past one (1) month (from November
21, 2016 to December 19, 2016), (c) a premium of 51.32% on 793 yen,
which is the simple average closing price of the Target Company’s Share
quoted for the past three (3) months (from September 20, 2016 to
December 19, 2016), and (d) a premium of 50.00% on 800 yen, which is the
simple average closing price of the Target Company’s Share quoted for
the past six (6) month (from June 20, 2016 to December 19, 2016).



The Tender Offer Price, 1,200 yen per share, represents (a) a premium of
18.46% on 1,013 yen, which is the closing price of the Target Company’s
Shares quoted on the Tokyo Stock Exchange on April 20, 2017, which is
the business day immediately preceding the announcement date of the
Tender Offer by the Tender Offeror, (b) a premium of 18.81% on 1,010
yen, which is the simple average closing price of the Target Company’s
Shares quoted for the past one (1) month (from March 21, 2017 to April
20, 2017), (c) a premium of 18.34% on 1,014 yen, which is the simple
average closing price of the Target Company’s Shares quoted for the past
three (3) months (from January 23, 2017 to April 20, 2017), and (d) a
premium of 28.62% on 933 yen, which is the simple average closing price
of the Target Company’s Shares quoted for the past six (6) months (from
October 21, 2016 to April 20, 2017).



(After addition and change)



The Tender Offer Price, 1,200 yen per share, represents (a) a premium of
40.35% (rounded to second decimal place; the same
applies to the calculation of premiums and discount
) on 855 yen,
which is the closing price of the Target Company’s Share quoted on the
First Section of the Tokyo Stock Exchange on December 19, 2016, which is
the business day immediately preceding the announcement date of the
Share Exchange and it is considered that such price is not affected by
the Transaction to Make the Target Company a Wholly Owned Subsidiary,
(b) a premium of 47.24% on 815 yen, which is the simple average closing
price of the Target Company’s Share quoted for the past one (1) month
(from November 21, 2016 to December 19, 2016), (c) a premium of 51.32%
on 793 yen, which is the simple average closing price of the Target
Company’s Share quoted for the past three (3) months (from September 20,
2016 to December 19, 2016), and (d) a premium of 50.00% on 800 yen,
which is the simple average closing price of the Target Company’s Share
quoted for the past six (6) month (from June 20, 2016 to December 19,
2016).



The Tender Offer Price, 1,200 yen per share, represents (a) a premium of
18.46% on 1,013 yen, which is the closing price of the Target Company’s
Shares quoted on the Tokyo Stock Exchange on April 20, 2017, which is
the business day immediately preceding the announcement date of the
Tender Offer by the Tender Offeror, (b) a premium of 18.81% on 1,010
yen, which is the simple average closing price of the Target Company’s
Shares quoted for the past one (1) month (from March 21, 2017 to April
20, 2017), (c) a premium of 18.34% on 1,014 yen, which is the simple
average closing price of the Target Company’s Shares quoted for the past
three (3) months (from January 23, 2017 to April 20, 2017), and (d) a
premium of 28.62% on 933 yen, which is the simple average closing price
of the Target Company’s Shares quoted for the past six (6) months (from
October 21, 2016 to April 20, 2017).
In
addition, the Tender Offer Price, 1,200 yen per share, represents (a) a
discount of 2.04% on 1,225 yen, which is the closing price of the Target
Company’s Shares quoted on the Tokyo Stock Exchange on April 27, 2017,
which is the business day immediately preceding the commencement date of
the Tender Offer, (b) a premium of 14.07% on 1,052 yen, which is the
simple average closing price of the Target Company’s Shares quoted for
the past one (1) month (from March 28, 2017 to April 27, 2017), (c) a
premium of 16.28% on 1,032 yen, which is the simple average closing
price of the Target Company’s Shares quoted for the past three (3)
months (from January 30, 2017 to April 27, 2017), and (d) a premium of
26.45% on 949 yen, which is the simple average closing price of the
Target Company’s Shares quoted for the past six (6) months (from October
28, 2016 to April 27, 2017).



(6) Transfer of Ownership Percentage of Shares through the Tender Offer,
etc.














































(Before addition and change)



Number of Voting Rights Represented by Shares Held by the Tender
Offeror before the Tender Offer, etc.

 

91,036

 

(Ownership Percentage of


Shares before the Tender Offer, etc.: 54.18%)



Number of Voting Rights Represented by Shares Held by the Special
Related Parties before the Tender Offer, etc.



To be



determined





(Ownership Percentage of



Shares before the Tender Offer, etc.: To be
determined
)



Number of Voting Rights Represented by Shares Held by the Tender
Offeror after the Tender Offer, etc.


168,021


(Ownership Percentage of


Shares after the Tender Offer, etc.: 100.00%)



Number of Voting Rights Represented by Shares Held by the Special
Related Parties after the Tender Offer, etc.


0


(Ownership Percentage of


Shares after the Tender Offer, etc.: 0.00%)



Total Number of Voting Rights of All Shareholders of the Target
Company


(As of September 30, 2016)



 

166,982

 

 

 


(Note 1) The “Number of Voting Rights Represented by Shares Held by the
Tender Offeror after the Tender Offer, etc.” is the number of voting
rights obtained by adding the “Number of Voting Rights Represented by
Shares Held by the Tender Offeror before the Tender Offer, etc.” to the
number of voting rights pertaining to the number of shares to be
purchased in the Tender Offer.



(Note 2) Although the “Number of Voting
Rights Represented by Shares Held by the Special Related Parties before
the Tender Offer, etc.” and its “Ownership
Percentage of Shares before the Tender Offer, etc.” are unknown at
present, such figures will be investigated and disclosed by April 27,
2017, the day before the commencement day of the Tender Offer Period
.
In addition, since all of the Target Company’s Shares held by the Target
Company which is a special related party (541,791 shares, as of March
31, 2017) are treasury shares, there are no voting rights. Further,
since the number of the Target Company’s Shares held by special related
parties is also subject to the Tender Offer, in spite of the results of
the investigation above, the “Number of Voting Rights Represented by
Shares Held by the Specially Related Parties after the Tender Offer,
etc.” and its “Ownership Percentage of Shares after the Tender Offer,
etc.” are described as 0 and 0.00%.



(Note 3) The “Total Number of Voting Rights of All Shareholders of the
Target Company” represents the total number of voting rights of all
shareholders of the Target Company as of September 30, 2016, as
described in the Target Company’s 60th FY 3Q Securities Report filed as
of February 10, 2017 (described on the basis that 1 unit is 1,000
shares). However, as fractional shares of less than one unit and
cross-held shares are subject to the Tender Offer, in calculating the
Ownership Percentage of Shares before the Tender Offer, etc.” and the
Ownership Percentage of Shares after the Tender Offer, etc.,” the
denominator is the number of voting rights (168,021) corresponding to
the number of shares (168,021,742 shares) obtained by deducting (a) the
number of treasury shares held by the Target Company as of March 31,
2017 (541,791 shares), from (b) the number of issued shares of the
Target Company as of March 31, 2017 (168,563,533 shares).



(Note 4) The “Ownership Percentage of Shares before the Tender Offer,
etc.” and the “Ownership Percentage of Shares after the Tender Offer,
etc.” are rounded up or down to second place.














































(After addition and change)



Number of Voting Rights Represented by Shares Held by the Tender
Offeror before the Tender Offer, etc.

 

91,036

 

(Ownership Percentage of


Shares before the Tender Offer, etc.: 54.18%)



Number of Voting Rights Represented by Shares Held by the Special
Related Parties before the Tender Offer, etc.



273



 


(Ownership Percentage of



Shares before the Tender Offer, etc.: 0.16%)



Number of Voting Rights Represented by Shares Held by the Tender
Offeror after the Tender Offer, etc.


168,021


(Ownership Percentage of


Shares after the Tender Offer, etc.: 100.00%)



Number of Voting Rights Represented by Shares Held by the Special
Related Parties after the Tender Offer, etc.


0


(Ownership Percentage of


Shares after the Tender Offer, etc.: 0.00%)



Total Number of Voting Rights of All Shareholders of the Target
Company


(As of September 30, 2016)



 

166,982

 

 

 


(Note 1) The “Number of Voting Rights Represented by Shares Held by the
Tender Offeror after the Tender Offer, etc.” is the number of voting
rights obtained by adding the “Number of Voting Rights Represented by
Shares Held by the Tender Offeror before the Tender Offer, etc.” to the
number of voting rights pertaining to the number of shares to be
purchased in the Tender Offer.



(Note 2) The “Number of Voting Rights Represented by Shares Held by the
Special Related Parties before the Tender Offer, etc.”
is the total number of the voting rights represented by the share
certificates, etc. held by each of the special related parties
(excluding the parties who are excluded from the special related
parties, pursuant to Article 3, Paragraph 2, Item 1 of the TOB Order, in
calculating the ownership percentage of share certificates, etc.
pursuant to each of the Items of Article 27-2, Paragraph 1 of the Act)
.
In addition, since all of the Target Company’s Shares held by the Target
Company which is a special related party (541,791 shares, as of March
31, 2017) are treasury shares, there are no voting rights. Further,
since the share certificates, etc. held by the special related parties
(excluding the treasury shares held by the Target Company) will also be
subject to the Tender Offer, the “Number of Voting Rights Represented by
Shares Held by the Special Related Parties before the Tender Offer,
etc.” is not added to the numerator in calculating the “Ownership
Percentage of Shares after the Tender Offer, etc.”



(Note 3) The “Total Number of Voting Rights of All Shareholders of the
Target Company” represents the total number of voting rights of all
shareholders of the Target Company as of September 30, 2016, as
described in the Target Company’s 60th FY 3Q Securities Report filed as
of February 10, 2017 (described on the basis that 1 unit is 1,000
shares). However, as fractional shares of less than one unit and
cross-held shares are subject to the Tender Offer, in calculating the
Ownership Percentage of Shares before the Tender Offer, etc.” and the
Ownership Percentage of Shares after the Tender Offer, etc.,” the
denominator is the number of voting rights (168,021) corresponding to
the number of shares (168,021,742 shares) obtained by deducting (a) the
number of treasury shares held by the Target Company as of March 31,
2017 (541,791 shares), from (b) the number of issued shares of the
Target Company as of March 31, 2017 (168,563,533 shares).



(Note 4) The “Ownership Percentage of Shares before the Tender Offer,
etc.” and the “Ownership Percentage of Shares after the Tender Offer,
etc.” are rounded up or down to second place.



4. Other Information



(2) Other Information Considered to be Necessary for Investors to
Determine Whether to Tender the Tender Shares in the Tender Offer



(Before addition and change)



(a) Details, etc. of Information Received on a Fact Concerning Launch of
a Tender Offer



The Tender Offeror received information from the Target Company on
February 22, 2017 that Oasis informed the Target Company of Oasis’s
intention to purchase the Target Company’s Shares at 1,050 yen per share
subject to due diligence and to conduct a tender offer subject to the
support of the Target Company as of February 22, 2017. In
addition, the Tender Offeror received information from the Target
Company as of today that the Target Company received a letter from Oasis
stating that Oasis has an intention to purchase all of the issued shares
of the Target Company.
For details of the information received,
the matters set forth in Article 62-2, Item 1 of the Cabinet Office
Ordinance on Restrictions on Securities Transactions, etc. are as
follows.













































 

Name of the tender offeror, etc. pertaining to the tender offer

 

Oasis Management Company Ltd.

Address or location


Ugland House, PO Box 309, Grand Cayman, KY1-1104, Cayman Islands.

Name of issuer of the relevant shares, etc. and the class thereof


PanaHome Corporation


Common shares



Period of the tender offer, etc.


Unknown

Price of the tender offer, etc.


JPY 1,050

Number of share certificates, etc. to be purchased


All of the issued shares


Details of the conditions set forth in each item of Article 27-13,
Paragraph 4 of the Act



 

Unknown

 


(b) Details, etc. of Information Received on a Fact Concerning Launch of
a Tender Offer



(Omitted)



(After addition and change)



(a) Details, etc. of Information Received on a Fact Concerning Launch of
a Tender Offer



The Tender Offeror received information from the Target Company on
February 22, 2017 that Oasis informed the Target Company of Oasis’s
intention to purchase the Target Company’s Shares at 1,050 yen per share
subject to due diligence and to conduct a tender offer subject to the
support of the Target Company as of February 22, 2017. In
addition, the Tender Offeror received information from the Target
Company on April 21, 2017 that the Target Company received a letter from
Oasis on the same day stating that Oasis’s proposal of such tender offer
is to purchase all of the issued shares of the Target Company subject to
the approval of the shareholder who holds majority of the Target
Company’s Shares.
For details of the information received, the
matters set forth in Article 62-2, Item 1 of the Cabinet Office
Ordinance on Restrictions on Securities Transactions, etc. are as
follows.













































 

Name of the tender offeror, etc. pertaining to the tender offer

 

Oasis Management Company Ltd.

Address or location


Ugland House, PO Box 309, Grand Cayman, KY1-1104, Cayman Islands.

Name of issuer of the relevant shares, etc. and the class thereof


PanaHome Corporation


Common shares



Period of the tender offer, etc.


Unknown

Price of the tender offer, etc.


JPY 1,050

Number of share certificates, etc. to be purchased


All of the issued shares

Details of the conditions set forth in each item of Article 27-13,
Paragraph 4 of the Act

 

Unknown

 


(b) Details, etc. of Information Received on a Fact Concerning Launch of
a Tender Offer



(Omitted)



(c) The Target Company’s Financial Results



The Target Company has announced “Consolidated
Financial Results for the Fiscal Year Ended March 31, 2017” as of April
27, 2017.
According to this announcement,
the consolidated profit and loss, etc. for the fiscal year ended March
31, 2017 (from April 1, 2016 to March 31, 2017) of the Target Company
are as follows.
According to the Target
Company, such financial results have not been audited by an auditing
firm pursuant to paragraph 1, Article 193-2 of the Act.
For
details, please refer to the Target Company’s announcement.
















































 


(i) Profit & Loss




Fiscal Year



 


Fiscal Year Ended March 31, 2017
(consolidated)




Net sales





359,607 million yen




Cost of Sales





277,928 million yen




Selling, general and administrative expenses





69,829 million yen




Non-operating income





481 million yen




Non-operating expenses





697 million yen




Net income attributable to owners of parent



 


7,559 million yen



 
































 


(ii) Per Share Information




Fiscal Year



 


Fiscal Year Ended March 31, 2017
(consolidated)




Net income per share





45.02 yen




Amount of cash dividends per share





21.00 yen




Net assets per share



 


915.49 yen



 


Moreover, according to this press release, the
Target Company determined that, if it is confirmed that the Target
Company would become a wholly owned subsidiary of the Tender Offeror by
the end of October 2017, the Target Company would not make interim
dividends for the fiscal year ended March 31, 2018.


































 


[Soliciting Regulations]



This press release is a news statement intended for the announcement
of the Tender Offer to the general public and is not intended for
soliciting an offer to sell the shares in connection with the Tender
Offer. If anyone desires to sell his or her shares, a shareholder
should, at his or her own responsibility, review the tender offer
explanatory statement for the Tender Offer and accept the Tender
Offer in his or her own discretion. This press release is not
considered as an offer or solicitation of sales of securities or
solicitation of offer of purchase of securities and does not
constitute any such part. This press release (or any part of it) or
the fact of its distribution does not provide a basis for any kind
of agreement pertaining to the Tender Offer, and it may not be
relied upon when executing any such agreement.


[Regulations of the United States]



The Tender Offeror, each of the financial advisors to the Tender
Offeror and the Target Company, and tender offer agent (including
their affiliated companies) may, in its ordinary business, purchase
shares in the Target Company’s Shares for its own account or for the
account of its clients prior to the Tender Offer or during the
tender offer period for the Tender Offer outside the Tender Offer in
accordance with the requirements of Rule 14e-5(b) of the U.S.
Securities Exchange Act of 1934 or take actions for such purchase to
the extent permitted by financial instruments and exchange related
laws and regulations and other applicable laws and regulations of
Japan. If any information concerning such purchase is disclosed in
Japanese, the purchasing party will disclose such information on its
English website (or by any other means of public disclosure).


[Forward-Looking Statements]



This press release includes “forward-looking statements” that
include those within the meaning of Section 27A of the U.S.
Securities Act of 1933, as amended, and Section 21E of the U.S.
Securities Exchange Act of 1934. Known and unknown risks,
uncertainties and other factors may cause the actual results to be
materially different from the forecast, etc. expressed or implied by
the “forward-looking statements”. The Tender Offeror and its related
parties do not warrant the achievement of the result expressed or
implied by the “forward-looking statements.” The “forward-looking
statements” in this press release is based on the information
currently available to the Tender Offeror. The Tender Offeror and
its related party undertake no obligation to publicly update or
revise the “forward-looking statements” to reflect the matters and
situations in the future unless it is required by the laws and
regulations.


[Other Countries]



In certain countries or regions, the announcement, issue or
distribution of this press release may be restricted by laws or
regulations. In such cases, you are required to be aware of such
restrictions and comply with the laws and regulations of such
countries or regions. This press release does not constitute any
solicitation of an offer to sell or offer to purchase shares in
relation to the Tender Offer, and shall be considered as a mere
distribution of informative materials.

 






































































































 


Disclaimer Regarding Forward-Looking Statements




This press release includes forward-looking statements of the
Panasonic Group. To the extent that statements in this press
release do not relate to historical or current facts, they
constitute forward-looking statements. These forward-looking
statements are based on the current assumptions and beliefs of the
Panasonic Group in light of the information currently available to
it, and involve known and unknown risks, uncertainties and other
factors. Such risks, uncertainties and other factors may cause the
Panasonic Group's actual results, performance, achievements or
financial position to be materially different from any future
results, performance, achievements or financial position expressed
or implied by these forward-looking statements. The Panasonic
Group undertakes no obligation to publicly update any
forward-looking statements after the date of this press release.
Investors are advised to consult any further disclosures by the
Tender Offeror in their subsequent filings under the Financial
Instrument and Exchange Act of Japan (the FIEA) and other publicly
disclosed documents.




The risks, uncertainties and other factors referred to above
include, but are not limited to, the factors listed below. The
factors listed below are not all-inclusive and further information
is contained in the most recent English translated version of the
Tender Offeror’s securities reports under the FIEA and any other
documents which are disclosed on its website.







 

 

Economic conditions, particularly consumer spending and corporate
capital expenditures in the Americas, Europe, Japan, China and other
Asian countries







Volatility in demand for electronic equipment and components from
business and industrial customers, as well as consumers in many
product and geographical markets







The possibility that excessive currency rate fluctuations of the
U.S. dollar, the euro, the Chinese yuan and other currencies against
the yen may adversely affect costs and prices of the Tender
Offeror’s products and services and certain other transactions that
are denominated in these foreign currencies







The possibility of the Panasonic Group incurring additional costs of
raising funds, because of changes in the fund raising environment







The possibility of the Panasonic Group not being able to respond to
rapid technological changes and changing consumer preferences with
timely and cost-effective introductions of new products in markets
that are highly competitive in terms of both price and technology







The possibility of not achieving expected results or incurring
unexpected losses in connection with the alliances or mergers and
acquisitions







The possibility of not being able to achieve its business objectives
through joint ventures and other collaborative agreements with other
companies, including due to the pressure of price reduction
exceeding that which can be achieved by its effort and decrease in
demand for products from business partners which Panasonic highly
depends on in B2B business areas







The possibility of the Panasonic Group not being able to maintain
competitive strength in many product and geographical areas







The possibility of incurring expenses resulting from any defects in
products or services of the Panasonic Group







The possibility that the Panasonic Group may face intellectual
property infringement claims by third parties;







Current and potential, direct and indirect restrictions imposed by
other countries over trade, manufacturing, labor and operations







Fluctuations in market prices of securities and other assets in
which the Panasonic Group has holdings or changes in valuation of
long-lived assets, including property, plant and equipment and
goodwill, deferred tax assets and uncertain tax positions; future
changes or revisions to accounting policies or accounting rules







The possibility of incurring expenses resulting from a leakage of
customers’ or confidential information from Panasonic Group systems
due to unauthorized access or a detection of vulnerability of
network-connected products of the Panasonic Group





 

 

Natural disasters including earthquakes, prevalence of infectious
diseases throughout the world, disruption of supply chain and other
events that may negatively impact business activities of the
Panasonic Group.

 

Contacts


Panasonic Corporation
Media Contacts:
Chieko
Gyobu (Japan)
Public Relations Department
(Tel:
+81-3-3574-5664)
Panasonic News Bureau (Japan)
(Tel:
+81-3-3542-6205)
Jim Reilly (U.S.)
(Tel: +1-201-392-6067)
Anne
Guennewig (Europe)
(Tel: +49-611-235-457)

or
Investor
Relations Contacts:
Yasumichi Murase (Japan)
Corporate
Planning Department
(Tel: +81-6-6908-1121)
Yuko Iwatsu (U.S.)
(Tel:
+1-201-348-7000)
Noboru Uchiyama (Europe)
(Tel:
+44-1344-853135)





Read full story here

パナソニック:中国 大連の車載用リチウムイオン電池新工場が開所 2017年04月27日 14時04分


車載電池セルのグローバル生産体制を構築


大阪--(BUSINESS WIRE)--(ビジネスワイヤ) -- パナソニック株式会社
オートモーティブ&インダストリアルシステムズ社は、中国大連市に建設を進めていた車載用リチウムイオン電池の新工場が竣工し、本日開所式を挙行しました。同工場は、中国における当社初の車載電池セルの生産拠点となります。日本・アメリカ・中国での生産体制を構築することで、車載電池のグローバル競争力を一層強化してまいります。








環境意識の高まりを背景に、ハイブリッド自動車、プラグインハイブリッド車、電気自動車など環境対応車の市場が年々拡大しています。当社は、グローバルで複数の自動車メーカーに車載用リチウムイオン電池の供給実績があり、車載電池市場をリードしています。また、高性能な車載用リチウムイオン電池の需要のさらなる高まりを受け、国内生産拠点での増産に加えて、2017年からはアメリカでの車載電池セル生産も開始します。今回竣工した工場は、2016年2月に大連遼無二電器有限会社と設立した車載電池製造の合弁会社の新工場となります。



当社は、創業100周年にあたる2018年度にインフォテインメントシステムやデバイスを含む車載事業全体で2兆円の売上を目指しています。今回の新工場を、中国における中核の製造拠点として成長させるとともに、さらなる車載電池事業の強化を図ってまいります。







































































【新工場概要】


敷地面積: 



 

約170,000㎡

建屋面積:



約80,000㎡



生産品目: 


環境対応車向けの角形リチウムイオン電池

生産開始: 


2017年度

 

【合弁会社概要】(2017年4月時点)

会 社 名: 


パナソニック オートモーティブエナジー大連有限会社

所 在 地: 


中国 遼寧省大連保税区海明路177号

設立時期: 


2016年2月

資 本 金:



2億7,300万元



代 表 者: 


董事長 劉 国臣、総経理 山西 伸和

事業内容: 


環境対応車向け電池の設計・製造・販売、サービス等

従業員数:


約500人(2017年度予定)

 


●写真ダウンロードホームページのご案内
「Panasonic Newsroom Japan」の各リリースページよりダウンロードできます。
URL: http://news.panasonic.com/jp/press




Contacts


【報道関係者 お問合せ先】
パナソニック株式会社
オートモーティブ&インダストリアルシステムズ社
広報2課 
電話06-6904-4732 

Panasonic Opens New Automotive Lithium-Ion Battery Factory … 2017年04月27日 14時04分


With this new factory in China, Panasonic establishes a global
battery cell production system for eco-friendly vehicles






OSAKA, Japan--(BUSINESS WIRE)--#automotive--Panasonic Corporation (TOKYO:6752) announced today that it held an
opening ceremony for a new automotive lithium-ion battery factory in
Dalian, China.






The factory is Panasonic's first automotive battery cell production site
in China. Panasonic will further strengthen its global competitiveness
in the automotive battery industry by the establishment of production
sites in Japan, the United States, and China.



With an increasing awareness of environmental issues, the market for
eco-friendly vehicles is expanding every year, including hybrid, plug-in
hybrid, and all-electric vehicles. Panasonic has provided automotive
lithium-ion batteries to a number of auto manufacturers on a global
basis and is leading the automotive battery market. Furthermore, in
response to further increase in the demand of high-performance
automotive lithium-ion batteries, Panasonic not only increased
production at Japanese sites but will also start automotive battery cell
production in the United States in 2017. The newly constructed factory
in China is a new production facility of Panasonic Automotive Energy
Dalian Co., Ltd., an automotive battery joint venture established
between Panasonic and Dalian Levear Electric Co., Ltd. in February 2016.



Panasonic is aiming to achieve 2 trillion yen in sales for the overall
automotive business, including infotainment systems and industrial
devices, in the fiscal year 2019 (ending March 31, 2019) which marks the
100th anniversary of the company’s founding. Panasonic will
develop the new factory into a core manufacturing site in China, and
further strengthen its automotive battery business.







































































[Overview of the new factory]

Site area:

 

Approx. 170,000 m2

Floor area:


Approx. 80,000 m2

Production items:


Prismatic type lithium-ion batteries for eco-friendly vehicles

Production launch:


Fiscal 2018, ending March 31, 2018

 

[Overview of the joint venture company (as of April 2017)]

Name:


Panasonic Automotive Energy Dalian Co., Ltd.

Location:


177 Haiming Street, Dalian Free Trade Zone, Liaoning, People's
Republic of China

Establishment:


February 2016

Capital:


273 million RMB

Representatives:


Chairman: Guochen Liu, Managing Director: Nobukazu Yamanishi

Business operations:


Design, manufacture, sales, and after-sales services of automotive
batteries for eco-friendly vehicles.

Employees:


Approx. 500 (FY2018 plan)

 


About Panasonic
Panasonic
Corporation is a worldwide leader in the development of diverse
electronics technologies and solutions for customers in the consumer
electronics, housing, automotive, enterprise solutions and device
industries. Since its founding in 1918, the company has expanded
globally and now operates 474 subsidiaries and 94 associated companies
worldwide, recording consolidated net sales of 7.553 trillion yen for
the year ended March 31, 2016. Committed to pursuing new value through
innovation across divisional lines, the company uses its technologies to
create a better life and a better world for its customers. To learn more
about Panasonic: http://www.panasonic.com/global.




Contacts


Media Contacts:
Public Relations Department
Panasonic
Corporation

Tel: +81-(0)3-3574-5664
Fax:
+81-(0)3-3574-5699



Astellas Reports Full Year FY2016 Financial Results 2017年04月27日 12時06分



  • Sales decreased (-4.4%) on a reported basis and increased
    approximately 2% excluding the factors associated with the transfer of
    the global dermatology business implemented in April 2016 and the
    impact of the foreign exchange; Increased core operating profit
    (+2.7%) and core profit (+7.3%)


  • Sales of XTANDI® (enzalutamide) and overall overactive
    bladder (“OAB”) treatments steadily increased on a constant currency
    basis


  • Sales in the Americas, EMEA1, Asia and Oceania decreased
    while increased on a constant currency basis. Sales in Japan decreased
    due to impacting factors such as a National Health Insurance (“NHI”)
    drug price revision


  • Astellas continues to create solid and resilient growth over the
    mid-to-long term



    • Astellas completed the acquisition of Ganymed Pharmaceuticals AG
      (“Ganymed”) in December 2016


    • Astellas entered into a definitive agreement under which Astellas
      has agreed to acquire Ogeda SA (“Ogeda”) in March 2017;
      The
      procedures required for this acquisition are still in progress (as
      of April 2017).




TOKYO--(BUSINESS WIRE)--Astellas Pharma Inc. (TOKYO:4503)(President and CEO: Yoshihiko Hatanaka,
“Astellas”) today announced the financial results for fiscal year 2016
(“FY2016”) ended March 31, 2017.




“We achieved multiple milestones including the acquisition of
Ganymed last December and an agreement with Ogeda shareholders to
acquire Ogeda last month. These acquisitions and other alliances will
expand Astellas’ late-stage pipeline and contribute to its mid-to-long
term growth,” said Yoshihiko Hatanaka, President and CEO, Astellas. “We
remain committed to creating innovative medical solutions and delivering
value for patients and all stakeholders, as we continue to advance our
strategic plan through maximizing the product value, creating innovation
and pursuing operational excellence in the fiscal year 2017.”


























































 


Consolidated Financial Results (April 1, 2016 – March 31, 2017)
(core basis)
(Millions of yen)



 

 

FY2015

 

FY2016

 

Change
(%)

Sales


1,372,706


1,311,665


-61,041


(-4.4%)



Core operating profit


267,456


274,554


+7,098


(+2.7%)



Core profit for the year


198,802


213,343


+14,541


(+7.3%)



Basic core earnings per share (yen)

 

92.12

 

101.15

 

+9.03


(+9.8%)



 


Full-Year Financial Results



Sales for the full-year of FY2016 decreased by 4.4% compared to the
previous fiscal year (“year-on-year”) and resulted in 1,311.7 billion
yen. Sales decreased due to the impact of foreign exchange as well as
the impact of the NHI drug price revision in Japan enforced in April
2016. Sales increased by approximately 2% year-on-year excluding the
factors associated with the transfer of the global dermatology business
implemented in April 2016 and the impact of the foreign exchange.



In terms of global products, sales of XTANDI® marginally
increased and sales of overall OAB treatments Vesicare®
(solifenacin succinate) and Betanis® / Myrbetriq®
/ BETMIGA® (mirabegron) decreased due to the impact of
foreign exchange, but sales of each product steadily increased on a
local currency basis. Prograf® (tacrolimus) sales also
decreased.



[ Sales by Region1 ]




  • Sales in Japan decreased by 3.3% year-on-year to 480.8 billion
    yen. Sales in the Japanese market decreased by 6.3% year-on-year to
    452.7 billion yen mainly due to the impact of the NHI drug price
    revision. Sales growth continued for products such as overall OAB
    treatments (Vesicare® and Betanis®), Celecox®
    (celecoxib), Symbicort® (budesonide and formoterol fumarate
    dihydrate) and Suglat® (ipragliflozin). Sales of XTANDI®
    decreased due to the impact of the NHI drug price revision. Sales of
    vaccines declined due to the continued impact of shipping restraints
    by the manufacturer in FY2015 (shipments of some of the products have
    already recommenced). Revenues were impacted by the decline in sales
    of products including Lipitor® (atorvastatin calcium) and
    Gaster® (famotidine) mainly due to the impact of generics.


  • Sales in the Americas decreased by 9.4% year-on-year to 412.4
    billion yen; however sales on a U.S. dollar basis increased by 0.5%
    year-on-year to 3,805 million USD. The increase in sales of CRESEMBA®
    (isavuconazonium sulfate) contributed to the sales growth. Sales of
    products including XTANDI®, overall OAB treatments (VESIcare®
    and Myrbetriq®) and Lexiscan® (regadenoson)
    decreased due to the impact of foreign exchange, while the sales of
    each product on a US dollar basis increased.


  • EMEA saw a 0.5% increase in sales year-on-year to 330.8 billion
    yen, with growth driven by XTANDI®. Sales on a euro basis
    increased by 12.1% year-on-year to 2,785 million euros. Sales of
    overall OAB treatments (Vesicare® and BETMIGA®)
    and Prograf® declined due to the impact of foreign exchange.


  • In Asia and Oceania, sales decreased by 3.8% year-on-year to
    87.7 billion yen, while the sales on a constant currency basis
    increased by approximately 9%. XTANDI® and overall OAB
    treatments (Vesicare® and BETMIGA®) contributed
    to the revenue growth. Sales of Prograf® and Harnal®
    (tamsulosin hydrochloride) declined mainly due to the foreign exchange
    impact.



Other Financial Highlights



Based on the transfer of the global dermatology business in April 2016,
the sales and expenses of the transferred products were not included in
FY2016; however the consideration for the business transfer was
recognized as revenue over certain periods. As a result, there were
certain positive impacts on sales and profit in FY2016.



Strategic Highlights in FY2016



Astellas continues to create sustainable growth over the mid-to-long
term through the pursuit of three main strategies – “Maximizing the
Product Value,” “Creating Innovation” and “Pursuing Operational
Excellence.” The company achieved multiple accomplishments throughout
FY2016 including the following highlights outlined below.



Maximizing the Product Value




  • Continued to maximize the growth of the oncology franchise centered on
    XTANDI® and the OAB franchise comprised of Vesicare®
    and Betanis® / Myrbetriq® / BETMIGA®
    with new launches across various countries and growth in sales


  • With respect to the update of the product label for XTANDI®,
    including the data from the head-to-head TERRAIN trial of enzalutamide
    versus bicalutamide, the Company obtained regulatory approvals in
    Europe and the U.S., and the product label was updated in April 2016
    in Europe, and October 2016 in the U.S.


  • Launched multiple products including Repatha® (evolocumab),
    PCSK9-inhibitor for the treatment of hypercholesterolemia in April
    2016; Micatrio® Combination Tablets (telmisartan /
    amlodipine besylate / hydrochlorothiazide) for the treatment of
    hypertension in November 2016; Kiklin® Granules (bixalomer)
    for the treatment of hyperphosphatemia in December 2016; and guanylate
    cyclase-C receptor agonist, LINZESS (linaclotide), for the treatment
    of the irritable bowel syndrome with constipation in March 2017 were
    all launched in Japan.



Creating Innovation




  • Completion of the acquisition of Ganymed.


  • Definitive agreement under which Astellas has agreed to acquire Ogeda.
    The
    procedures required for this acquisition are still in progress (as of
    April 2017).



The following list highlights alliances with external partners announced
during FY2016:




  • Entered into a collaborative research agreement with the National
    Institute of Advanced Industrial Science and Technology to discover
    anti-protozoan parasite drugs for the treatment of Chagas’ disease in
    April 2016.


  • Announced the conclusion of a joint research agreement with Daiichi
    Sankyo Company, Limited and Takeda Pharmaceutical Company Limited to
    comprehensively acquire and analyze fundamental biomarker data in May
    2016.


  • Entered into a collaborative development agreement with the Institute
    of Medical Science, the University of Tokyo, to develop a rice-based
    oral vaccine in June 2016.


  • Expanded its collaboration agreement in skeletal muscle activators
    with Cytokinetics, Inc. (U.S.) (“Cytokinetics”) to include amyotrophic
    lateral sclerosis (“ALS”) in July 2016. Through this amendment, the
    development of fast skeletal troponin activator, CK-2127107 for the
    potential treatment of ALS, will be conducted.


  • Established DigiTx Partners LLC (U.S.), a digital health investment
    company in partnership with MPM Capital, Inc. (U.S.) in July 2016.
    DigiTx Partners LLC will invest in the digital health space broadly.


  • Signed a memorandum of understanding to create a method for analyzing
    circulating tumor cells, with Sysmex Corporation and Daiichi Sankyo
    Company Limited in December 2016.


  • Executed a license agreement with respect to an exclusive worldwide
    license for the AU-935 program for the treatment of chronic tympanic
    membrane perforation with Auration Biotech, Inc. (U.S.) in January
    2017.


  • Entered into an exclusive worldwide license agreement to develop and
    commercialize a vaccine targeting Streptococcus pneumoniae
    (pneumococcus) with Affinivax, Inc. in February 2017.



The following lists the main development advances achieved during FY2016:




  • Submitted applications for approval of extended-release tablets of
    quetiapine fumarate (generic name, development code: FK949E) for the
    indication of the improvement of depressive symptoms associated with
    bipolar disorder in August 2016 in Japan.


  • Obtained approval of Kiklin® Granules in September 2016 in
    Japan.


  • Submitted applications for the approval of XTANDI® Tablets
    in September 2016 in Japan.


  • Obtained marketing approval for a guanylate cyclase-C receptor
    agonist, LINZESS®, for the indication of irritable bowel
    syndrome with constipation in December 2016 in Japan.


  • Submitted an application for the approval of romosozumab (generic
    name, development code: AMG 785) for the treatment of osteoporosis for
    those at high risk of fracture in December 2016 in Japan.



Pursuing Operational Excellence



The following lists the main operational excellence initiatives which
occurred during FY2016:




  • Transferred the global dermatology business to LEO Pharma S/A
    (headquarters: Denmark) in April 2016.


  • Began operations for Malaysia-based subsidiary, Astellas Pharma
    Malaysia Sdn. Bhd. in April 2016. In addition, the SESA Umbrella
    Organization which is responsible for overseeing operations in the
    South East and South Asia regions was established and began operation
    in April 2016.


  • Transferred the manufacturing subsidiary, Astellas Pharma
    Technologies, Inc. (U.S.) to Avara Norman Pharmaceutical Services,
    Inc. (U.S.) in August 2016.


  • Decided to outsource facility and equipment management support in
    Japan, and dissolve Astellas Business Service Company Limited in
    November 2016.


  • Transferred commercial rights for Qutenza® (capsaicin 8%
    patch) to Grünenthal in December 2016.


  • Concluded a memorandum of understanding concering the extablishment of
    a new structure in Sapporo, Hokkaido with Takeda Pharmaceutical
    Company Limited, Teva Takeda Pharma Ltd. and Teva Takeda Yakuhin Ltd.
    in February 2017.


  • Entered into an agreement providing Kyowa Pharmaceutical Industry Co.,
    Ltd. the exclusive right to distribute and promote extended-release
    tablets of quetiapine fumarate in Japan in February 2017.


  • Entered into an asset purchase agreement with LTL Pharma Co., Ltd.,
    under which Astellas will transfer its marketing authorization of 16
    long-listed products (the “Products”) in Japan, supply business of
    active pharmaceutical ingredients / bulk of the Products to third
    parties inside and outside of Japan and royalty business of the
    Products to LTL Pharma, in March 2017.



2017 Financial Guidance



The forecasts for the fiscal year ending March 31, 2018 (“FY2017”) (core
basis) are shown in the table below. The sales forecast is 1,279.0
billion yen (-2.5% year-on-year). While we anticipate continuous sales
growth for XTANDI®, our mainstay product, and also for OAB
treatments due to the growth of Betanis® / Myrbetriq®
/ BETMIGA®, we expect negative impact on sales and profit
from the transfer of the global dermatology business implemented in
April 2016 and the transfer of long-listed products in Japan for which
an agreement was concluded in March 2017. We project a core operating
profit of 254.0 billion yen (-7.5% year-on-year). However, we forecast
core operating profit excluding the factors associated with the
transfers of the dermatology business and long-listed products in Japan
as stated above and the impact of the foreign exchange to be higher
year-on-year.





























































 


Consolidated Full-year Business Forecasts (core basis)




(Millions of yen)



 

 

FY2016


Full-year results



 

FY2017


Full-year forecasts



 

Change
(%)

Sales


1,311,665


1,279,000


-32,665


(-2.5%)



Core Operating profit


274,554


254,000


-20,554


(-7.5%)



Core Profit for the year


213,343


195,000


-18,343


(-8.6%)



Basic earnings per share (yen)

 

101.15

 

94.43

 

-6.72


(-6.6%)



 


NOTE: For further information on the results, please refer to the
reference documents: Financial Results, Supplementary Documents,
Overview of R&D Pipeline and Presentation Material for Information
Meeting available on the Astellas website.



About Astellas



Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to
improving the health of people around the world through the provision of
innovative and reliable pharmaceutical products. We focus on Urology,
Oncology, Immunology, Nephrology and Neuroscience as prioritized
therapeutic areas while advancing new therapeutic areas and discovery
research leveraging new technologies/modalities. We are also creating
new value by combining internal capabilities and external expertise in
the medical/healthcare business. Astellas is on the forefront of
healthcare change to turn innovative science into value for patients.
For more information, please visit our website at www.astellas.com/en.



Cautionary Notes



In this press release, statements made with respect to current plans,
estimates, strategies and beliefs and other statements that are not
historical facts are forward-looking statements about the future
performance of Astellas. These statements are based on management’s
current assumptions and beliefs in light of the information currently
available to it and involve known and unknown risks and uncertainties. A
number of factors could cause actual results to differ materially from
those discussed in the forward-looking statements. Such factors include,
but are not limited to: (i) changes in general economic conditions and
in laws and regulations, relating to pharmaceutical markets, (ii)
currency exchange rate fluctuations, (iii) delays in new product
launches, (iv) the inability of Astellas to market existing and new
products effectively, (v) the inability of Astellas to continue to
effectively research and develop products accepted by customers in
highly competitive markets, and (vi) infringements of Astellas’
intellectual property rights by third parties.
Information about
pharmaceutical products (including products currently in development)
which is included in this press release is not intended to constitute an
advertisement or medical advice.



1 Europe, the Middle East and Africa
2 Based
on location of sellers




Contacts


Contacts for inquiries or additional information:
Astellas
Pharma Inc.
Corporate Communications
TEL: +81-3-3244-3201
FAX:
+81-3-5201-7473
or
US Media:
Astellas US LLC
Tarsis
Lopez, 224-205-8833
tarsis.lopez@astellas.com

横河電機 「Total Insight」コンセプトのもと電磁流量計「ADMAG… 2017年04月27日 11時00分


~製品ライフサイクル全般にわたって運用コスト低減に貢献~


東京--(BUSINESS WIRE)--(ビジネスワイヤ) -- 横河電機株式会社(本社:東京都武蔵野市 代表取締役社長:西島 剛志)は、「Total Insight(トータル
インサイト)」コンセプトのもと、電磁流量計の新シリーズとして「ADMAG Total Insight(アドマグ・トータル・インサイト)」シリーズを開発、5月15日に発売しますのでお知らせします。
「ADMAG
Total Insight」
シリーズは、口径400mm以下の「ADMAG
AXF(アドマグ・エーエックスエフ)」を刷新した口径500mm以下の「ADMAG AXG(アドマグ・エーエックスジー)」と、従来の対応口径500mm~1800mmを25mm~1800mmに拡大した「ADMAG
AXW(アドマグ・エーエックスダブリュ)」
の2つのラインアップで構成されます。








「Total
Insight」は、製品のライフサイクル全般にわたりお客様の運用コスト低減に貢献する当社流量計のコンセプトです。当社は本コンセプトのもと、幅広くお客様のニーズに応え、電磁流量計分野においてより一層のシェア拡大を目指します。



開発の背景



電磁流量計は工業計測の中で重要とされる流量計測のなかでも汎用性や適用口径バリエーションの広さ、対応用途の広さに優れ、幅広く使用されています。当社は高精度、高耐食性を要求される用途を中心に400mm以下の口径において、世界初となる二周波励磁方式を実現し、耐流体ノイズ性などで高い基本性能を持つ「ADMAG
AXF」を提供してきました。また、水や水をベースとした流体を中心とした汎用的で500mm以上の口径の用途に「ADMAG AXW」を提供してきました。
今回、「Total
Insight」コンセプトのもと、ライフサイクルのフェーズごとに必要な機能やアプリケーションごとに求められる性能を見直し、導入コスト最適化、保守コストの削減、機器の最大活用などが可能となるようこれまでの機種構成の見直しと機能の追加を行い、「ADMAG
Total Insight」
シリーズを開発しました。



製品の特長



新シリーズでは、高精度、高耐食性が求められる用途に「ADMAG AXG」、水や水をベースとした流体を中心とした汎用用途に「ADMAG
AXW」
をラインアップしています。接液ライニング材質は「ADMAG AXG」では従来機種の「ADMAG
AXF」と同様、信頼性に定評のあるセラミックスやフッ素樹脂PFAを選択可能で、「ADMAG AXW」では対応口径の種類を増やしたことにより25mm~400mmの口径でも、フッ素樹脂PTFEや天然硬質ゴムなどが選択可能です。お客様はご自身のプロセスに応じた材質・精度の製品を選ぶことで、初期導入費用を抑制することができます。また、新搭載の機能により、製品・プラントライフサイクル全般にわたる運用コスト低減を実現します。














































 


【製品ラインアップ】



名称

 

アプリケーション

 

対応口径

 

接液ライニングの材質

 

指示値に対する
測定精度

ADMAG AXG


化学薬品、スラリー、食品・飲料



2.5mm~500mm




フッ素樹脂PFA、セラミックス


±0.15%
(高精度型)

ADMAG AXW

 

水、水ベースの流体

 

25mm~1800mm

 


フッ素樹脂PTFE、ポリウレタンゴム、



天然硬質ゴム、天然軟質ゴム



 

±0.35%

 


1.導入時のソリューション~適切な機器の選択



用途別に一般用、サニタリー用(食品・薬品用)、水中用(一時的な水没用)、危険場所用の防爆用※1などがあり、それぞれ口径、ライニング材質、信号入出力の点数、精度によって、非常に多様な製品選択肢をご提供します。仕様の選定ツール※2を利用することで簡単に最適な機器の選定が可能になります。パラメータは、指定の値を設定して出荷することができ、また現場で変換器の表示画面から対話形式で、簡単に設定変更することもできます。



※1:2017年12月 発売予定
※2:2017年10月 公開予定



2.運用時のソリューション~機器状態の効率的な管理



流量計の状態を示す多彩なアラームの機能を持っており、それぞれのアラームにおいて、警告や警報として取り扱うかどうかを個別に設定することが可能です。また、アラーム発生時の出力信号の動作も、パルス信号、アナログ信号それぞれで個別に設定することができ、機器の効率的な管理を実現します。さらに今回新たに搭載したデータロギング機能により、4種類の異なる種類の出力信号を同時に記録することができます。オプションのmicroSDカードを使用することにより記録したデータを取り出すことが可能になり、不具合発生時の解析作業効率が向上します。



3. 導入後のソリューション~予防保全への貢献と柔軟な機能拡張



運転中でも機器の健全性を総合的に診断することができる「健全性診断機能」を搭載しており、機器は自ら磁気回路、励磁回路、演算回路、アラーム履歴などのチェックを行います。これにより、従来の時間ベースの定期的メンテナンスから、機器の状態に応じた適切なタイミングでの保守が可能となり、保守コスト削減につながります。併せて、プロセスの異常を検出する「アプリケーション診断機能」も搭載しました。流体の気泡混入や流体の導電率低下などの異常を検知した場合には、アラーム発報の接点信号を出力させることを可能にしました。信号が安定しない場合には、パラメータの設定による細かな調整が可能です。



【 主な市場 】
石油・ガス、化学、紙パルプ、食品・飲料、鉱業などの各種産業



【 用途 】
導電性液体の流量測定



【 製品に関する詳細情報 】
「ADMAG Total Insight」シリーズ www.admagti.com




Contacts


●本プレスリリースに関するお問い合わせ先:
横河電機株式会社
コミュニケーション統括センター 広報室
Yokogawa-pr@cs.jp.yokogawa.com

Yokogawa Develops the ADMAG Total Insight Electromagnetic F… 2017年04月27日 11時00分


–Optimizing operations and reducing maintenance costs at all phases of
the product lifecycle–


TOKYO--(BUSINESS WIRE)--Yokogawa Electric Corporation (TOKYO:6841) announces that it has
developed the ADMAG Total Insight (TI) series, a new portfolio of
electromagnetic flowmeters, and will release it on May 15.








The ADMAG TI series consists of the ADMAG AXG and the ADMAG AXW
electromagnetic flowmeters. The ADMAG AXG is a complete redesign of the
ADMAG AXF and will accommodate bore diameters from 2.5 mm up to 500 mm,
while the revamped ADMAG AXW will accommodate bore diameters ranging
from 25 mm to 1800 mm.



Total Insight is a Yokogawa concept for optimizing operations and
reducing maintenance costs through every phase of the product lifecycle.
Based on this concept, Yokogawa aims to better meet its customer needs
and expand its share of the electromagnetic flowmeter market.



Development Background



Thanks to their versatile ability to handle a wide range of applications
and accommodate pipes of all sizes, electromagnetic flowmeters are
widely used for measuring flow rates, which is an important function for
the control of industrial processes. For enhanced immunity to flow
noise, Yokogawa pioneered the use of the dual frequency excitation
method in electromagnetic flowmeters, and employed this technology in
its development of the ADMAG AXF, which comes in sizes of up to 400 mm
and is intended for applications that require high accuracy and high
corrosion resistance. For general-purpose applications, Yokogawa has
been providing the ADMAG AXW. This accommodates pipe sizes 500 mm and up
and is ideal for water and water-based fluid applications.



In keeping with its Total Insight concept, Yokogawa has reviewed the
functions needed for each phase of the product lifecycle and the
performance required for each application. The company has thus reviewed
its product lineup and developed ADMAG TI, a portfolio of
electromagnetic flowmeters with new functions that will help to optimize
CAPEX, reduce OPEX, and accommodate a wider range of applications.



Product Features



The ADMAG AXG is intended for applications that require high accuracy
and high corrosion resistance, while the ADMAG AXW is for general
purpose applications that mainly involve water and water-based fluids.
As with the ADMAG AXF, ceramic and fluorocarbon PFA linings will be
available for the wetted parts of the ADMAG AXG, for added reliability.
With the revamped ADMAG AXW, fluorocarbon PTFE and natural hard rubber
linings will be available. (The ability to use these linings with bore
sizes between 25 and 400 mm is a Yokogawa first.) By choosing products
with the optimum materials and required level of accuracy for their
process, customers can reduce their CAPEX. New functions have been added
that will help reduce OPEX throughout the product and facility lifecycle.














































 


ADMAG TI portfolio



 

 

Application

 

Size

 

Lining material for wetted parts

 

Accuracy (of rate)

ADMAG AXG


Chemicals, slurries, foods & beverages


2.5 mm to 500 mm


Fluorocarbon PFA, ceramics



±0.15%
(High precision type)



ADMAG AXW

 

Water, water-based fluids

 

25 mm to 1800 mm

 


Fluorocarbon PTFE, polyurethane rubber, natural hard rubber,
natural soft rubber



 

±0.35%

 


1. Introduction phase solutions – selection tool and interactive guidance
The
ADMAG TI series includes general purpose, sanitary (for foods and
pharmaceuticals), submersible (for limited periods of time), and
explosion-proof*1 (for use in hazardous areas) models. For
each of these models, a variety of sizes, lining materials, number of
signal inputs/outputs, and precision levels will be available. A
selection tool*2 will simplify the process of selecting the
right flowmeter for a specific application. Device parameters can be set
before shipment and can also be easily changed by operators in the
field, using a wizard function on the device display.
*1 To be
released in December 2017
*2 To be released in October 2017



2. Operational phase solution – for the efficient management of
flowmeters
The ADMAG TI flowmeters have a variety of alarm
functions. For the various check items monitored by the ADMAG TI
flowmeters, users will be able to whether a warning message or alarm
will be issued. For optimal management of these devices, it will also be
possible to configure whether alarms are to be output as pulse or analog
signals. In addition, to facilitate troubleshooting, a new logging
function will be available for the simultaneous logging of four
different kinds of output signals. An optional microSD Card function
will also be available to facilitate the retrieval of data from the
field.



3. Post-implementation phase solution: facilitating preventive
maintenance and advanced flexibility
The ADMAG TI flowmeters will
have a built-in verification function that will be able to check their
magnetic, excitation, and operational circuits as well as alarm logs
while they are in operation. This function will help to facilitate the
shift from conventional periodical maintenance to condition-based
preventive maintenance, thus reducing OPEX. In addition, a new
application verification function will output an alarm contact signal
when a condition such as the presence of air bubbles or low conductivity
in a fluid is detected. And when an unstable output signal is detected,
parameter settings can be adjusted to fine-tune a process.



Major Target Markets



Industries such as oil and gas, mining, chemicals, pulp and paper, and
food and beverages



Applications



Measuring flow rates of conductive liquids



About Yokogawa



Yokogawa's global network of 114 companies spans 59 countries. Founded
in 1915, the US$3.7 billion company engages in cutting-edge research and
innovation. Yokogawa is active in the industrial automation and control
(IA), test and measurement, and aviation and other businesses segments.
The IA segment plays a vital role in a wide range of industries
including oil, chemicals, natural gas, power, iron and steel, pulp and
paper, pharmaceuticals, and food. For more information about Yokogawa,
please visit http://www.yokogawa.com



For more information



ADMAG Total Insight: www.admagti.com



The names of corporations, organizations, and products herein are either
trademarks or registered trademarks of their respective holders.




Contacts


Yokogawa Electric Corporation
Public Relations, Integrated
Communications Center
Yokogawa-pr@cs.jp.yokogawa.com

Starbucks Announces Reserve® Roastery Coming to Chicago’s M… 2017年04月26日 19時00分


One-of-a-kind coffee experience will be built in an iconic retail
space on North Michigan Avenue



Chicago Reserve® Roastery to be the third in the U.S. and sixth
internationally for the company as Starbucks continues to transform the
global coffee industry



New Roastery expands Starbucks portfolio of premium retail
experiences in Chicago, including a new Reserve® store concept opening
in 2018 and multiple Starbucks® stores with Reserve bars


SEATTLE--(BUSINESS WIRE)--Starbucks Coffee Company (NASDAQ: SBUX) today announced it will open a
Starbucks Reserve® Roastery in Chicago in 2019. Located on North
Michigan Avenue and Erie Street on Chicago’s Magnificent Mile, the
Chicago Reserve® Roastery represents the company’s third Roastery
location in the U.S. following Seattle, which opened in December 2014,
and New York City, which is on track to open in 2018. The company also
plans to offer customers multiple international Roastery experiences,
including Shanghai, opening late 2017, alongside Milan and Tokyo, slated
to open in 2018.








“Having opened our first Starbucks store in Chicago nearly thirty years
ago, our first outside of Seattle, this is a very special city for me.
At the time, it was a true test for Starbucks because the Chicago
customer is so savvy and discerning about their coffee,” said Howard
Schultz, Starbucks executive chairman. “Chicago is a city of
neighborhoods, so we took our time to find an incredible space to match
the unprecedented coffee experience our premium Roastery will offer. To
be located on one of the best-known retail streets in the world is a
proud moment for all of us and we can’t wait to bring Chicago and the
world a coffee experience worthy of their most premier real estate.”



“Chicago’s Magnificent Mile brings in millions of visitors from across
this globe and is the perfect location for a world-class coffee
destination,” Chicago Mayor Rahm Emanuel said. “This Starbucks Reserve
Roastery will be an investment in Chicago and a strong addition to
Michigan Avenue, where residents and visitors can enjoy incredible
coffees from around the world in a remarkable environment.”



Much like its flagship Seattle location, which was the most successful
store opening in the company’s history, the new Chicago Roastery will be
a fully sensorial coffee environment dedicated to roasting, brewing and
packaging its rare, small-batch Starbucks Reserve coffees from around
the world. Tailored to the Chicago customer, the interactive four-story,
43,000-square-foot space will also be designed to bring coffee craft to
life by offering multiple brewing methods, specialty Reserve beverages
and mixology.



“Howard and I share the same passion for the companies we created, each
centered around the customer experience and a relentless attention to
detail. This building has a unique way of becoming a beacon for a brand,
and I can’t think of a better retailer than Starbucks to offer Chicago
something new and exciting with its Reserve Roastery,” said Gordon
Segal, Founder, Crate and Barrel.



As announced at the company’s December Investor Day, Starbucks will also
include fresh baking on-site in all Reserve Roastery locations courtesy
of Italian baker Rocco Princi. Known for his artisan breads created from
traditional family recipes, Princi’s handcrafted food pairs perfectly
with Reserve coffee, elevating every daypart – breakfast, lunch and
dinner – in all Starbucks Roasteries. Princi food will also be available
in the company’s new Reserve stores, a retail concept inspired by the
Roastery but not yet open to the public. Starbucks has announced a
Reserve store coming to the West Loop in Chicago in 2018 and Seattle in
2017. During last year’s Investor Day, Starbucks confirmed that it would
open 20-30 Roastery locations, globally, over time and up to 1,000
Reserve stores.



The premium Starbucks Reserve brand is also coming to life in Starbucks
stores with the inclusion of Reserve experience bars in select locations
worldwide. Currently, there are 20 Starbucks stores in the U.S. with
Reserve bars – three in downtown Chicago and one in Lake Forest,
Illinois. This spectrum of Starbucks retail experiences is not new for
Chicago: Since opening in 1987, the Chicago customer has seen many
firsts from the company including early iterations of the third-place
experience, modular Drive Thru stores made from shipping containers, an
express format focused on the commuting customer, and more recently, the
opening of its first store in Englewood, providing job skills training
to youth in addition to investing in local women- and minority-owned
businesses while creating dozens of Chicago-area jobs.



About Starbucks



Since 1971, Starbucks Coffee Company has been committed to ethically
sourcing and roasting high-quality arabica coffee. Today, with more than
25,000 stores around the globe, Starbucks is the premier roaster and
retailer of specialty coffee in the world. Through our unwavering
commitment to excellence and our guiding principles, we bring the unique
Starbucks Experience to life for every customer through every cup. To
share in the experience, please visit our stores or online at news.starbucks.com
and Starbucks.com.



About Princi



Princi is a Milanese institution built around baking a range of quality
hand-made, wood-fired breads. You can learn more at http://www.princi.com/.


Contacts


Starbucks
Haley Drage, 206-318-7100
press@starbucks.com

Virtus Partners Acquires Front Office Financial Technology … 2017年04月26日 19時00分


Virtus Partners Acquires Alphakinetic


HOUSTON--(BUSINESS WIRE)--#VirtusPartners--Virtus Partners Holdings, LLC (“Virtus”), a market leader in
technology-enabled solutions for alternative asset managers, and
Alphakinetic, a London- based financial technology firm, announced today
the completed strategic acquisition of Alphakinetic’s business and
assets by Virtus. Alphakinetic is the developer of the Glide platform-
fund management software with trade order management, credit analysis
and risk management capabilities used by front office personnel at
investment management companies.



“The flexibility of Glide is 'best-in-class' for a front office platform
and very compatible with our existing technology stack,” stated Kelly
Faykus, Co-Founder and Managing Partner of Virtus. “This deal fits our
strategy of investing in capabilities to serve the needs of our clients
through every part of the fund management process.”



Virtus provides a comprehensive, integrated suite of front, middle, and
back office products and services for alternative assets. Its global
offering extends across collateral administration services for
structured transactions, middle office outsourcing, syndicated loan
data, fund administration, loan agency, and settlements. Today, the
company administers over $300 billion in global assets across its
platform.



“The deal is a fit at so many levels,” said Jon Hodges, Alphakinetic’s
CEO. “Glide is a uniquely flexible proposition for the front office and
we have a strong background in credit. We look forward to continuing to
drive forward our offering under the Virtus umbrella.” Mr. Hodges will
continue in a senior technology role and focus on the expansion of
Virtus Partners front office capabilities."



Mr. Faykus added, “By combining the Virtus Partners managed services
platform with Alphakinetic’s Glide software, we can provide credit
managers with a turnkey cloud-based credit platform. This combination is
a major step forward for the credit markets; we are now able to provide
a fully integrated platform that covers all aspects of trading from
trade order management to clearing for buyside clients. It is
transformative.”



About Alphakinetic



Alphakinetic is an established financial technology firm focused on
building flexible and scalable software for cross asset trading and risk
management. Alphakinetic is based in London. For more information please
visit: www.alphakinetic.com.



About Virtus Partners Holdings, LLC



Virtus specializes in tailored middle and back office solutions for
fixed income and alternative asset managers looking to outsource or
augment their administrative capabilities. Offices are in Houston,
Austin, New York, Nanjing, Dublin and London. For more information
please visit: www.virtusllc.com.




Contacts


Virtus Partners Holdings, LLC
Joe Elston
joe.elston@virtusllc.com

KKR Announces Tender Offer to Acquire Hitachi Kokusai Elect… 2017年04月26日 18時21分


Japan Industrial Partners and Hitachi to each acquire 20% of Hitachi
Kokusai’s Video and Communication Solutions segment following the
division of Hitachi Kokusai’s businesses


TOKYO--(BUSINESS WIRE)--Leading global investment firm KKR, Hitachi Ltd., (“Hitachi”) and Japan
Industrial Partners, Inc. (“JIP”) today announced that HKE Holdings G.K.
(the “Offeror”), an entity owned by investment funds managed by KKR,
intends to make a tender offer for the common shares of Hitachi Kokusai
Electric Inc. (“Hitachi Kokusai” or the “Company”; TSE stock code 6756).







Hitachi Kokusai operates two business segments: a Video and
Communication Solutions business engaged in video security, IoT
high-reliability wireless, and railroad solutions, and a Thin-Film
Process Solutions business focusing on semiconductor manufacturing
equipment as well as systems maintenance and sales of parts and used
equipment.



In connection with the tender offer, the Offeror has entered into an
agreement (the “Agreement”) with Hitachi, the lead shareholder in
Hitachi Kokusai, and HVJ Holdings Co., Ltd., (“HVJ”), an entity backed
by funds managed/ serviced by JIP. Under the terms of the Agreement,
following a share consolidation after the tender offer, Hitachi Kokusai
will acquire Hitachi’s 51.67% holding of Hitachi Kokusai’s common shares
in a share repurchase. Thereafter, Hitachi Kokusai will conduct an
absorption-type company split pursuant to which the Offeror will succeed
to 100% of the Company’s Thin-Film Process Solutions business.
Subsequently, the Offeror will transfer 20% of the shares of Hitachi
Kokusai to each of Hitachi and HVJ, resulting in 60%, 20%, and 20%
ownership of Hitachi Kokusai’s Video and Communication Solutions
business for the Offeror, Hitachi and HVJ, respectively.



Through this joint investment, KKR will collaborate with Hitachi Group
to further expand Hitachi Kokusai’s businesses, promote overseas growth,
and establish a stable business base through structural reforms. JIP
will support the maximization of the latent growth potential of Hitachi
Kokusai’s Video and Communications Solutions business utilizing the
wealth of experience it has accumulated in conducting multiple strategic
carve-outs from Japanese companies.



The Offeror expects to commence the tender offer in early August 2017,
subject to regulatory approvals in Japan and other jurisdictions. For
details regarding the conditions for the commencement of the tender
offer, please refer to the full text of the press release issued today
by Hitachi Kokusai titled “Announcement of Opinion regarding the Tender
Offer for the Shares of Hitachi Kokusai Electric Inc. by HKE Holdings
G.K.” and its attachment titled “Announcement Regarding the Tender Offer
for the Shares of Hitachi Kokusai Electric Inc. (Securities Code 6756)”
(the “HKE press release”).



The proposed tender offer price of JPY 2,503 per share and the share
repurchase price of JPY 1,710.34 per share have been determined based on
negotiations among KKR, Hitachi, and JIP. For further details, please
refer to the Hitachi Kokusai Press Release.



The proposed tender offer price represents:1




  • A premium of 62.46% to Hitachi Kokusai’s 12-month average closing
    price to October 3, 2016


  • A premium of 59.12% to Hitachi Kokusai’s 6-month average closing price
    to October 3, 2016.



Since the total number of Hitachi Kokusai’s outstanding shares
(excluding treasury shares) is equal to 102,703,392 (as of March 31,
2017), the proposed tender offer price values Hitachi Kokusai at
approximately JPY 257.1 billion (approx. US$2.3 billion at the exchange
rate of US$1=JPY111).



Mr. Hiro Hirano, Member of KKR and CEO of KKR Japan, said: “Hitachi
Kokusai is a world-class provider of video and communications equipment
and semiconductor manufacturing solutions and is part of an industry
that is set to benefit from the proliferation of three-dimensional NAND
flash memory. We look forward to leveraging KKR’s global network,
experience and resources, in partnership with Hitachi and JIP, to
strengthen Hitachi Kokusai’s business and support its growth as an
industry leader on the global stage.”



Mr. Hidemi Moue, CEO of JIP, said: “Hitachi Kokusai’s Video and
Communication Solutions business has a strong track record of sales of
communications and wireless equipment to local municipalities and
government agencies in Japan. In partnership with Hitachi and KKR, JIP
is fully committed to supporting the further enhancement of the
business’ products and services, and realizing a significant uplift in
growth as a fulfilling workplace for executives and employees, by
leveraging our expertise, network, and extensive investment experience
in carve-outs from major corporations in Japan.”



KKR expects to make its investment from its Asian private equity fund.
KKR has been investing in Japan through its pan-regional private equity
funds since 2010. Japan has been and continues to be a key focus for KKR
in the region. To date, KKR has completed five acquisitions in the
market: Intelligence Ltd., a leading human resources services company;
Panasonic Healthcare, the carve-out health care business of Panasonic
Corporation; and Pioneer DJ, the carve-out DJ equipment business of
Pioneer Corporation. More recently, KKR announced the closing of its
tender offers for Hitachi Koki Co., Ltd. and Calsonic Kansei Corporation.



JIP supports the revitalization of Japanese companies by providing funds
and management support, mainly associated with business carve-outs and
restructuring of major corporations. JIP has made a total of 20
investments within Japan across investment targets primarily within the
manufacturing industry in diverse areas including food, distribution and
services, and with investment experience across various investment
methods including business carve-outs and MBOs.



This press release should be read in conjunction with the full text of
the Hitachi Kokusai Press Release, a copy of which is available on www.jpx.co.jp



This press release has been prepared for the purpose of informing the
public of the tender offer and has not been prepared for the purpose of
soliciting an offer to sell, or making an offer to purchase, any
securities. If shareholders wish to make an offer to sell their shares
in the tender offer, they should first read the Tender Offer Explanation
Statement for the tender offer and offer their shares or stock options
for sale at their own discretion. This press release shall neither be,
nor constitute a part of, an offer to sell or purchase, or a
solicitation of an offer to sell or purchase, any securities, and
neither this press release (or a part thereof) nor its distribution
shall be interpreted to be the basis of any agreement in relation to the
tender offer, and this press release may not be relied on at the time of
entering into any such agreement.



The tender offer will be conducted in accordance with the procedures
and information disclosure standards prescribed by Japanese law, which
may differ from the procedures and information disclosure standards in
the United States. In particular, Section 13(e) and Section 14(d) of the
U.S. Securities Exchange Act of 1934 and the rules prescribed thereunder
do not apply to the tender offer, and the tender offer does not conform
to those procedures and standards.



Unless otherwise specified, all procedures relating to the tender
offer are to be conducted entirely in Japanese. If all or any part of a
document relating to the tender offer is prepared in the English
language and there is any inconsistency between the English-language
documentation and the Japanese-language documentation, the
Japanese-language documentation will prevail.



The financial advisors to the Offeror, the Company, JIP and Hitachi
as well as the tender offer agent (including their respective
affiliates) may engage prior to the commencement of, or during, the
tender offer period in the purchase or arrangement to purchase shares of
the Company for their own account or for their customers’ accounts to
the extent permitted under the Japanese Financial Instruments and
Exchange Act, Rule 14e-5(b) of the U.S. Securities Exchange Act of 1934,
as amended, and other applicable laws and regulations. Such purchases
may be made at the market price through market transactions, or at a
price determined by negotiation outside of the market. In the event
information regarding such purchases is disclosed in Japan, such
information will also be disclosed on the English homepage of the
financial advisor or tender offer agent conducting such purchases or
will otherwise be made publicly available.



About KKR



KKR is a leading global investment firm that manages investments across
multiple asset classes including private equity, energy, infrastructure,
real estate, credit and hedge funds. KKR aims to generate attractive
investment returns by following a patient and disciplined investment
approach, employing world‐class people, and driving growth and value
creation at the asset level. KKR invests its own capital alongside its
partners’ capital and brings opportunities to others through its capital
markets business. References to KKR’s investments may include the
activities of its sponsored funds. For additional information about KKR
& Co. L.P. (NYSE:KKR), please visit KKR’s website at www.kkr.com
and on Twitter @KKR_Co.



About Japan Industrial Partners, Inc.



JIP was established in November 2002, as a Japanese fund specializing in
carve-outs to develop the private equity business and contribute to
corporate reorganization and restructuring of Japanese companies. JIP
has specific expertise in companies working towards selecting and
focusing their businesses and with carve-outs of business divisions and
subsidiaries. In addition to helping companies provide high quality
products and services, JIP’s objective is to create a fulfilling
workplace for employees and support the acceleration of business growth.



1 The figures set out above are based on the Hitachi Kokusai
closing share prices extracted from Bloomberg as at and prior to the
last full trading day (October 3, 2016) immediately prior to the day of
speculative publication of media reports regarding the tender offer (the
‘unaffected price’).


Contacts


For KKR
Anita Davis (Asia)
+852 3602 7335
anita.davis@kkr.com
or
Kristi
Huller (New York)
+1 212 230 9722
kristi.huller@kkr.com
or
Ashton
Consulting (For KKR Japan)
+81-3-5425-7220
KKRJapanPR@ashton.jp
or
For
JIP

Toshikazu Ugawa
+81-3-6266-5781
jipinc@jipinc.com

The Industrial Internet Consortium and the Industrial Value… 2017年04月26日 17時40分

HANNOVER, Germany--(BUSINESS WIRE)--#IIConsortium--The
Industrial Internet Consortium
® (IIC), the world’s leading
organization transforming business and society by accelerating the
Industrial Internet of Things (IIoT), and the Industrial Value Chain
Initiative (IVI), a forum of smart manufacturing for connected
industries based in Japan, announced they have signed a memorandum of
understanding (MoU). Under the agreement, the IIC and the IVI will work
together to align efforts to maximize interoperability, portability,
security and privacy for the industrial Internet.







Joint activities between the IIC and the IVI will include:




  • Sharing use cases


  • Sharing IIoT architecture information


  • Identifying and sharing IIoT best practices for manufacturing


  • Collaborating on opportunities for future joint testbed projects


  • Other activities to which both parties agree



“We look forward to a productive collaboration with the Industrial Value
Chain Initiative as both organizations are set to greatly benefit from
it,” said Dr. Jacques Durand, Director of IoT Engineering and Standards,
Fujitsu North America, Inc., IIC Liaison Officer to IVI and IIC Steering
Committee Member. “IVI understands industrial manufacturing and
supply-chains very well and has a lot of experience in deploying IIoT
for this mature sector. At the same time, the IIC has the capability to
globally harmonize IIoT best practices and models across countries and
industries.”



“The Industrial Internet Consortium is an international organization,
with about 260 member companies and 27 testbeds operating in 31
countries,” said Dr. Richard Mark Soley, Ph.D., Executive Director,
Industrial Internet Consortium. “We consider it especially important to
work closely with regional and national IoT initiatives and are very
much looking forward to our cooperation with the Industrial Value Chain
Initiative to further the industrial Internet in the world.”



“We are delighted about this new liaison for further collaboration with
the Industrial Internet Consortium,” said Prof. Dr. Yasuyuki Nishioka,
President of the Industrial Value Chain Initiative. “We believe the
smart manufacturing use cases obtained by our bottom up approach can
contribute towards a comprehensive reference architecture for global
cooperation.”



The Liaison Working Group is the gateway for formal relationships with
standards and open-source organizations, consortia, alliances,
certification and testing bodies and government entities/agencies. The
agreement with the IVI is one of a number of agreements made by the
IIC’s Liaison
Working Group
. For a list of current
liaisons, click here.



The Cross Industry Committee (CIC) of IVI, chaired by Ms. Hatsuko
Kouroku, is the contact point for formal relationships with other IIoT
initiatives. As a next step, the CIC and the Liaison Working Group of
the IIC have cooperatively targeted a joint workshop on June 8, 2017 at
Tokyo Big Sight to share use case information. For the latest list and
the brief introduction of IVI’s use cases, click here.



About the Industrial Value Chain Initiative



The Industrial Value Chain Initiative (IVI), based in Japan, is a forum
consisting of industrial and academic members that works on promotion of
smart manufacturing for connected industries. It aims at fostering
ecosystems by activities including provision of support to workgroups
made up of member companies/organizations for creating use cases,
coordination of platforms to provide the workgroups with solutions and
compilation of specifications at different granularity from requirement
specification of each workgroup to a reference architecture. For more
information, visit https://iv-i.org/en/.



About the Industrial Internet Consortium



The Industrial Internet Consortium is the world’s leading organization
transforming business and society by accelerating the Industrial
Internet of Things. Our mission is to deliver a trustworthy Industrial
Internet of Things in which the world’s systems and devices are securely
connected and controlled to deliver transformational outcomes. The
Industrial Internet Consortium is managed by the Object Management Group
(OMG). For more information, visit www.iiconsortium.org.



Note to editors: Industrial Internet Consortium is a registered
trademark of OMG. For a listing of all OMG trademarks, visit www.omg.org/legal/tm_list.
All other trademarks are the property of their respective owners.




Contacts


Industrial Value Chain Initiative
Shio OHTOMO
Secretariat
global_office@iv-i.org
or
Industrial
Internet Consortium
Karen Quatromoni, +1-781-444-0404 x146
quatromoni@iiconsortium.org



World Phenoxybenzamine Sales, Price Analysis, & Sales Forec… 2017年04月26日 05時16分

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Phenoxybenzamine
Sales, Price Analysis, & Sales Forecast - 2017"
report to
their offering.




Find out the sales of Phenoxybenzamine worldwide and by countries in
North America, Europe, Japan, BRIC, and Australia. Discover the growth
trends of Phenoxybenzamine by countries, and also find out the sales
forecast until 2021.



The research also provides Phenoxybenzamine unit price by countries. The
sales and price data from this report is useful for analyzing
Phenoxybenzamine sales trends, sales forecast for Phenoxybenzamine,
brand planning, Phenoxybenzamine generics trends, product positioning,
strategic forecasts, BD&L, competitive intelligence, pricing analysis,
and price benchmarks.



Research Scope:



- Companies marketing Phenoxybenzamine and by brand name in major
countries



- Historic Phenoxybenzamine sales revenues worldwide and by countries,
sales trends



- Phenoxybenzamine unit price by countries, trends, and benchmarks



- Phenoxybenzamine sales forecast worldwide and by countries



Benefits to the User



- Identify companies marketing Phenoxybenzamine by major countries



- Find out Phenoxybenzamine sales, growth, and sales forecast by major
countries; use it for your market planning - market assessments, market
sizing, market shares, BD&L, product strategy, positioning, and
competitive intelligence



- Determine the price of Phenoxybenzamine in major markets; use it to
devise pricing strategies, estimate patient shares, develop patient
forecast models, and estimate annual therapy costs



- Derive unit sales of Phenoxybenzamine by countries using pricing and
sales data; use it for your market planning - market assessments, market
sizing, market shares, BD&L, product strategy, positioning, and
competitive intelligence



Key Topics Covered:



1. Phenoxybenzamine - Introduction



2. Phenoxybenzamine Sales Analysis



3. Phenoxybenzamine Sales by Countries



4. Phenoxybenzamine Price Analysis by Countries



5. Phenoxybenzamine Sales Forecast



6. Phenoxybenzamine Sales Forecast by Countries



For more information about this report visit http://www.researchandmarkets.com/research/mfxd2b/phenoxybenzamine.




Contacts


Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For
EST Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related
Topics: Oncology
Drugs

Akebia and Otsuka Expand Relationship with Collaboration to… 2017年04月26日 05時05分


- Maximises Efficiency of Global Development and Commercialisation -



- Committed Capital and Potential Milestone Payments from Otsuka of
up to $865 Million, including $208 million or more in Upfront Payment
and Development Funding, as well as Tiered, Double-Digit Royalties -



- Total Committed Development Funding from all of Akebia’s Vadadustat
Collaborations Plus Cash Exceeds $600 Million -


CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)--Akebia
Therapeutics
, Inc. (NASDAQ: AKBA) and Otsuka
Pharmaceutical Co., Ltd.
today announced that they have expanded
their collaboration for vadadustat by entering into a collaboration and
license agreement for Europe, China and other territories. Vadadustat is
an oral hypoxia-inducible factor (HIF) stabiliser currently in Phase 3
development for the treatment of anaemia associated with chronic kidney
disease (CKD). Anaemia related to CKD arises from the kidney’s failure
to produce adequate amounts of erythropoietin, a key hormone stimulating
the production of red blood cells.1 Left untreated, anaemia
significantly accelerates patients' overall deterioration of health with
increased morbidity and mortality. 2, 3




This agreement follows a previously announced collaboration between the
companies in which they equally share the costs of developing and
commercialising vadadustat in the U.S., as well as the profits from
potential future sales of vadadustat in the $3.5 billion renal anaemia
market. The total committed development funding from all vadadustat
collaborations, combined with Akebia’s cash, is expected to exceed $600
million.



Under the terms of this collaboration agreement, Akebia will receive
$208 million or more in committed capital from Otsuka, including $73
million upon signing and $135 million or more of development funding. In
addition, Akebia is eligible to receive up to $657 million in milestone
payments, representing a total transaction value of approximately $865
million. Otsuka will also make tiered, double-digit royalty payments of
up to 30% on net sales of vadadustat in Otsuka’s territory, which
includes Europe, Russia, China, Canada, Australia and the Middle East,
but excludes Latin America and other previously licensed countries. In
the five major markets in the European Union, sales of erythropoiesis
stimulating agents (ESAs), the current standard of care for the
treatment of renal anaemia, were approximately $1.5 billion. 4



Mr. Tatsuo Higuchi, president and representative director of Otsuka
Pharmaceutical Co., Ltd., commented, “Thanks to Akebia’s expertise in
developing vadadustat, we anticipate that it holds significant promise
for renal anaemia. We are also convinced that by strengthening our
cardio-renal portfolio with a drug candidate like this, following our
own tolvaptan, we can contribute to changing the standard of care
worldwide for patients with complex kidney diseases."



“We are very pleased to expand our strategic relationship with Otsuka, a
company who shares our vision to improve the lives of patients with
kidney disease,” stated John P. Butler, President and Chief Executive
Officer of Akebia. “We now have a single, strong collaborator for the
two largest markets, the U.S. and Europe. This simplifies governance and
decision making, maximising the efficiency of our global Phase 3
development programme and ultimately the commercialisation of
vadadustat. We are able to accomplish this while obtaining substantial
funding for our vadadustat development programme and retaining
significant long-term value for Akebia.”



Akebia has established three significant collaborations for vadadustat
in a little over a year, which together total more than $2.2 billion in
potential value and include $573 million or more in upfront payments and
committed development funding. In addition to this agreement and the
U.S. collaboration with Otsuka, Akebia has established a collaboration
with Mitsubishi Tanabe Pharma Corporation for the development and
commercialisation of vadadustat in Japan, Taiwan, South Korea,
Indonesia, India and select other countries in Asia.



About Vadadustat



Vadadustat is an oral hypoxia-inducible factor (HIF) stabilizer
currently in development for the treatment of anaemia related to chronic
kidney disease. Vadadustat exploits the same mechanism of action used by
the body to adapt naturally to lower oxygen availability associated with
a moderate increase in altitude. At higher altitudes, the body responds
to lower oxygen availability with increased production of HIF, which
coordinates the interdependent processes of iron mobilisation and
erythropoietin production to increase red blood cell production and,
ultimately, improve oxygen delivery.



About Anaemia Associated with CKD



Anaemia results from the body's inability to coordinate red blood cell
production in response to lower oxygen levels due to the progressive
loss of kidney function with inadequate erythropoietin production. Left
untreated, anaemia significantly accelerates patients' overall
deterioration of health with increased morbidity and mortality. Anaemia
is currently treated with injectable recombinant erythropoiesis
stimulating agents, which are associated with inconsistent hemoglobin
responses and well-documented safety risks.5 The prevalence
of anaemia increases with the severity of CKD and is higher in people
with CKD who are over age 60.



About Akebia Therapeutics



Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered
in Cambridge, Massachusetts, focused on delivering innovative therapies
to patients with kidney disease through hypoxia-inducible factor
biology. Akebia’s lead product candidate, vadadustat, is an oral,
investigational therapy in development for the treatment of anaemia
related to chronic kidney disease in both non-dialysis and dialysis
patients. Akebia’s global Phase 3 programme for vadadustat, which
includes the PRO2TECT studies for non-dialysis patients with
anaemia secondary to chronic kidney disease and the INNO2VATE
studies for dialysis-dependent patients, is currently ongoing. For more
information, please visit our website at www.akebia.com.



About Otsuka



Otsuka Pharmaceutical is a global healthcare company with the corporate
philosophy: “Otsuka–people creating new products for better health
worldwide.” Otsuka researches, develops, manufactures and markets
innovative and original products, with a focus on pharmaceutical
products to meet unmet medical needs and nutraceutical products for the
maintenance of everyday health.



Otsuka Pharmaceutical is a subsidiary of Otsuka Holdings Co., Ltd.,
headquartered in Tokyo, Japan, with 2016 consolidated sales of
approximately EUR 9.9 billion.



Otsuka established a presence in Europe in 1974 and today Otsuka
Pharmaceutical Europe Ltd. (OPEL) employs over 600 people who channel
their passion and energy into converting the latest science into
much-needed medicines. OPEL has a particular focus on therapies in
mental health, oncology, cardio-renal and nephrology, as well as on
medical devices. Otsuka is also exploring how digital health technology
can provide additional options for patients, caregivers and healthcare
professionals.



All Otsuka stories start by taking the road less travelled. Learn more
about Otsuka in the EU at https://www.otsuka-europe.com.
and about Otsuka globally at www.otsuka.co.jp/en/.



_________________



1Iseki K and Kohagura K. Anemia as a risk factor for chronic
kidney disease. Kidney Int Suppl. 2007;107: S4-9.
2Culleton
B, Manns B, Zhang J, et al. Impact of anemia on hospitalization and
mortality in older adults. Blood. 2006;107(10): 3841-3846.
3Portolés
J, Gorriz J, Rubio E, et al. The development of anemia is associated to
poor prognosis in NKF/KDOQI stage 3 chronic kidney disease. BMC
Nephrology. 2013;14 (1):2.
4IMS MIDAS, 2016.
5Singh
AK. What is causing the mortality in treating the anemia of chronic
kidney disease: erythropoietin dose or hemoglobin level? Curr Opin
Nephrol Hypertens. 2010;19:420-424.




Contacts


Otsuka Pharmaceutical
Otsuka Pharmaceutical Europe Ltd.
Alison
Ross, +44 7768337128
aross@Otsuka-Europe.com
Otsuka
Pharmaceutical Co., Ltd.
Jeffrey Gilbert, 81-3-6361-7379
Leader
Pharmaceutical
Public Relations
Gilbert.jeffrey@otsuka.jp
or
Akebia
Theresa
McNeely, 1-617-844-6113
SVP
Corporate Communications and
Investor Relations
tmcneely@akebia.com



Akebia and Otsuka Expand Relationship with Collaboration to… 2017年04月26日 05時01分


Maximizes Efficiency of Global Development and Commercialization



Committed Capital and Potential Milestone Payments from Otsuka of up
to $865 Million, Including $208 million or More in Upfront Payment and
Development Funding, as well as Tiered, Double-Digit Royalties



Total Committed Development Funding from all of Akebia’s Vadadustat
Collaborations Plus Cash Exceeds $600 Million



Akebia to Host Conference Call at 4:30 p.m. Eastern Time Today


CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)--Akebia
Therapeutics
, Inc. (NASDAQ:AKBA) and Otsuka
Pharmaceutical Co., Ltd.
today announced that they have expanded
their collaboration for vadadustat by entering into a collaboration and
license agreement for Europe, China and other territories. Vadadustat is
an oral hypoxia-inducible factor (HIF) stabilizer currently in Phase 3
development for the treatment of anemia associated with chronic kidney
disease (CKD). Anemia related to CKD arises from the kidney’s failure to
produce adequate amounts of erythropoietin, a key hormone stimulating
the production of red blood cells.1 Left untreated, anemia
significantly accelerates patients' overall deterioration of health with
increased morbidity and mortality.2, 3



This agreement follows a previously announced collaboration between the
companies in which they equally share the costs of developing and
commercializing vadadustat in the United States, as well as the profits
from potential future sales of vadadustat in the $3.5 billion renal
anemia market. The total committed development funding from all
vadadustat collaborations, combined with Akebia’s cash, is expected to
exceed $600 million.



Under the terms of this collaboration agreement, Akebia will receive
$208 million or more in committed capital from Otsuka, including $73
million upon signing and $135 million or more of development funding. In
addition, Akebia is eligible to receive up to $657 million in milestone
payments, representing a total transaction value of approximately $865
million. Otsuka will also make tiered, double-digit royalty payments of
up to 30% on net sales of vadadustat in Otsuka’s territory, which
includes Europe, Russia, China, Canada, Australia and the Middle East,
but excludes Latin America and other previously licensed countries. In
the five major markets in Europe, sales of erythropoiesis stimulating
agents (ESAs), the current standard of care for the treatment of renal
anemia, were approximately $1.5 billion.4



Mr. Tatsuo Higuchi, president and representative director of Otsuka
Pharmaceutical Co., Ltd., commented, “Thanks to Akebia’s expertise in
developing vadadustat, we anticipate that it holds significant promise
for renal anemia. We are also convinced that by strengthening our
cardio-renal portfolio with a drug candidate like this, following our
own tolvaptan, we can contribute to changing the standard of care
worldwide for patients with complex kidney diseases."



“We are very pleased to expand our strategic relationship with Otsuka, a
company who shares our vision to improve the lives of patients with
kidney disease,” stated John P. Butler, President and Chief Executive
Officer of Akebia. “We now have a single, strong collaborator for the
two largest markets, the U.S. and Europe. This simplifies governance and
decision making, maximizing the efficiency of our global Phase 3
development program and ultimately the commercialization of vadadustat.
We are able to accomplish this while obtaining substantial funding for
our vadadustat development program and retaining significant long-term
value for Akebia.”



Akebia has established three significant collaborations for vadadustat
in a little over a year, which together total more than $2.2 billion in
potential value and include $573 million or more in upfront payments and
committed development funding. In addition to this agreement and the
U.S. collaboration with Otsuka, Akebia has established a collaboration
with Mitsubishi Tanabe Pharma Corporation for the development and
commercialization of vadadustat in Japan, Taiwan, South Korea,
Indonesia, India and select other countries in Asia.



Conference Call and Webcast



Akebia management will host a conference call to review the details of
the transaction beginning at 4:30 p.m. Eastern Time today, Tuesday,
April 25, 2017. A live audio webcast of the presentation will be
available on the company's website at http://ir.akebia.com/events.cfm.
An archived presentation will be available for 90 days.



To access the conference call, follow these instructions:



Dial: (877) 458-0977 (U.S.); (484) 653-6724 (international)
Conference
ID: 12787133



About Vadadustat



Vadadustat is an oral hypoxia-inducible factor (HIF) stabilizer
currently in development for the treatment of anemia related to chronic
kidney disease. Vadadustat exploits the same mechanism of action used by
the body to adapt naturally to lower oxygen availability associated with
a moderate increase in altitude. At higher altitudes, the body responds
to lower oxygen availability with increased production of HIF, which
coordinates the interdependent processes of iron mobilization and
erythropoietin production to increase red blood cell production and,
ultimately, improve oxygen delivery.



About Anemia Associated with CKD



Anemia results from the body's inability to coordinate red blood cell
production in response to lower oxygen levels due to the progressive
loss of kidney function with inadequate erythropoietin production. Left
untreated, anemia significantly accelerates patients' overall
deterioration of health with increased morbidity and mortality. Anemia
is currently treated with injectable recombinant erythropoiesis
stimulating agents, which are associated with inconsistent hemoglobin
responses and well-documented safety risks.5 The prevalence
of anemia increases with the severity of CKD and is higher in people
with CKD who are over age 60.



About Akebia Therapeutics



Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered
in Cambridge, Massachusetts, focused on delivering innovative therapies
to patients with kidney disease through hypoxia-inducible factor
biology. Akebia’s lead product candidate, vadadustat, is an oral,
investigational therapy in development for the treatment of anemia
related to chronic kidney disease in both non-dialysis and dialysis
patients. Akebia’s global Phase 3 program for vadadustat, which includes
the PRO2TECT studies for non-dialysis patients with anemia
secondary to chronic kidney disease and the INNO2VATE studies
for dialysis-dependent patients, is currently ongoing. For more
information, please visit our website at www.akebia.com.



About Otsuka



Otsuka Pharmaceutical is a global healthcare company with the corporate
philosophy: “Otsuka – people creating new products for better health
worldwide.” Otsuka researches, develops, manufactures and markets
innovative and original products, with a focus on pharmaceutical
products to meet unmet medical needs and nutraceutical products for the
maintenance of everyday health.



In pharmaceuticals, Otsuka is a leader in the challenging area of mental
health and also has research programs on several under-addressed
diseases including tuberculosis, a significant global public health
issue. These commitments illustrate how Otsuka is a “big venture”
company at heart, applying a youthful spirit of creativity in everything
it does.



Otsuka Pharmaceutical is a subsidiary of Otsuka Holdings Co., Ltd.,
headquartered in Tokyo, Japan, with 2016 consolidated sales of
approximately $11 billion.



All Otsuka stories start by taking the road less travelled. Learn more
about Otsuka in the U.S. at www.otsuka-us.com
and connect with us on LinkedIn
and Twitter at @OtsukaUS.
Otsuka Pharmaceutical Co., Ltd.’s global website is accessible at www.otsuka.co.jp/en/.



Forward-Looking Statements



This press release includes forward-looking statements. Such
forward-looking statements include those about Akebia's strategy, future
plans and prospects, including statements regarding the potential
indications and benefits of vadadustat, the potential commercialization
of vadadustat if approved by regulatory authorities, anticipated
contributions from Otsuka pursuant to the Collaboration and License
Agreement, Otsuka’s responsibilities pursuant to the Agreement, and the
amount of collaboration-related funds able to be realized by Akebia. The
words “anticipate,” “appear,” “believe,” “estimate,” “expect,” “intend,”
“may,” “plan,” “predict,” “project,” “target,” “potential,” “will,”
“would,” “could,” “should,” “continue,” and similar expressions are
intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Each
forward-looking statement is subject to risks and uncertainties that
could cause actual results to differ materially from those expressed or
implied in such statement, including the risk that existing preclinical
and clinical data may not be predictive of the results of ongoing or
later clinical trials; the ability of Akebia to successfully complete
the clinical development program for vadadustat; the funding required to
develop Akebia's product candidates and operate the company, and the
actual expenses associated therewith; the actual costs incurred in the
global Phase 3 studies of vadadustat and the availability of financing
to cover such costs; the timing of any additional studies initiated by
Akebia or its collaborators for vadadustat; the timing and content of
decisions made by regulatory authorities; the rate of enrollment in
clinical studies of vadadustat; the actual time it takes to initiate and
complete clinical studies; Akebia’s ability to satisfy its obligations
under the Collaboration and License Agreement; early termination of the
Collaboration and License Agreement by Akebia or Otsuka, the success of
competitors in developing product candidates for diseases for which
Akebia is currently developing its product candidates; and Akebia's
ability to obtain, maintain and enforce patent and other intellectual
property protection for vadadustat around the world. Other risks and
uncertainties include those identified under the heading “Risk Factors”
in Akebia's Annual Report on Form 10-K for the year ended December 31,
2016, and other filings that Akebia may make with the Securities and
Exchange Commission in the future. Akebia does not undertake, and
specifically disclaims, any obligation to update any forward-looking
statements contained in this press release.



_________________
1Iseki K and Kohagura K. Anemia as a
risk factor for chronic kidney disease. Kidney Int Suppl. 2007;107: S4-9.
2Culleton
B, Manns B, Zhang J, et al. Impact of anemia on hospitalization and
mortality in older adults. Blood. 2006;107(10): 3841-3846.
3Portolés
J, Gorriz J, Rubio E, et al. The development of anemia is associated to
poor prognosis in NKF/KDOQI stage 3 chronic kidney disease. BMC
Nephrology. 2013;14 (1):2.
4IMS MIDAS, 2016.
5Singh
AK. What is causing the mortality in treating the anemia of chronic
kidney disease: erythropoietin dose or hemoglobin level? Curr Opin
Nephrol Hypertens. 2010;19:420-424.


Contacts


Akebia
Theresa McNeely, 617-844-6113
SVP, Corporate
Communications and Investor Relations
tmcneely@akebia.com
or
Otsuka
Pharmaceutical

(In Japan)
Jeffrey Gilbert, 81-3-6361-7379
Leader,
Pharmaceutical Public Relations
Gilbert.jeffrey@otsuka.jp
or
(In
the US)
Otsuka America Pharmaceutical, Inc.
Kimberly
Whitefield, +1-609-535-9259
Corporate Communications
kimberly.whitefield@otsuka-us.com

World Naloxone / Oxycodone Sales, Price Analysis, & Sales F… 2017年04月26日 04時51分

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Naloxone
/ Oxycodone Sales, Price Analysis, & Sales Forecast - 2017"

report to their offering.




Find out the sales of Naloxone / Oxycodone worldwide and by countries in
North America, Europe, Japan, BRIC, and Australia. Discover the growth
trends of Naloxone / Oxycodone by countries, and also find out the sales
forecast until 2021.



The research also provides Naloxone / Oxycodone unit price by countries.
The sales and price data from this report is useful for analyzing
Naloxone / Oxycodone sales trends, sales forecast for Naloxone /
Oxycodone, brand planning, Naloxone / Oxycodone generics trends, product
positioning, strategic forecasts, BD&L, competitive intelligence,
pricing analysis, and price benchmarks.



Research Scope:



- Product: Naloxone / Oxycodone



- Country Scope: US, Germany, France, Italy, Spain, UK, Japan, Brazil,
Russia, India, China, Canada, and Australia



- Companies marketing Naloxone / Oxycodone and by brand name in major
countries



- Historic Naloxone / Oxycodone sales revenues worldwide and by
countries, sales trends



- Naloxone / Oxycodone unit price by countries, trends, and benchmarks



- Naloxone / Oxycodone sales forecast worldwide and by countries



Benefits to the User



- Identify companies marketing Naloxone / Oxycodone by major countries



- Find out Naloxone / Oxycodone sales, growth, and sales forecast by
major countries; use it for your market planning - market assessments,
market sizing, market shares, BD&L, product strategy, positioning, and
competitive intelligence



- Determine the price of Naloxone / Oxycodone in major markets; use it
to devise pricing strategies, estimate patient shares, develop patient
forecast models, and estimate annual therapy costs



- Derive unit sales of Naloxone / Oxycodone by countries using pricing
and sales data; use it for your market planning - market assessments,
market sizing, market shares, BD&L, product strategy, positioning, and
competitive intelligence



Key Topics Covered:



1. Naloxone / Oxycodone - Introduction



2. Naloxone / Oxycodone Sales Analysis



3. Naloxone / Oxycodone Sales by Countries



4. Naloxone / Oxycodone Price Analysis by Countries



5. Naloxone / Oxycodone Sales Forecast



6. Naloxone / Oxycodone Sales Forecast by Countries



For more information about this report visit http://www.researchandmarkets.com/research/2jgkgc/naloxone.




Contacts


Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For
EST Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related
Topics: Immune
Disorders Drugs
, Analgesics,
Drugs
by Therapeutic Area

Japan Industrial Control Systems Security Market 2017 - For… 2017年04月26日 03時28分

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Japan
Industrial Control Systems Security Market, Forecast to 2020"

report to their offering.




The Japanese Industrial Control Systems (ICS) Security market is
expected to witness a phenomenal compound annual growth rate of 55.9%
during 2015 to 2020. This is one of the largest growth rates among the
Asia-Pacific regions. The ICS security market is estimated to grow from
$46.5 million in 2015 to $428.1 million by 2020.



Key Questions This Study Will Answer



- How is the existing threat landscape for Industrial Control Systems
(ICS) in Japan?



- What are the drivers and restraints towards adopting ICS security?



- What are the trends in the ICS security market?



- What are the value propositions of ICS security solutions?



- What are the growth opportunities and calls to action in this market?



- Is the ICS security solutions market growing? How long will it
continue to grow, and at what rate?



Key Topics Covered:



1. Market Overview



- Market Definition-Taxonomy of ICS Security Solutions



- Common Threats Towards Industrial Control Systems



- Market Overview-Research Methodology



- Market Overview-Geographical Coverage



- Market Overview-Key Questions this Study will Answer



2. Threats Analysis



- Understanding the State of Connected ICS Devices



- Industrial Sector Threats and Vulnerabilities Influencing Security
Adoption



- Identified Gaps in ICS Security



3. Forecasts and Trends



- Forecast Assumptions



- Japan ICS Security Market-Revenue Forecast



- Japan ICS Security Market-Revenue Forecast Discussion



- ICS Devices Detected in Japan



4. Growth Opportunities and Call to Action



- Transformation in ICS Security Industry Ecosystem-2016



- Growth Opportunity 1-Security for Smart Metering



- Growth Opportunity 2-Protection of Legacy ICS Systems



- Growth Opportunity 3-Security for IIoT Platform Providers



- Growth Opportunity 4-ICS Security Training and Certification



- Growth Opportunity 5-Expanding the Channel Ecosystem



- 5 Major Growth Opportunities



- Strategic Imperatives for Success and Growth



5. ICS Security Vendor Analysis



- About ICS Security Vendor Profiling



- Belden (Tofino/Hirschmann)



- CYBERBIT



- Darktrace



- Wurldtech by GE



- Indegy



- Sasa Software



- SCADAfence



- Updates of ICS Security Solutions by ICT Security Vendors



6. The Last Word



7. Appendix



For more information about this report visit http://www.researchandmarkets.com/research/tjjmp4/japan_industrial




Contacts


Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related
Topics: Engineering,
Industrial
Automation

$5.98 Billion Position Sensor Market 2017 - Global Forecast… 2017年04月26日 03時09分

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Position
Sensor Market by Type (Linear and Rotary), Contact Type (Contact and
Non-Contact) Output (Analog and Digital), Application (Machine Tools,
Robotics, Motion Systems, Material Handling), Industry, and Geography -
Global Forecast to 2022"
report to their offering.




The position sensor market is expected to reach USD 5.98 billion by
2022, at a CAGR of 6.27% between 2017 and 2022.



The key factors contributing to the growth of the studied market include
the increasing investment in manufacturing infrastructure, integration
of position sensors in modern automobiles, and growing adoption of
position sensors in the aerospace industry. Moreover, the growth of the
market is driven by the growing trend in industrial automation. However,
rise in pricing pressure acts as a restraint for the growth of the
studied market.



Machine tool is one of the main applications of the position sensors.
Position sensors are used in numerous areas in the machine tool
application, including assembly and welding robot, automated guided
vehicle, bending press, laser cutting machine, coil storage and
handling, as well as sheet metal processing. In the assembly line, the
use of position sensors ensures the smooth transit of products, which
enables large-scale production along with the optimum utilization of
resources. Moreover, the use of position sensors in machine tools
includes ensuring operation efficiency of the assembly line and
simplifying task at a lower cost in the metal work industry. Thus, this
market is likely to witness an increased growth between 2017 and 2022.



The position sensor market in Asia Pacific (APAC), by country, has been
subsegmented into China, Japan, South Korea, India, and Rest of APAC
(RoAPAC). APAC plays a pivotal role in the development of the electrical
and electronics industry. Several electronic manufacturing companies
outsource their production to low-cost countries in Asia. This is more
distinct in segments with higher demand for labor-intensive work such as
passive electronic components, semiconductor assembly, and testing
operations, than those with relatively less labor-intensive work such as
semiconductor fabrication.



Market Dynamics



Drivers




  • Increasing Emphasis on Measurement and Inspection in the Manufacturing
    Industry


  • Growing Adoption of Position Sensors in the Aviation and Aerospace
    Industry


  • Amalgamation of Position Sensors in Modern Automobiles



Restraints




  • High Prices of Components and Raw Materials Could Affect the
    Profitability of Position Sensors



Opportunities




  • Growing Trend in Industrial Automation


  • High Potential for Industrial Robotics Application



Challenges




  • Lack of Proper Standards to Measure Performance Indicators



Companies Mentioned




  • Allegro Microsystems, LLC


  • Alliance Sensor Group


  • ams AG


  • Bourns Inc.


  • Dr. Johannes Heidenhain GmbH


  • Hans TURCK GmbH Co. KG


  • HELLA KGaA Hueck & Co.


  • Infineon Technologies AG


  • MTS Systems Corporation


  • Netzer Precision


  • Novotechnik Messwertaufnehmer OHG


  • Panasonic Corporation


  • Piher Sensors & Controls


  • Posital Fraba


  • Positek Ltd.


  • Qualcomm Technologies Inc.


  • Renishaw Plc


  • Sensata Technologies


  • SIKO GmbH


  • STMicroelectronics N.V.


  • TE Connectivity Ltd.


  • Variohm Eurosensor Ltd.


  • Vishay Intertechnology Inc.


  • Zettlex UK Ltd.



For more information about this report visit http://www.researchandmarkets.com/research/zl3md7/position_sensor.




Contacts


Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For
EST Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related
Topics: Capacitive
Sensors

Immersion Signs Multi-Year License Renewal With ALPS 2017年04月25日 21時30分


ALPS will continue licensing Immersion’s haptics IP for automotive
applications


SAN JOSE, Calif.--(BUSINESS WIRE)--Immersion Corporation (NASDAQ:IMMR), the leading developer and licensor
of touch feedback technology, today announced that it has renewed a
multi-year license agreement with ALPS Electric Co. Ltd., a
multinational corporation headquartered in Tokyo, Japan. Building on a
longstanding relationship the companies formed in 2000, ALPS has
licensed Immersion’s haptics IP for its automotive control devices.




Immersion's technology appeals to users' sense of touch through
high-quality tactile effects and feedback in user interfaces and
applications. Increasingly, tactile effects are being designed into
automotive applications, enhancing in-vehicle controls for operations
such as climate control and entertainment.



“We are excited to continue working with ALPS as they integrate haptics
into the user interface of its automotive applications,” said Nobumitsu
Shimada, Immersion’s Representative Director and Country Manager, Japan.



About Immersion



Immersion Corporation (NASDAQ: IMMR) is the leading innovator of touch
feedback technology, also known as haptics. The company provides
technology solutions for creating immersive and realistic experiences
that enhance digital interactions by engaging users’ sense of touch.
With more than 2,400 issued or pending patents, Immersion's technology
has been adopted in more than 3 billion digital devices, and provides
haptics in mobile, automotive, advertising, gaming, medical and consumer
electronics products. Immersion is headquartered in San Jose, California
with offices worldwide. Learn more at www.immersion.com.



Forward-looking Statements



This press release contains "forward-looking statements" that involve
risks and uncertainties, as well as assumptions that, if they never
materialize or prove incorrect, could cause the results of Immersion
Corporation and its consolidated subsidiaries to differ materially from
those expressed or implied by such forward-looking statements.



All statements, other than the statements of historical fact, are
statements that may be deemed forward-looking statements, including, but
not limited to, statements regarding the benefits of Immersion’s
technology, future collaboration between Immersion and its customers,
including ALPS, and the continuing incorporation by ALPS of Immersion’s
technology into its products.



Immersion's actual results might differ materially from those stated or
implied by such forward-looking statements due to risks and
uncertainties associated with Immersion's business, which include, but
are not limited to: unanticipated difficulties and challenges
encountered in product development efforts by Immersion and its
licensees; unanticipated difficulties and challenges encountered in
implementation efforts by Immersion’s licensees; adverse outcomes in any
future intellectual property-related litigation and the costs related
thereto; the effects of the current macroeconomic climate; delay in or
failure to achieve adoption of or commercial demand for Immersion's
products or third party products incorporating Immersion's technologies;
and a delay in or failure to achieve the acceptance of touch feedback as
a critical user experience. Many of these risks and uncertainties are
beyond the control of Immersion.



For a more detailed discussion of these factors, and other factors that
could cause actual results to vary materially, interested parties should
review the risk factors listed in Immersion's most current Form 10-K,
and Form 10-Q, both of which are on file with the U.S. Securities and
Exchange Commission. The forward-looking statements in this press
release reflect Immersion's beliefs and predictions as of the date of
this release. Immersion disclaims any obligation to update these
forward-looking statements as a result of financial, business, or any
other developments occurring after the date of this release.



Immersion and the Immersion logo are trademarks of Immersion Corporation
in the United States and other countries. All other trademarks are the
property of their respective owners.



(IMMR - C)




Contacts


Media Inquiries:
Edelman
Colleen Kuhn, 650-762-2804
colleen.kuhn@edelman.com
or
Investor
Inquiries:
The Blueshirt Group
Jennifer Jarman, +1-415-217-5866
jennifer@blueshirtgroup.com

AtriCure's AtriClip System Surpasses 100,000 Units Sold Wor… 2017年04月25日 21時00分


AtriClip is the most widely used device globally for left atrial
appendage management


MASON, Ohio--(BUSINESS WIRE)--AtriCure,
Inc.
(Nasdaq:
ATRC
), a leading innovator in surgical treatments for atrial
fibrillation (Afib) and left atrial appendage management, today
announced it has sold more than 100,000 AtriClip® Left Atrial
Appendage Exclusion System devices worldwide, which makes it the most
widely used of all devices for excluding the left atrial appendage (LAA).




“The AtriClip franchise is one of the fastest growing parts of our
business and is a meaningful driver of our broadening presence in the
Afib market, which is vastly underserved and underpenetrated,” said Mike
Carrel, President and Chief Executive Officer of AtriCure. “This
milestone represents an incredible amount of hard work on the part of
our employees and our customers as we pursue our mission to decrease the
global Afib epidemic and heal the lives of those affected.”



The LAA is a muscular pouch attached to the heart’s left atrium. In
patients with Afib and other cardiac arrhythmias, blood can pool and
form clots in the appendage, which may then leave the heart and cause
strokes. One study concluded that more than 90 percent of detected blood
clots in patients with atrial fibrillation are formed in the LAA.1



Patients who suffer from Afib have a 500 percent greater risk of stroke,
compared with the general population.2 Afib-related strokes
are associated with higher morbidity and mortality than non-Afib related
strokes.Prior to the invention of the AtriClip system,
cardiac surgeons typically addressed the LAA during open heart surgery
by cutting it off or closing off the opening of LAA to the atrium. This
approach required extra time on the heart-lung machine and posed a risk
of hemorrhaging and or reopening over time.



“Since the launch of the AtriClip system in 2010, we have continued to
add capabilities and new technology to the platform,” continued Carrel.
“These innovations, most recently with the AtriClip PRO2™ device which
was launched in 2016, have served to fuel continued adoption in both
open and minimally-invasive cardiac surgery. Moving forward, we are
excited about our robust pipeline of products coming to market.”



The AtriClip System is cleared by the Food and Drug Administration with
an indication for occlusion of the left atrial appendage, under direct
visualization, in conjunction with other open cardiac surgical
procedures. The clearance resulted in part from the successful EXCLUDE
trial (NCT00779857), which showed the LAA was closed successfully with
the AtriClip device in 98.4 percent of patients, with no device-related
mortality.4



In February of 2016, AtriCure enrolled the first patient in the ATLAS (AtriClip®
Left Atrial Appendage
Exclusion Concomitant to Structural Heart
Procedures) clinical study. This observational study can enroll up to
2,000 patients without a documented pre-operative history of Afib but
who present with significant risk factors for developing post-operative
AF (POAF) and also have significant risk factors for bleeding on
commonly prescribed medication to decrease the risk of Afib-related
stroke.



This randomized prospective study (AtriClip vs. no AtriClip) will
evaluate resource utilization, including hospital length of stay,
emergency room and/or hospital re-admissions, and costs associated with
specific adverse events that may be related to atrial fibrillation
through 365 days post index procedure.



About AtriCure, Inc.



AtriCure, Inc. provides innovative technologies for the treatment of
Afib and related conditions. Afib affects more than 33 million people
worldwide. Electrophysiologists and cardiothoracic surgeons around the
globe use AtriCure technologies for the treatment of Afib and reduction
of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation
System is the first and only medical device to receive FDA approval for
the treatment of persistent Afib. AtriCure’s AtriClip Left Atrial
Appendage Exclusion System products are the most widely sold LAA
management devices worldwide, with more than 100,000 implanted to date.
For more information, visit AtriCure.com or follow us on Twitter
@AtriCure.



_______________________________________



1 Jeff S. Healey, MD, Eugene Crystal, MD, Andrew Lamy, et al.
“Left Atrial Appendage Occlusion Study (LAAOS): Results of a randomized
controlled pilot study of left atrial appendage occlusion during
coronary bypass surgery in patients at risk for stroke.” American Heart
Journal. 2005 Aug; 150:288-93.
2 Benjamin EJ, Chen PS,
Bild DE, et al. Prevention of atrial fibrillation: report from a
national heart, lung, and blood institute workshop. Circulation.
2009 Feb 3; 119(4):606-18.
3 Marini C, De Santis F,
Sacco S, et al. “Contribution of atrial fibrillation to incidence and
outcome of ischemic stroke: results from a population-based
study.” Stroke. 2005 Jun; 36 (6):1115-9.
4 Data on
file at AtriCure. IDE G080095, EXCLUDE study.


Contacts


AtriCure, Inc.
Media Relations
Valerie
Storch-Willhaus, 612-605-3311
Director, Corporate Marketing
and Communications
vstorch-willhaus@atricure.com
or
Investor
Relations
Andy Wade, 513-755-4564
Senior Vice President
and Chief Financial Officer
awade@AtriCure.com

Santen Announces U.S. FDA Filing Acceptance of New Drug App… 2017年04月25日 21時00分

OSAKA, Japan--(BUSINESS WIRE)--Santen Pharmaceutical Co., Ltd. (hereinafter, “Santen”), a specialized
ophthalmology company headquartered in Osaka, Japan, today announced
that the U.S. Food and Drug Administration (FDA) has accepted for review
the New Drug Application (NDA) for intravitreal (IVT) sirolimus (440
µg), development code DE-109, for the treatment of non-infectious
uveitis of the posterior segment (NIU-PS). The FDA has set an action
date of December 24, 2017 to complete its review of the IVT sirolimus
NDA, per the Prescription Drug User Fee Act (PDUFA). IVT sirolimus was
granted orphan drug designation by the FDA and the European Commission
(EC) in 2011.




IVT sirolimus, an mTOR inhibitor, is an investigational first-in-class
targeted, immunoregulator being developed by Santen for the treatment of
patients with NIU-PS. NIU-PS is a progressive and chronic inflammatory
disease of the eye that can lead to vision impairment and blindness. The
NDA for IVT sirolimus is supported by data from the SAKURA Program, the
largest Phase III global clinical program to date evaluating patients
with NIU-PS.



“The FDA acceptance of the NDA for IVT sirolimus is an important
milestone, and brings us closer to potentially offering a
locally-administered treatment option for patients with NIU-PS,” said
Naveed Shams, M.D. Ph.D, Chief Scientific Officer and Head of Global R&D
at Santen.



About IVT Sirolimus
IVT
sirolimus (440 μg), an mTOR inhibitor, is a first-in-class targeted
immunoregulator being developed for the treatment of NIU-PS – a
progressive and chronic inflammatory disease of the eye. IVT sirolimus
inhibits the protein kinase, mTOR, which plays a key role in
inflammation. The result is immunoregulation by: interrupting the
inflammatory cascade through the inhibition of T-cell activation,
differentiation and proliferation; and, promoting immune tolerance,
increasing regulatory T lymphocytes (Tregs).



About Uveitis
Uveitis is a
leading cause of preventable blindness in working-age adults and is
estimated to account for 10 to 15 percent of cases of total blindness in
the developed world.1 It is characterized by intraocular
inflammation that is often chronic, can flare up at any time and can
lead to visual impairment and vision loss. NIU-PS includes intermediate,
posterior and panuveitis.



About Santen
As a specialty
company dedicated to the ophthalmic field, Santen carries out research,
development, marketing, and sales of pharmaceuticals and devices. Santen
is the market leader in Japan for prescription ophthalmic
pharmaceuticals and sells products in over 50 countries. As a leading
company in the field of ophthalmology, Santen aims to contribute to
society by supplying valuable products and services to satisfy unmet
medical needs. For more details, please see Santen’s website (www.santen.com).



Santen Forward-looking Statements
Information
provided in this press release contains so-called “Forward-looking
Statements.” The realizations of these forecasts are subject to risk and
uncertainty from various sources. Therefore, please note that the actual
results may differ significantly from the forecasts. Business
performance and financial condition are subject to the effects of change
in regulations made by the governments of Japan and other nations
concerning medical insurance, drug pricing and other systems, and to
fluctuations in market variables such as interest rates and foreign
exchange rates.



1 Durrani OM, Tehrani NN, Marr JE, Moradi P, Stavrou P,
Murray PI. Degree, duration, and causes of visual loss in uveitis. Br
J of Ophthalmol
. 2004;88(9):1159-1162.








Contacts


Santen Pharmaceutical Co., Ltd.
Christopher Hohman, General
Manager, Corporate Communications Group
Tel: +81-6-4802-9360
E-mail:
ir@santen.co.jp

Take Home the Beauty of Kyoto: Camera Sharing Service PaN O… 2017年04月25日 20時13分

KYOTO, Japan--(BUSINESS WIRE)--Panasonic Corporation, NTT Communications Corporation ("NTT
Communications") and Dai Nippon Printing Co., Ltd. ("DNP") are
conducting a demonstration of their camera sharing service PaN ("Photo
and Network") with the cooperation of two temples in Kyoto, Japan:
Kenninji, the oldest zen temple in Kyoto, and Entokuin, known for its
gardens.








[Video] Camera Sharing Service PaN at Two Temples in Kyoto
YouTube: https://www.youtube.com/watch?v=63bBn__2GGA
Vimeo:
https://vimeo.com/214614669/8467947a27



What is PaN?



PaN is a new service that allows visitors to share pre-installed cameras
arranged at tourist destinations, amusement parks, and event venues to
take their own souvenir photos. This service has been brought to life by
the combination of Panasonic's photo-shooting technology and NTT
Communications' cloud-network technology. The photographs are stored
automatically online in the cloud and can be downloaded easily to a
user's computer or smartphone.



Summary of Demonstration



Using photo vouchers distributed at the entrance of Kenninji and
Entokuin temples, visitors can take selfies using PaN cameras arranged
at various photo spots on the grounds. One card gives access to all
cameras within a temple. Visitors can purchase prints and/or data of
their photographs before they leave.



Key Features of the Event



1. The demonstration includes DNP's photo print system so that
photographs shot with the PaN cameras will not only be stored in the
cloud but may also be printed at the temples as mementos.
2. This
service allows visitors to take unique photographs not typically
available. For example, certain photo spots feature special camera
angles on the temple grounds, and one spot offers a composite image
using a green screen for an added experience.
3. Organizing this
demonstration at Kenninji and Entokuin temples simultaneously will
direct people from one temple to the other to enhance their sightseeing
experience.



Prices (tax inclusive):
Data (*1): 600 yen per photo spot
(includes data for all photos taken at one spot)
Print: 600 yen/copy
One
photo print & all data shot within a temple (*2): 1,000 yen
*1:
If multiple photographs are taken at a single photo spot, visitors will
be able to download data for all shots taken at the same spot.
*2:
All data of all photos shot within a temple.



Where & When
Period: April 25 to 30, 2017
Times:
10:00 - 17:00
Locations:
Kenninji
584
Komatsu-cho, Higashiyama-ku, Kyoto, Japan 605-0811 [Google
Map
]
Entokuin Temple
530
Shimogawara-cho, Kodaiji, Higashiyama-ku, Kyoto, Japan 605-0825 [Google
Map
]



*PaN: Stands for Photo and Network. Combining Panasonic's photo
technology and NTT Communications' cloud/network technologies, the PaN
brings to life an all-new photo experience and cloud storage service.



Inquiries about Camera Sharing Service PaN
E-mail: pan_support@ntt.com
Homepage
(in Japanese): https://pan.ntt.com/business/
*NOTE:
Please refrain from calling temples about this service.



Related Links:
[Video] Camera Sharing Service PaN at Two
Temples in Kyoto
YouTube: https://www.youtube.com/watch?v=63bBn__2GGA
Vimeo:
https://vimeo.com/214614669/8467947a27
[Photo
Album] https://goo.gl/photos/VoPXBA2WNBo2Rn957



Share Your Memories with Ultraman (Apr 25, 2017)
http://news.panasonic.com/global/topics/2017/46350.html
Experience
the Camera Sharing Service, "PaN," at the Mercedes-Benz Christmas Event
in Tokyo (Nov 29, 2016)
http://news.panasonic.com/global/topics/2016/45758.html
Panasonic's
IoT Tech Transforms the Way to Enjoy Everyday Life #CEATEC 2016 (Oct 19,
2016)
http://news.panasonic.com/global/topics/2016/45645.html
Panasonic
Business http://www.panasonic.com/global/business.html
Kenninji
http://www.kenninji.jp/english/index.html
Entokuin
Temple [PDF: 545 KB]
http://www.kodaiji.com/entoku-in/pdf/entokuin_e.pdf



NTT Communications Corporation http://www.ntt.com/en/
Dai
Nippon Printing Co., Ltd. http://www.dnp.co.jp/eng/



Source: http://news.panasonic.com/global/topics/2017/46517.html




Contacts


Panasonic Corporation
Global Communications Department
Media
Promotion Office
presscontact@gg.jp.panasonic.com



Chubu Electric Power Selects Bidgely for Modern Customer En… 2017年04月25日 20時00分

MOUNTAIN VIEW, Calif. & NAGOYA, Japan--(BUSINESS WIRE)--Bidgely
and leading Japanese utility Chubu
Electric Power
are working together to become the first to bring
residential disaggregation technology to Japan. The partnership is part
of an enhanced
customer engagement strategy
underway at Chubu that seeks to
incorporate innovative digital technologies into the utility’s service
offerings.







Chubu is looking for ways to use smart meter data to develop new
services for its consumers and believe that Bidgely has the right
technology to both deepen customer engagement and enhance business
intelligence.



“Demand for our disaggregation platform continues to accelerate across
the globe, pulling Bidgely into new geographies and capturing the
attention of preeminent utilities,” said Bidgely CEO Abhay Gupta.
“Chubu’s proactive move toward a modern customer engagement platform
ahead of the competition shows they are amongst the utilities that are
evolving with the digital era, rather than falling behind the times. We
look forward to a successful partnership and implementing new and
innovative ways for Chubu to build lasting relationships with its
customers.”



Bidgely’s market leading disaggregation platform will provide Chubu the
possibility to offer its customers with a breakdown of energy usage by
appliance on their electricity bill as well as personalized
recommendations on how to become more energy efficient.



For more information about the Bidgely Platform, visit: http://bidgely.com/solutions/



About Chubu Electric Power



Chubu Electric Power Co., Inc. is Japan’s third-largest electric power
company in power generation capacity, electric energy sold, operating
revenues, and total assets. The company serves an area of nearly 39,000
square kilometers in five prefectures of central Japan and 16 million
people.



About Bidgely



Bidgely is transforming the way utility customers use energy. By
combining the power of SaaS-based analytics with consumer-friendly Web
and mobile applications, Bidgely provides personalized and actionable
insights that help customers save energy and enable utilities to build
enduring customer relationships. The company works with utilities
serving residential customers worldwide. For more information, please
visit www.bidgely.com
or the Bidgely blog at bidgely.com/blog.




Contacts


for Bidgely
Christine Bennett
press@bidgely.com

NTT Com Acquires International Telecom License in India 2017年04月25日 15時00分


First Japanese ICT provider to receive this license


MUMBAI, India--(BUSINESS WIRE)--NTT Communications (NTT Com), the ICT solutions and international
communications business within the NTT Group, today announced that it
acquired a Virtual Network Operator – International Long Distance
(VNO-ILD) license in India through its affiliate, NTT Communications
India Network Services (NTTCINS), on March 1 this year.




The license acquisition will allow NTT Com to add Arcstar Universal One
International Network Services to its portfolio of existing services in
India. Currently, NTT Com provides National Long Distance “NLD” network
services through NTTCINS and Colocation, Managed Hosting, Cloud and ICT
Management Services through Netmagic, an affiliate. Beginning this July,
NTT Com will leverage its full stack of high-quality ICT solutions to
help enterprise customers build their ICT environments for business
expansion in India.



"With the enhanced network capabilities coupled with Managed Hosting and
Cloud services, we are always committed to enable our customers to reap
the maximum value from their technology investments. This suite of
offerings provides a robust value proposition as an ICT provider to meet
our customers’ IT infrastructure and connectivity requirements,” said
Sharad Sanghi, Managing Director and CEO of Netmagic Solutions.



NTT Com now looks forward to offering a comprehensive range of ICT
solutions, including WAN, LAN, Data Centers and associated Value Added
Services to support Indian businesses and multinational corporations.



NTT Com also plans to enhance its network services by adding Internet
access options and to improve the service quality by way of closer
relationships with local carriers.



Service Image
http://www.ntt.com/en/about-us/press-releases/news/article/2017/0425/a.html



About NTT Communications India Network Services



NTT Communications India Network Services is a wholly owned subsidiary
of NTT Com and currently provides national long distance network
services to enterprises in India.



About Netmagic Solutions (An NTT Communications Company)



Netmagic, an NTT Communications company, is India’s leading Managed
Hosting and Cloud service provider, with 9 carrier-neutral,
state-of-the-art data centers and serving more than 2000 enterprises
globally. Headquartered in Mumbai, Netmagic also delivers Remote
Infrastructure Management (RIM) services to various Enterprise customers
globally including NTT Communication’s customers across Americas, Europe
and Asia-Pacific region. The Company was the first in India to launch
services – Cloud Computing, Managed Security, Disaster
Recovery-as-a-Service (DRaaS) and Software-Defined Storage. Netmagic has
been recognized with 6 awards at the CIO Choice Award 2016 and Frost &
Sullivan India ICT Award 2016. To learn more, visit us at: www.netmagicsolutions.com.



About NTT Communications Corporation



NTT Communications provides consultancy, architecture, security and
cloud services to optimize the information and communications technology
(ICT) environments of enterprises. These offerings are backed by the
company’s worldwide infrastructure, including the leading global tier-1
IP network, the Arcstar Universal One™ VPN network reaching 196
countries/regions, and 140 secure data centers worldwide. NTT
Communications’ solutions leverage the global resources of NTT Group
companies including Dimension Data, NTT DOCOMO and NTT DATA.



www.ntt.com | Twitter@NTT
Com
 | Facebook@NTT
Com
 | LinkedIn@NTT
Com




Contacts


For further information, please contact –
Netmagic
Solutions (An NTT Communications Company)

Sikta Samantaray
Sikta.s@netmagicsolutions.com



Report on the Successful Demonstration of Innovative Basic … 2017年04月25日 13時00分


-- Elastic access-metro integrated network that flexibly changes the
transmission speed and optical frequency bandwidth towards future
multiple services accommodation beyond 2030 --


TOKYO--(BUSINESS WIRE)--Nippon Telegraph and Telephone Corporation (NTT, Chiyoda-ku, Tokyo, CEO:
Hiroo Unoura), Hitachi, Ltd. (Hitachi, Chiyoda-ku, Tokyo, President &
CEO: Toshiaki Higashihara), Oki Electric Industry Co., Ltd. (OKI,
Minato-ku, Tokyo, President Shinya Kamagami), Keio University (Keio,
Minato-ku, Tokyo, President Professor Atsushi Seike), KDDI Research,
Inc. (KDDI Research, Fujimino-shi, Saitama, president, CEO: Yasuyuki
Nakajima) and Furukawa Electric Co., Ltd. (Furukawa Electric,
Chiyoda-ku, Tokyo, President: Keiichi Kobayashi) have jointly challenged
the advanced future network for 2030 and beyond by conducting innovative
studies on “Elastic Lambda Aggregation Network (EλAN)”.
EλAN sets
an adaptive modulation OFDM transmission system, which leads to the
significant improvement of optical frequency utilization efficiency,
into the access (subscriber’s home-central office)-metro (central
office-central office) network that directly connects the subscriber’s
home and the metro central offices via fibers and WSSs. Therefore, EλAN
provides flexible assignment of the transmission speed and optical
frequency bandwidth to support diversified services with different types
of traffic, such as internet, enterprise line, and mobile services.
We
demonstrated the reliability of EλAN through a prototype testbed network
which utilizes optical path provisioning and switching technologies. The
demonstration successfully showed, for the first time, that the service
accommodated in the failed office was automatically re-connected within
10 sec to another office some 10km away with the same transmission speed
as before the failure. The project accomplishments will be presented at
an international conference on optical communications, iPOP2017 (The
13th International Conference on IP + Optical Network 2017:
Kawasaki-city, Kanagawa, Japan: June 1-2, 2017).




This research and development project was contracted with the National
Institute of Information and Communications Technology (NICT) of Japan
under a research contract titled “Research and development of elastic
lambda aggregation network.”



[Background]
Along with the wider penetration of FTTH (Fiber
to the Home) services, efficient operation of a large number of network
sets is essential in recent optical access networks. Moreover, the
future access network must support, in addition to conventional FTTH
service, multiple access services, such as mobile, high-definition video
and IoT (Internet of Things) services.
Until now, multiple access
services have been provided using distinctly different network
infrastructures to meet the disparate service requirements. However, to
provide them more efficiently, all services should coexist on the same
service-adaptive network that can flexibly meet individual service
requirements. If multiple access services share an optical fiber
network, high reliability is essential so that the network can keep
providing services by autonomous reconfiguration of the network
resources remaining after a disaster. Furthermore, high optical
frequency utilization efficiency (transmission rate per unit of optical
frequency) should also be provided to accommodate a large number of
services and subscribers.
From this background, as advanced
research studies targeting beyond 2030, the six institutions (NTT,
Hitachi, OKI, Keio, KDDI Research, and Furukawa Electric) have been
researching EλAN, a service adaptive access-metro network that provides
multiple services with high reliability and high optical frequency
utilization efficiency.



[Elastic lambda Aggregation Network (EλAN)]
In conventional
access networks, the central office equipment (OLT) is located at access
central offices close to subscribers’ homes. EλAN, on the other hand,
transfers the OLT to a metro central office that aggregates the traffic
of metro networks. Moreover, EλAN improves the reliability of
access-metro networking, which will need to accommodate a huge number of
subscribers, by using WSSs to switch optical paths flexibly. This
innovative architecture offers lower end-to-end latency and power
consumption, since Optical-Electrical-Optical (O-E-O) conversion in the
access central office is not needed.
EλAN employs a digital
coherent OFDM system with adaptive modulation, a technique that can
realize dramatically high optical frequency utilization efficiency and
large-scale flexible service allocation by using the elastic control of
transmission speed and optical frequency bandwidth. In addition, EλAN
applies the world’s first dynamic bandwidth allocation algorithm in
OLTs. This makes it possible for the users to share the additional bits
in a fair manner regardless of optical distribution network (ODN)
conditions.



[Future Outlook]
We will work to enhance the maturity and
the reliability of basic technologies for EλAN, and will carry out
further development activities.




Contacts


[Press Contact]
Nippon Telegraph and Telephone Corporation
Information
Network Laboratory Group
Planning Department, Public Relations
Section
TEL: +81-422-59-3663
Email: inlg-pr@lab.ntt.co.jp
or
Hitachi,
Ltd.
Public Relations and Investor Relations Dept.
Corporate
Brand & Communications Division
Kensuke Katagiri
TEL: +81
3-5208-9324
or
Oki Electric Industry Co., Ltd.
Public
Relations Division
TEL: +81-3-3501-3835
Email: press@oki.com
or
Keio
University
Office of Communications and Public Relations
TEL:
+81-3-5427-1541
Email: m-koho@adst.keio.ac.jp
or
KDDI
Research, Inc.
Sales and Public Relations Department
E-mail: inquiry@kddi-research.jp
or
Furukawa
Electric Co., Ltd.
IR Department
Shin Katoh
TEL:
+81-3-3286-3049
E-mail: fec.pub@furukawaelectric.com



ユニアデックス、ライムライト・ネットワークス CDN配信サービ… 2017年04月25日 11時00分

日東京--(BUSINESS WIRE)--(ビジネスワイヤ) -- ユニアデックス株式会社(本社:東京都江東区、社長:東 常夫、以下
ユニアデックス)とライムライト・ネットワークス・ジャパン株式会社(本社:東京都港区、日本法人代表:田所 隆幸、以下ライムライト・ネットワークス)は、コンテンツ配信事業の強化を目的に、「CDN(コンテンツ・デリバリー・ネットワーク)(注1)配信サービス」における販売代理店契約を締結しました。




ライムライト・ネットワークスのCDNは、世界最大規模の自社プライベートネットワーク経由でデジタルコンテンツを配信できるネットワークサービスです。ユニアデックスは、インフラトータルサービス、クラウドサービス事業者として、国内初の販売代理店となります。



インターネットの普及により、デジタルコンテンツの増加、動画・画像再生デバイスの多様化に伴い、Webサイトへのアクセス、動画再生・音楽視聴などに大量のトラフィックが発生しています。そのような状態においても、Webサイトのページ更新やソフトウエアのダウンロードをスムーズに実行することは、ユーザーエクスペリエンスの向上ならびに、Webサイトへのアクセスなどが中断されることによる機会損失の抑制にもつながります。



ライムライト・ネットワークスのCDNは、グローバル規模で自社プライベートネットワークを利用するため、インターネットが不安定になった場合にも影響を受けることなく、安定したサービス運用を続けられます。また集中するアクセスに対応するアーキテクチャーによる、高いキャッシュヒット率(注2)により、データを頻繁にWebサーバー経由で取得する必要がないためWebサイトの高速化と低い運用コストを提供することが可能です。



両社は協業の第一弾として、ライムライト・ネットワークスのCDNを活用した「CDN配信サービス」を提供します。お客さまは、本サービスを利用することで、オンラインショッピング、動画視聴、オンラインゲーム、アプリケーションのダウンロードなどをストレスなく実行できる環境を整備できます。さらに、本サービスでは、CDNのキャッシュヒット率に応じた最適なサーバー台数や回線キャパシティーなどを構築できます。また、ライムライト・ネットワークスが提供するWebアプリケーションへの攻撃を防御するWAFやDDoS攻撃対策などのクラウドセキュリティーソリューションは、Webサイトの安全性の担保に役立ち、ユニアデックスが扱うオンプレミスのセキュリティー製品と組み合わせることで、お客さまの状況に応じた最適なソリューションを提供していきます。



今後、両社は、ユニアデックスのクラウドサービスであるU-Cloud®に本サービスを追加することも計画しております。これにより、U-Cloud
IaaSのお客さまは、Web環境の構築・サポートにCDNを選択することが可能となります。また、両社はユニアデックスのクラウドサービス事業などで培われた知見や両社の強みを活かし、お客さまニーズに対応するサービスを提供していきます。



注1:CDN(コンテンツ・デリバリー・ネットワーク)
デジタルコンテンツをインターネット経由で配信するために最適化されたネットワークを指します。CDNのメリットは以下のとおりです。
1.サイト高速化
Webサイトへのアクセス速度は、サービス、そして企業のブランドに大きな影響を及ぼします。CDNによりWebサイトの高速化を実現し、閲覧者のユーザーエクスペリエンスを改善します。
2.急激な配信量の増加などによるピーク対策
マーケティングキャンペーン、ゲームアップデートのリリースや突然のニュース掲載などで大量
のリクエストが瞬間的に発生しても、Webサイトダウン、遅延をもたらさず、安定した配信を担 保します。
3.Webサイトのセキュリティー対策
CDNは世界中に大規模帯域のネットワークを網羅しているため、CDNプラットフォーム自体を一時的なDDoS攻撃などを吸収するために活用することが可能です。万が一大規模な攻撃が発生したとしても、トラフィックをCDN側で受け止め、Webサーバーへのアクセスを最小限に抑え、負荷軽減にも役立ちます。



注2:キャッシュヒット率
企業のWebサーバーに代わり、CDNからWebサイトや動画ファイルなどのコンテンツを配信する割合をキャッシュヒット率といいます。サイト表示速度はページの離脱率に直結することからも、キャッシュヒット率の高さは非常に重要な要素となります。



◆ユニアデックス株式会社 クラウドITOサービス事業本部 本部長 三宅 権
ユニアデックスはライムライト・ネットワークス様との販売代理店契約締結を歓迎いたします。デジタルビジネスにおいて多くのアプリケーションやコンテンツがクラウドへ移行し、Web配信におけるパフォーマンスやセキュリティーについての保証がますます求められています。ライムライト・ネットワークス様の高速かつ高品質なコンテンツデリバリーサービスは、競合に比して圧倒的なキャッシュヒット率やスループットなどを実現します。ライムライト・ネットワークス様のCDNにおけるテクノロジーとユニアデックスの技術とノウハウが蓄積されたハイクオリティーマネージドクラウドU-Cloudを融合させることでお客さまのデジタルビジネスのさらなる発展をご支援できることを楽しみにしています。



ライムライト・ネットワークス・ジャパン株式会社 カントリーマネージャー 田所 隆幸
ライムライト・ネットワークスは、ユニアデックス様との戦略的なパートナーシップを歓迎いたします。お客さまはユニアデックスが提供するフルマネージド型クラウドサービスU-Cloudと共に弊社のソリューションを利用して、ユーザーが快適なオンライン体験を実現できるクラウド環境を構築可能です。ユニアデックス様の国内での長い経験とライムライト・ネットワークスのテクノロジーを通じてより多くの日本のお客さまのデジタル変革に向けた取り組みをサポートしていくことを楽しみにしています。



◆ユニアデックス株式会社 http://www.uniadex.co.jp
1997年設立。日本ユニシスグループの「インフラトータルサービス」企業です。ICT基盤構築・運用・保守、設備設計・工事などを、ベンダーを問わず高い顧客満足度で提供しています。データセンター、サーバー、ネットワーク、デバイスなどを統合的に取り扱い、ICTインテグレーション、システムマネジメント、ファシリティー、保守サポート、グローバル対応、さらに複数のクラウドサービス利用を支援する「クラウドフェデレーションサービス」などを軸に、多様なソリューションとサービスメニューで支援しています。



ライムライト・ネットワークス・ジャパン株式会社 https://jp.limelight.com/
ライムライト・ネットワークス・ジャパン株式会社は、ビジネス、エンターテイメントの新しい形を実現するコンテンツ配信パートナーである米国ライムライト・ネットワークス社(本社:米国アリゾナ州
NASDAQ上場証券コード:LLNW)の日本法人として2007年に設立されました。実績のあるライムライト・ネットワークスの独自アーキテクチャーは、お客様が配信を希望される様々なフォーマットのコンテンツをPC、各種モバイルデバイスに対し最も効率の良い方法で配信いたします。



※U-Cloudは、日本ユニシス株式会社の登録商標です。
※その他記載の会社名および商品名は、各社の商標または登録商標です。




Contacts


<報道関係問い合わせ窓口>
ユニアデックス株式会社 企画部広報室 石崎・神戸(ごうど)
電話:03-4579-1081
press-box@ml.uniadex.co.jp
または
ライムライト・ネットワークス・ジャパン株式会社
マーケティング本部

電話:03-5571-4230
khoshi@llnw.com

イマージョン、アルプス電気との複数年ライセンス契約を更新 2017年04月25日 05時30分


アルプス電気は今後も車載アプリケーションに イマージョンのタッチフィードバックIP を継続使用


米カリフォルニア州サンノゼ--(BUSINESS WIRE)--(ビジネスワイヤ) -- タッチ フィードバック技術の開発とライセンス供与を行うイマージョン コーポレーション (NASDAQ: IMMR)
は本日、東京に本社を置く日本の大手電子部品メーカー、アルプス電気株式会社との複数年にわたるライセンス契約を更新したことを発表しました。2000
年に始まった長年に渡る両社の関係に基づき、アルプス電気は自動車用入力デバイスにイマージョンのタッチフィードバックIP を使用してきました。




ユーザーインターフェイスとアプリケーションにおいて質の高い触感効果とフィードバックを提供するイマージョンの技術は、ユーザーの感覚に訴えかけるテクノロジーとして知られています。今日、自動車の空調や車内エンターテイメントなどの操作性を高めるために触感効果はますます多くの車載アプリケーションに取り入れられるようになっています。



「車載アプリケーションのユーザーインターフェイスにタッチフィードバック技術を取り入れているアルプス電気と引き続き提携できることは、当社にとって大変嬉しいことです。」と、イマージョン・ジャパン株式会社の代表取締役社長、嶋田展光は述べています。



イマージョンについて



イマージョン コーポレーション (NASDAQ: IMMR)
は、タッチフィードバック技術で世界をリードするイノベーター企業。イマージョンのタッチ フィードバック
ソリューションによって、ユーザは快適な触感を楽しめ、没入感およびリアル感に優れたデジタルの世界を経験できます。合計 2,400
件以上の特許(出願中の件数を含む)を有するイマージョンの技術は、30
億台以上ものデジタル機器に取り入れられており、携帯電話、自動車、広告、ゲーム、医療、コンシューマーエレクトロニクスなどの製品にタッチフィードバック技術を提供しています。イマージョンは米国カリフォルニア州サンノゼに本社を構え、世界中で事業を展開しています。詳しくは、https://www.immersion.com/ja/をご覧ください。



将来見通しに関する記述について



本プレスリリースには「将来見通しに関する記述」が含まれています。これは、リスクおよび不確実性を伴い、それらの記述が具体化しないか不正確であると判明した場合、イマージョン
コーポレーションおよび同社の連結子会社の業績が、そのような将来の見通しに関する記述で表明もしくは示唆された内容から著しく乖離する可能性があることを前提としています。



すべての記述は、歴史的事実を除き、将来見通しに関する記述である可能性を含むものとします。そのような記述とは、具体的には、イマージョンの
技術の利点、イマージョンとイマージョンの顧客 (アルプス電気を含む)
との将来的な提携、アルプス電気がその製品にイマージョンの技術を継続的に組み込むこと等に関するものですが、これらに限定されません。



イマージョンの実際の業績は、イマージョンの事業に伴うリスクや不確実性により、かかる将来見通しに関する記述で表明または示唆された内容から著しく乖離する場合があります。そのようなリスクや不確実性には、イマージョンや当社のライセンシーが製品開発に努めている最中に遭遇する予測不可能な困難や問題、イマージョンのライセンシーが実装の取り組みにおいて遭遇する予測不可能な困難や問題、将来的な知的財産関連の訴訟とその訴訟に関連した費用による不利な結果、現在のマクロ経済環境の影響、イマージョン製品やイマージョンのテクノロジーを搭載したサードパーティ製品に対する商業的需要の獲得の遅延や失敗、ならびに重要なユーザー
エクスペリエンスとしてのタッチ
フィードバックの受け入れの遅延や失敗が含まれますが、これらに限定されるものではありません。こうしたリスクや不確実性の多くは、イマージョンによる管理の範囲を超えています。



これらの要因や、実際の業績が大幅に異なる場合の原因となり得るその他の要因については、イマージョンが米国証券取引委員会に提出した最新のフォーム
10-K およびフォーム 10-Q
に記載のリスク要因をご参照ください。本プレスリリースの将来見通しに関する記述は、リリース作成時点におけるイマージョンの考えや予想に基づいています。イマージョンは、本リリース発表以降に発生した財務・事業上の結果やその他の展開による結果としてこれらの将来見通しに関する記述を更新する一切の義務を否定します。



イマージョンおよびイマージョンのロゴは、米国およびその他諸国のイマージョンコーポレーションの商標です。その他すべての商標は各所有者の所有物です。



(IMMR - C)




Contacts


メディア関連のご質問は以下の連絡先まで:
Edelman
コリーン・クーン (Colleen
Kuhn)、650-762-2804
colleen.kuhn@edelman.com
または
投資関連のご質問は以下の連絡先まで:
The
Blueshirt Group
ジェニファー・ジャーマン (Jennifer Jarman)、+1-415-217-5866
jennifer@blueshirtgroup.com

J:COM Transforms VOD Experience with Market-Wide Rollout of… 2017年04月24日 22時00分

LAS VEGAS--(BUSINESS WIRE)--#CloudTV--J:COM pay-TV subscribers are enjoying enhanced, web-like video-on-demand
experiences on their existing set-top boxes, thanks to the first
deployment in Japan of transformative cloud-based technology.




J:COM has used the cloud to reimagine the VOD interface and enable
expedited content discovery, a key factor in driving take rates for
on-demand content. The new experience includes faster, more nimble
responsiveness; a larger, more informative display; and the ability to
personalize searches – without changing the equipment in consumers’
homes.



Shifting the browsing environment to the cloud has allowed J:COM to
accelerate availability at scale of an entirely new user experience that
enhances the capabilities of existing devices and performs identically
across every STB in its service footprint. In addition, the flexibility
of the cloud allows J:COM to quickly update the UX to deliver new
services to meet consumer needs.



“The user interface is the customer’s point of entry to our on-demand
library,” said Masaaki Agaya, General Manager, Service Planning Division
for J:COM. “The power of the cloud has enabled us to offer our
subscribers a next-generation UX that overnight is opening the door to
engaging new viewing experiences on the same familiar set-top boxes.”



J:COM is using cloud virtualization technology from ActiveVideo® to add
new functionality to its existing set-top boxes. ActiveVideo CloudTV
GuideCast enables pay-TV operators to augment current STB functionality
by making the user experience independent of device CPU speeds, memory
size and graphics capabilities. GuideCast renders a state-of-the-art
HTML5 user interface in the cloud, and delivers the output as an
interactive MPEG video stream to any cable QAM or IP STB that is
supported by a downloadable or preinstalled client with a CloudTV Nano
module.



“As pay-TV operators deploy new services, the time-to-market required to
ensure universal availability across the entire footprint can be
daunting,” said Jeff Miller, President and CEO of ActiveVideo. “J:COM’s
success is further proof of how STB virtualization allows operators to
rapidly transform user experiences for every subscriber by enabling
delivery of faster, larger and more intuitive user experiences.”



About Jupiter Telecommunications Co., Ltd.



Established in 1995, Jupiter Telecommunications Co., Ltd.(J:COM) is
Japan's largest multiple system and multiple channel operator. In system
operation, J:COM provides cable television, high speed Internet access,
telephony, mobile, and electric power service to customers through 28
consolidated subsidiaries at the local level serving 5.28 million
subscribing households in Sapporo, Sendai, Kanto, Kansai, and
Kyushu-Yamaguchi regions. The number of serviceable households or “homes
passed” in J:COM franchise areas is 21.13 million. In channel operation,
J:COM invests in and operates 17 thematic channels which are provided to
CATV, satellite and telecom operators.



* The above household figures are as of December 31, 2016.



About ActiveVideo



ActiveVideo® is the developer of CloudTV, the only software platform
that enables service providers, content aggregators and CE manufacturers
to virtualize CPE functions in the cloud for the purposes of
delivering online content, advanced user interfaces and interactive
advertising for TV to all generations of set-top boxes and connected
devices. CloudTV delivers consistent, branded video experiences from the
cloud, eliminating the cost and time to market of writing content for
multiple device makes and models. ActiveVideo is a joint venture of
ARRIS International plc (NASDAQ: ARRS) and Charter Communications
(NASDAQ: CHTR). The company is based in San Jose, CA with offices in
Hilversum, the Netherlands. Visit us at www.activevideo.com
or https://www.linkedin.com/company/activevideo;
follow us at www.twitter.com/activevideo.




Contacts


PSPR, Inc. for ActiveVideo
Paul Schneider, +1 215-817-4384
pspr@att.net

KDDI: TELEHOUSE OSAKA 2 Data Center in Osaka to Provide Dir… 2017年04月24日 18時00分


- Partnership achieves further expansion of TELEHOUSE connectivity -


TOKYO & OSAKA, Japan--(BUSINESS WIRE)--KDDI
CORPORATION
(TOKYO:9433) (KDDI) and Japan Internet Exchange Co.,
Ltd. (JPIX) have agreed to establish a JPIX connection point (PoP [1])
within the
TELEHOUSE OSAKA 2 data center
operated by KDDI in Osaka, Japan,
and will begin providing Internet exchange (IX) services as a new JPIX
Osaka Kyobashi site on April 24, 2017.








The partnership, which aims to meet the growing demand for IX and
colocation [2] services in Osaka, will give TELEHOUSE OSAKA 2 users
access to KDDI’s capability to support the high power demand while
offering high reliability and connectivity to KDDI's network, and to
JPIX’s environment that supports large numbers of connections with low
latency, which ranks among the most extensive in Japan, enabling them to
expand their businesses.



This move will expand the TELEHOUSE Interconnect [3] service used by
KDDI’s more than 3,000 connectivity partners (carriers, mobile
providers, ISPs, content providers, enterprises, etc.) worldwide.



KDDI and JPIX will use this opportunity to utilize this robust
connectivity and support the expansion of our customers’ global business.



[Reference]
About TELEHOUSE
TELEHOUSE
[4] is the KDDI Group’s data center brand and provides services at 48
sites, which are located in 24 cities in 13 countries and regions around
the world, including Tokyo, Osaka, New York, London, Paris, and Hong
Kong. The KDDI Group provides high-quality, attentive services by
leveraging the expertise of TELEHOUSE, whose proud record of achievement
spans approximately 30 years.



About JPIX
JPIX, which will mark the 20th anniversary of its
founding this July, is a leading IX service provider that ranks among
the largest in Japan. The company provides connections between more than
160 partner companies, and it has supported the Internet backbone in
Japan since it was established.



























 

[1]

 

Abbreviation of "Point of Presence", which refers to the switches
that make up the JPIX backbone network.

[2]


Services that provide rack space for installing equipment such as
the customer's servers and communication devices, as well as power,
communication lines, etc.

[3]


Concept expressing the connectivity within TELEHOUSE.

[4]


TELEHOUSE is the registered trademark of the KDDI Group.



Contacts


KDDI
Public Relations Department
prdpt@kddi.com



Nikon Initiates Global Legal Actions Against ASML and Carl … 2017年04月24日 16時01分

NEW YORK & LONDON--(BUSINESS WIRE)--Nikon Corporation ("Nikon") today initiated a series of legal actions in
the Netherlands, Germany and Japan intended to halt infringement of its
intellectual property by Dutch semiconductor lithography system
manufacturer ASML Holding N.V. and its related companies (“ASML”), and
by ASML’s optical component supplier Carl Zeiss SMT GmbH (“Zeiss”). The
basis of Nikon’s claim is that ASML and Zeiss employ Nikon’s patented
technology in ASML’s lithography systems, which are used globally to
manufacture semiconductors, without Nikon’s permission, thereby
infringing Nikon’s patents.



Nikon has met with ASML and Zeiss with the aim of reaching a resolution
of these issues, but those efforts, guided by a highly experienced
mediator, have failed to produce a settlement. The continued
unauthorized use of Nikon’s patented technology by ASML and Zeiss has
given Nikon no alternative but to enforce its legal rights in the courts
of law.



Nikon has initiated eleven patent infringement cases against ASML in the
District Court of The Hague in the Netherlands and is filing patent
infringement cases against ASML in Tokyo District Court in Japan and
against Zeiss in Mannheim, Germany where the company manufactures
optical components used in ASML’s immersion lithography systems that are
the subjects of these suits.



According to ASML’s publicly reported data for 2016, 76.3% of its sales
in the year ended December 2016, or approximately €3.5 billion, was
derived from immersion lithography systems sales. Nikon believes these
systems use Nikon's patented technology. The complaints seek injunctions
barring ASML’s and Zeiss’s sale and distribution of these systems, as
well as damages.



Immersion lithography technology, which Nikon pioneered in the early
2000s, has become essential in fabricating the state-of-the-art
semiconductors used in smartphones, memory chips and countless other
products. Today, ASML and Nikon are the only companies in the world that
make and sell immersion lithography systems.



“Through substantial and sustained investment in R&D, Nikon has
developed advanced lithography technologies, including immersion
lithography technology, that have revolutionized the semiconductor
industry,” said Kazuo Ushida, President, Representative Director of
Nikon. “Semiconductors are core components of the electronic devices on
which consumers, companies and the global economy rely. We are proud of
the role that our technology has played in advancing the global
information society. “



“We firmly believe that ASML’s unauthorized use of Nikon patents on our
most advanced technologies, including immersion lithography technology,
has enabled ASML to expand its lithography business. Respect for
intellectual property is fundamental to fair and healthy competition,
and is essential to promoting innovations that provide society with the
most advanced products and services. That is why we have decided to
commence this litigation.”



Nikon has previously had to bring legal actions against ASML and Zeiss
in relation to unauthorized use of its patented technology. Previous
cases in the United States were settled on terms favorable to Nikon.
Now, thirteen years later, Nikon intends again to pursue remedies
vigorously and to the fullest extent permitted by applicable law,
including injunctive relief to stop ASML and Zeiss from using Nikon's
intellectual property without authorization, as well as damages.



Background of Nikon/ASML/Zeiss Dispute




  • In the 1990s, Nikon was the world’s leading maker of lithography
    systems for semiconductor fabrication.


  • In December 2001, Nikon filed lawsuits in the United States accusing
    ASML of using technology without authorization that Nikon had
    developed and patented.


  • In 2004, a comprehensive settlement was reached, and Nikon entered
    into cross-license agreements with ASML and Zeiss. Under the
    agreements, older patents were licensed permanently and some patents
    with a later filing date were licensed for a limited period until
    December 31, 2009.


  • The parties agreed in the license agreements not to sue each other for
    patent infringement during a non-assertion period from January 1, 2010
    to December 31, 2014.


  • In accordance with the cross-license agreements, however, Nikon is
    allowed to seek damages now for ASML and Zeiss's infringement during
    the non-assertion period.


  • During the non-assertion period ASML introduced products that Nikon is
    asserting in the litigation infringe its patents.


  • Since the license under the cross-license agreement terminated on
    December 31, 2009, Nikon has attempted to negotiate with ASML and
    Zeiss to reach agreement on a new license agreement. However, ASML and
    Zeiss have not been willing to accept terms reflecting the value of
    Nikon’s patented technology. Nikon believes that both ASML and Zeiss
    are continuing their use of Nikon's patented technology without
    authorization, so Nikon has initiated new lawsuits against them to
    enforce its patents.



Actions in the Netherlands, Germany and Japan




  • In the District Court of The Hague in the Netherlands, where ASML
    assembles its lithography systems, Nikon is asserting [11] patents
    against ASML: European Patent Nos. [1,598,855; 1,652,003; 1,881,521;
    2,157,480; 2,264,531; 2,624,282; 2,717,098; 2,752,714; 2,765,595;
    2,808,737; and 2,937,734.]


  • In the Mannheim District Court in Germany, where Zeiss manufactures
    the optical components used in ASML’s lithography systems, Nikon is
    asserting two patents against Zeiss: European Patent Nos. 1,881,521
    and 2,157,480.


  • In the Tokyo District in Japan, where Nikon is headquartered, Nikon is
    asserting two patents against ASML: Japanese Patent No. 4,604,452 and
    5,708,546.



About Nikon Corporation



Nikon Corporation has been a pioneer in optical technology markets
worldwide since its inception in 1917. Today, Nikon offers a wide range
of products utilizing advanced technologies, from consumer optics such
as digital cameras, camera-related products and binoculars, to
industrial precision equipment including Semiconductor and FPD
Lithography Systems, microscopes, measuring instruments and medical
devices.



Nikon’s Precision Equipment Business supports the electronics-based
society through the development and production of semiconductor
lithography systems that produce semiconductors, as well as FPD
lithography systems for manufacturing liquid crystal panels and OLED
panels.



This press release contains forward-looking statements as that term is
defined in the Private Securities Reform Act of 1995, which are subject
to known and unknown risks and uncertainties that could cause actual
results to differ materially from those expressed or implied by such
statements. Such statements are subject to risks, uncertainties and
changes in condition, particularly those related to industry
requirements and other risks. The Company undertakes no obligation to
update the information in this press release.



###


Contacts


Nikon Corporation
Japan
John
Sunley / Brendan Jennings, +81-3-5425-7220
Ashton Consulting
Nikon-AC@ashton.jp
or
New
York

Jim Barron / Gloria Labbad, +1-212-687-8080
Sard
Verbinnen & Co
Nikon-SVC@sardverb.com
or
California
Scott
Lindlaw, +1-415-618-8750
Sard Verbinnen & Co
Nikon-SVC@sardverb.com
or
London
Conrad
Harrington, +44-20-3178-8914
Sard Verbinnen & Co
Nikon-SVC@sardverb.com
or
Netherlands
Charles
Huijskens / Clemens Sassen, +31-20-6-855-955
HuijskensBickerton
Nikon@huijskensbickerton.com
or
Germany
Jan
Hromadko / Kornelia Spodzieja, +49-69-794090-44
Charles Barker
Corporate Communications GmbH
Nikon-CB@charlesbarker.de

Toshiba Machine Expands Chinese Production of Its EC-SXII S… 2017年04月24日 12時00分


New models for high productivity and stable precision molding of
automobile parts added to product lineup


NUMAZU, Japan--(BUSINESS WIRE)--Toshiba
Machine Co., Ltd.
(TOKYO:6104) announced that its EC-SXII
series
of all-electric injection molding machines, one of the
best-selling products in Japan, will add the EC280SXII, featuring a
clamping force of 2,744 kN (280 tf), and the EC350SXII,
featuring a clamping force of 3,430 kN (350 tf), as two additional
models to its production lineup at its China factory. These two new
models are expected to help better meet customer needs for precision
molding of automobile optical parts.








Main Features of EC-SXII Series



Wide array of available injection (plasticized) devices for use in
specific applications



A wide variety of injection devices are available with high-load,
high-injection pressure, and high-speed injection specifications for
automobile parts, optical parts, the medical and food container sectors,
and more. Customers can select the optimum injection device for their
specific application.



High-added value controller with improved control performance and
scalability



The cutting-edge INJECTVISOR V50/S51 Control System includes a
new core-back (foam molding) control circuit (option) for enabling more
lightweight designs for molded products and also supports various
plug-ins such as sub-injection units for double injection molding
machines for providing wider functionality and greater ease of operation.
Preventive
maintenance, remote maintenance, and other IoT technologies are utilized
to contribute to higher productivity in molding plants targeting zero
downtime.



Special package specifications for optical parts available



A special plasticizing system was developed for reducing foreign matter
and yellowing defects in thick optical parts. This system features a
high-rigidity die clamping unit and multistage compression control
(PRESTROL) for enabling the shape accuracy, high microscopic transfer,
and mitigation and homogenization of internal stress that are required
for molding of thick lenses.



"Combined with our industrial robots, which will be produced in our
China factory, this is a system solution for meeting the needs of our
customers,” said Masafumi Ito of the Regional Operating Headquarters
(East Asia). “The EC-SXII series features a wide of array of packages
for optical parts such as automobile LED headlight lenses, in-car
lighting and displays, and more, for contributing to higher productivity
and more stable precision molding."




Contacts


Toshiba Machine
Media inquiries:
Toyokazu Ohata,
+81-55-926-5141
General Affairs & Public Relations Group
oohata.toyokazu@toshiba-machine.co.jp
or
Product
inquiries:
Kang Shao Hua, +86-21-5442-0606*360
Injection
Molding Machine Sales Department
kangshaohua@toshiba-machine.com.cn



World's First! App-CM Inc. Launches a New Service "Voty" 2017年04月22日 19時30分


"Which do you like better?"


JAKARTA, Indonesia--(BUSINESS WIRE)--App-CM Inc. (Head office: Tokyo, Japan, CEO: Atsufumi Otsuka) will
release the 2-choice Q & A service "Voty (voty-app.com)" on April 22,
2017.








App-CM Inc. is a start-up company that creates innovative Internet
services.
By 2017, we have accumulated a cash total of 1.7 million
dollars, and we are developing business mainly in Southeast Asia, Japan
and the United States.



Voty is the simplest and fun Q & A service in the world.
Everyone
can easily create attractive two-choice Q & A and share it to friends
and people all over the world.
And the biggest feature is the
world's first mechanism that you can vote by tapping images from the Web
and the App.



It is simultaneous release of iOS, Android, and Web, and all smartphone
users can vote.



From now on, App-CM Inc. will develop this "Voty" as the largest Q & A
community in Indonesia.




Contacts


App-CM Inc.
Atsufumi Otsuka
Call: +81-90-4803-1421
Mail: info@app-cm.co.jp
Facebook:
https://www.facebook.com/atsufumi.otsuka



企業をしらべれば人生が変わる! -就活やビジネスを成功に導くユーレット活用術-
スポンサードリンク
Ullet経審

他社比較

help他社比較するには?


注目情報

他社比較
「味の素はどっち?」いろんな会社を比較してみよう!
Ulletニュース
過去の掲載記事等の一覧。

マイリスト

ページ

ここに企業名をドラッグ&ドロップすると、リストに追加することが出来ます。

戻る次へ

閲覧履歴

ページ

ここに閲覧した企業の履歴が表示されます。

戻る次へ

関連サービス

Ulletモバイル
何時でもどこでも携帯で見れる!
Ullet経審 New
160,000社の決算書データ公開。売上高や評点別ランキングも。
aera 西野グローバルIT研究所 環境新聞・ユーレット合同企画『CO2と経営』
Ulletモバイル試験運用開始 QRコードを読込